



Audited annual report
Candriam Equities L

31 December 2022

*01.01.2022 – 31.12.2022
SICAV under Luxembourg Law
R.C.S. Luxembourg B-47449*



Candriam Equities L

SICAV under Luxembourg Law

Audited annual report for the year
from January 1, 2022 to December 31, 2022



Table of contents

Administration of the SICAV	4
Details about the SICAV	5
Report of the Board of Directors	6
Audit report	11
Statement of net assets as at December 31, 2022	14
Statement of changes in net assets for the year ended December 31, 2022	19
Statistics	24
Investment portfolio as at December 31, 2022	28
Candriam Equities L Australia	28
Candriam Equities L Biotechnology	30
Candriam Equities L Emerging Markets	34
Candriam Equities L EMU Innovation	38
Candriam Equities L Europe Innovation	41
Candriam Equities L Europe Optimum Quality	44
Candriam Equities L Global Demography	47
Candriam Equities L Life Care	50
Candriam Equities L Meta Globe	54
Candriam Equities L Oncology Impact	57
Candriam Equities L Risk Arbitrage Opportunities	60
Candriam Equities L Robotics & Innovative Technology	62
Notes to the financial statements - Schedule of derivative instruments	65
Other notes to the financial statements	69
Additional unaudited information	84
Sustainable Finance Disclosure Regulation (SFDR)	90



Administration of the SICAV

Board of Directors

Chairman

Tanguy DE VILLENFAGNE
Member of the Group Strategic Committee
Candriam - Belgian Branch (previously Candriam Belgium)

Directors

Thierry BLONDEAU
Independent Director

Isabelle CABIE
Global Head of Corporate Sustainability
Candriam - Belgian Branch (previously Candriam Belgium)

Catherine DELANGHE
Independent Director

Pascal DEQUENNE
Global Head of Operations
Candriam - Belgian Branch (previously Candriam Belgium)

Vincent HAMELINK
Member of the Group Strategic Committee
Candriam - Belgian Branch (previously Candriam Belgium)

Jean-Yves MALDAGUE
Managing Director
Candriam (previously Candriam Luxembourg)

Registered Office

5, Allée Scheffer
L-2520 Luxembourg

Depositary and Principal Paying Agent

CACEIS Bank, Luxembourg Branch
5, Allée Scheffer
L-2520 Luxembourg

Management Company

Candriam (previously Candriam Luxembourg)
SERENITY - Bloc B
19-21, Route d'Arlon
L-8009 Strassen

The functions of **Administrative Agent**, **Domiciliary Agent** and **Transfer Agent** (including the **Register Holding** business) have been delegated to:

CACEIS Bank, Luxembourg Branch
5, Allée Scheffer
L-2520 Luxembourg

Implementation of the **Portfolio Management** activities (except for the sub-fund Candriam Equities L Australia) is performed directly by Candriam (previously Candriam Luxembourg) and/or by one or more of its branches:

Candriam – Belgian Branch
(was previously delegated to Candriam Belgium until 30.06.2022)
58, Avenue des Arts
B-1000 Bruxelles

Candriam – Succursale française
40, Rue Washington
F-75408 Paris Cedex 08

Candriam – UK Establishment
Aldersgate Street 200,
London EC1A 4 HD

For Candriam Equities L Australia, the implementation of **Portfolio Management** is delegated to:

Ausbil Investment Management Limited
Grosvenor Place, Level 27, 225 George Street
Sydney NSW 2000 Australia

Implementation of the **securities lending and borrowing transactions** is performed by Candriam (previously Candriam Luxembourg) and/or by one or more of its branches and is party delegated to:

CACEIS Bank, Luxembourg Branch
5, Allée Scheffer
L-2520 Luxembourg

“Réviseur d’entreprises agréé”

PricewaterhouseCoopers, Société coopérative
2, Rue Gerhard Mercator
L-2182 Luxembourg

Financial Services

in Belgium :
Belfius Banque S.A.
11, Place Rogier
B-1210 Brussels



Details about the SICAV

Candriam Equities L (the "SICAV") publishes a detailed annual report on its activities, the assets under management. The report includes a combined statement of net assets and a combined statement of changes in net assets expressed in EUR, investment portfolio of each sub-fund and the audit report. This report is available at the registered office of the SICAV and at the registered office of the banks designated to provide financial services in the countries in which the SICAV is sold.

Furthermore, every six months a report is issued containing notably the composition of the portfolio, the number of shares in circulation and the number of shares issued or repurchased since the date of the previous report.

The shares are only available in registered form.

The Annual General Meeting of Shareholders of the SICAV is held each year at the registered office of the SICAV or at any other place in Luxembourg as specified in the convening notice. It shall take place within 6 months after the financial year-end.

Notice for all general meetings is sent to all registered shareholders by registered mail at their address specified in the share registrar, at least 8 days before the General Meeting. These notices indicate the time and place of the General Meeting as well as the conditions of admission, the agenda and the quorum and majority required under Luxembourg law.

In addition, notice shall be published in the "Recueil électronique des sociétés et associations" ("RESA") of the Grand Duchy of Luxembourg and in a Luxembourg newspaper the "Luxemburger Wort" as well as in the press of the countries where the SICAV is marketed if the legislation so requires.

The financial year of the SICAV ends on December 31, of each year.

The net asset value per share of each share class of each sub-fund, the subscription, redemption or conversion's price of each share class of each subfund may be obtained from the registered office of the SICAV and from the banks designated to provide financial services in the countries where the shares of the SICAV are distributed.

A detailed statement of the movements in the portfolio is available free of charge upon request at the registered office of the SICAV.

The prospectus, Key Investor Information Documents, the SICAV's Articles of Incorporation and financial reports are available to the public free of charge, at the SICAV's registered office.



Report of the Board of Directors

Economic and financial background

In the United States, although GDP was down slightly in the first quarter (-0.4% quarter-on-quarter) due to a drop in public spending and a negative contribution from the external balance, private demand remained strong. Over the first quarter, more than 1.6 million jobs were created. In March, the unemployment rate stood at 3.6%, while inflation rose to 8.5% and core inflation to 6.4%. ISM activity indicators remained well above 50. In this environment, given the weak economic links between Russia and the United States and fears that tensions in Europe could lead to additional pressure on prices, the Federal Reserve on 16 March raised its key rate by 25 basis points to 0.5%. The sharp rise in commodity prices and the prospect of monetary tightening to bring inflation back to its 2% target pushed the stock market down (-4.9% in the first quarter), while the 10-year rate rose 83 basis points to 2.33%. In the second quarter, supply chain bottlenecks were exacerbated by the very large-scale zero-Covid policy in China. Despite the collateral effects of the conflict in Ukraine on commodity and oil prices (around \$110 per barrel on average in the second quarter), activity indicators remained strong and tension on the labour market persisted. These developments pushed the 10-year rate to nearly 3.5% in mid-June. In response to the increase in prices, the Federal Reserve raised its key rate twice: the first time in early May by 50 basis points and then in mid-June by 75 basis points. In this new environment, with credit becoming more expensive and household purchasing power under pressure, consumer confidence saw a sharp decline. Finally, growth was once again very slightly negative (-0.1%). The 10-year rate rose 65 basis points to 2.97% over the quarter. The stock market lost 16.4%. In July, the 10-year rate fluctuated around 3% in line with the data. Indeed, the ISM manufacturing survey and monthly job creations were slightly lower than in previous months, while in mid-July, inflation exceeded 9%. At the end of July, however, the Federal Reserve's 75-basis point increase to 2.5% and the tension created by Nancy Pelosi's visit to Taiwan weighed on rates. Despite the first decline in inflation month-on-month since May 2020, the Chairman of the Federal Reserve did not fail to reiterate at the end of August, at the Jackson Hole conference, that the return to price stability - inflation was still 8.3% year-on-year - would require a restrictive monetary policy for a certain period of time. Indeed, despite a slowdown in the manufacturing sector partly due to the significant appreciation of the dollar, the economy continued to create more than one million jobs every three months and the unemployment rate was close to 3.5% and wage growth remained strong. In this environment, on 21 September, FOMC members (Federal Reserve) raised the key rate by 75 basis points to 3.25%, and sharply revised their forecasts for the federal funds rate upwards for the coming years. For 2023, FOMC members expect the latter to be around 4.65% versus an estimate of only 3.85% in June. The 10-year rate ended the third quarter at 3.8%, up 83 basis points from the end of June. The latest developments and the impact of much higher mortgage rates on the real estate sector weighed negatively on the stock market, which fell 5.3% over the quarter. In the fourth quarter, following the decline in the global manufacturing sector, the ISM manufacturing survey fell to below 50 in response to the rise in the dollar and the global economic slowdown. Although the pace of monthly job creations slowed a little - they remained above 250,000 - core inflation still stood at 6% and the services sector remained strong. Therefore, in order to ensure that inflation would return to 2% in the medium term, the Federal Reserve raised its key rate twice: the first time at the beginning of November by 75 basis points and then by 50 basis point (to 4.5%) in mid-December. All in all, 2022 was the year of the unexpected with a conflict at Europe's door, much higher than expected inflation, the largest monetary tightening since 1980 and, despite everything, growth that rebounded 0.8% quarter-on-quarter in the third quarter. However, developments in 2022 and weak growth prospects for 2023 weighed on the S&P500 index, which ended the year down 19.4% to 3840 despite a rebound of more than 7% over the last quarter. The 10-year rate changed little over the last quarter. Indeed, headline inflation seems to have passed its peak and, whenever inflation falls, the markets revise their projections for the Federal Reserve's terminal rate, pushing the 10-year rate downwards. It ended the year at 3.83%, an increase of 233 basis points over the year.

In the eurozone, activity resumed until the end of February 2022 at the pace of the easing of preventive measures. Despite rising gas and electricity prices, consumer confidence remained high. Tension on the labour market persisted. In February, the unemployment rate stood at 6.8% but inflation reached 5.9%. In the wake of the global rate hike movement, the German 10-year rate turned positive again for the first time since early 2019, also pushed upwards by the European Central Bank (ECB), which, at its February meeting, did not close the door to rate hikes in 2022. On the other hand, as core inflation stood at only 2.7%, the normalisation of monetary policy would be less pronounced than in the United States. However, after the invasion of Ukraine, tensions on commodity and agricultural prices pushed rates up sharply. The German 10-year rate ended the first quarter at 0.51%, up 69 basis points from end-December 2021. While consumer and business confidence held up until February, it fell sharply in March. These developments naturally weighed on the European stock market, which fell by 9.4%. The second quarter was marked by high energy, industrial metals and agricultural commodities prices, the cut in gas supply from Russia for countries refusing to pay in rubles and a reduction in the flow of gas to Germany. All in all, from May onwards, inflation stood at more than eight percent. In this environment, the markets priced in several rate hikes by the ECB, pushing all European rates upwards. The German 10-year rate surpassed 1.7%, while the Italian 10-year rate exceeded 4%. The extent of the widening of interest rates led the ECB to meet urgently on 15 June and to announce a new "anti-fragmentation" instrument for the eurozone. From mid-June, however, the possibility of recession became a slightly more likely scenario for the markets, pushing the German 10-year rate downwards. The German 10-year rate fell 86 basis points to 1.37% over the quarter. The stock market lost 12%. Despite the above-mentioned developments, GDP was up 0.8% quarter-on-quarter in the second quarter and the unemployment rate was historically low (6.7%), with household and business confidence falling slightly more in July. Indeed, despite the drop in prices of many commodities, the extremely high level of gas prices as well as supply shortage risks weighed on confidence. In this environment, despite an expected slowdown in growth, but with inflation continuing to rise, on 21 July, for the first time in eleven years, the ECB raised its key rate by 50 basis points to 0.5% and put the deposit facility rate at 0%. This temporarily stopped the depreciation of the euro against the dollar, which was at parity. However, the outlook for growth and inflation only deteriorated over the summer. PMI activity indicators all fell below the fifty mark (zone of contraction in activity) and, at the same time, inflation reached nearly ten percent in September. In addition to this, the euro continued to depreciate against the dollar (below parity), which also weighed on inflation via imported inflation, leading the ECB to increase its key rate by 75 basis points to 1.25% on 8 September. At the end of September, the 10-year German rate closed the third quarter at 2.11%, an increase of 74 basis points compared to June. The stock market lost 4.7% over the same period. However, despite these developments, growth remained positive until the third quarter, thanks in particular to the labour market, which remained buoyant. At the beginning of the fourth quarter, in order to counter the expected decline in oil prices in response to the slowdown in global growth - the IMF forecasts global growth of 2.7% in 2023 after 3.2% in 2022 - OPEC+ decided to cut production by 2 million barrels a day from November. Therefore, in order to ensure that inflation expectations remain anchored, especially as European governments announce more or less substantial economic support programmes, the ECB raised its key rate twice: for the first time, by 75 basis points at the end of October, and again in mid-December by 50 basis points (to 2.5%). At the end of October, Germany announced a €200 billion plan. Developments in 2022 and weak growth prospects for 2023 weighed on the stock market. However, thanks to the strong performance of the stock market in the fourth quarter (+12.5%), the decline was limited to 14.5% over the year. As for the German 10-year rate, after the ECB's announcements in mid-December (continued monetary tightening and reduction of the Asset Purchase Programme), it ended December on an upturn while closing the year at 2.56%, an increase of 274 basis points over the year.



Report of the Board of Directors

Candriam Equities L Biotechnology - Candriam Equities L Global Demography - Candriam Equities L Life Care - Candriam Equities L Meta Globe - Candriam Equities L Oncology Impact - Candriam Equities L Robotics & Innovative Technology - Candriam Equities L EMU Innovation - Candriam Equities L Europe Innovation - Candriam Equities L Europe Optimum Quality - Candriam Equities L Emerging Markets

Global

Global financial markets started the year on a false note. After finishing 2021 strong, the market was spooked by a more hawkish Federal Reserve. This resulted in a sell-off of long duration stocks and one of the most violent rotations to value in years. February was even worse due to Russia's invasion of Ukraine, leading to historic reactions and sanctions from the Western world and threatening both the geopolitical situation and the macroeconomic environment with energy and commodity prices going through the roof. Investors had to wait for the end of March to finally see a minor stock market recovery after the sell-off, as the FED embarked on its tightening campaign and raised interest rates to fight inflation. Almost all sectors dropped significantly in this context, except for energy and materials benefiting from increase commodity prices, and the more defensive utilities sector.

The second quarter wasn't easy either for equity markets, even after an already tough start to the year on the back of geopolitical tensions, inflation, and recession fears. The Federal Reserve said to do all it takes to get inflation under control, while energy prices remained high with a barrel of Brent crude oil ending the quarter at almost 115 US dollar. As a result, equity markets dropped significantly in the second quarter of the year. The energy sector continued to outperform the broader market, benefiting from high energy prices, and was the best performing sector in Q2. Also, the more defensive sectors, such as consumer staples and health care, outperformed the broader market, whereas consumer discretionary and information technology were the strongest underperformers.

In the third quarter, equity markets dropped for the third consecutive quarter. Despite the initial relief rally in July, investors were shocked by aggressive central banks trying to bring down sticky high inflation. Central banks increased hawkishness with policy rate hikes totalling 150 bps from the Fed and 125 bps from the European Central Bank. US 10-year yields ended the quarter significantly higher at more than 3.8%. As a result, equity markets dropped significantly in Q3 as well. Consumer discretionary and energy outperformed the broader market, whereas real estate and communication services were amongst the worst performing sectors. Both sectors were penalized by the strong increase in long-term interest rates.

Finally, global equity markets were able to rebound in the fourth quarter. October was marked by a strong rebound on the back of easing global supply-chain constraints, European governments taking steps to reduce the energy crisis and mitigate the recession risks. Meanwhile, inflation remained at high levels and growth fears were unchanged, suggesting a lot of bad news was already integrated in equity markets. The recovery continued into November and December, buoyed by easing US inflation figures and the first steps in China towards the end of the Zero Covid-19 policy. In the end, global equity markets ended the year with a strong loss, with Europe outperforming both the US and emerging markets. From a sector perspective, energy was the sole sector posting a positive performance over the year, whereas the defensive sectors utilities, health care and consumer staples were the strongest outperformers. Communication services, consumer discretionary, information technology and real estate were the strongest underperformers in 2022.

Europe

European equities closed the first quarter of 2022 lower. Europe having been a huge importer of oil and natural gas from Russia, the area became highly vulnerable to the Russia-Ukraine conflict. Consumer confidence moved sharply lower in March, hurt by the surge in prices. The European Commission announced ambitious plans to reduce imports of gas from Russia via more diversification, energy efficiency and by accelerating investments in wind and solar power plants.

European equities dropped again in the second quarter. In Europe, consumer confidence continued to fall dramatically. The reduction in gas supplies coming from Russia has driven prices up significantly and raised fears of outright shortages and rationing. Europe started to anticipate grave consequences from gas shortages for its economy. Even without gas rationing, the business surveys have started to weaken in Q2. At the same time, the difference between the rate at which the Italian and German governments could borrow has widened materially, as it did in the run up to the eurozone sovereign debt crisis about a decade ago.

Q3 was the third consecutive quarter of negative performance for the European equity market. In Europe, the energy crisis continued to dominate the headlines as Russia completely halted gas flows through the key Nord Stream 1 pipeline at the start of September. However, what had been considered the worst-case scenario for Europe didn't lead to new highs in gas prices. On the economic front, the situation continued to deteriorate during the third quarter, to the extent that a recession became the main scenario. Most economic data published in the quarter pointed to a slowdown, such as the euro area composite PMI business survey. Industrial production also dropped sharply in July. While growth was decelerating in Europe, this was not the case for inflation. In this context, the European Central Bank has become more hawkish, hiking its policy rate by 0.75% in September.

European equities finally closed the fourth quarter higher. Of the Stoxx600 companies that have reported Q3, 62% beat EPS estimates. The war in Ukraine and central banks' battle against inflation have been the main sources of equity markets' struggles. However, the final quarter of the year has at least brought some relief although China reopening did not go as expected. Regarding ECB, mid-December meeting marked an abrupt hawkish shift, even if some aspects feel odd. Consumer confidence in December improved more than expected.

US

US equity markets dropped in Q1. Russia's invasion of Ukraine resulted in a range of strict sanctions from the US and allies. President Biden banned Russian oil imports, while a slew of major international corporations withdrawn from Russia. The invasion amplified inflation pressure concerns through food and energy with the annual US CPI hitting almost 8% in February. In this context, the Federal Reserve raised interest rates. Energy and utility companies were amongst the strongest performers in relative terms over the month, outperforming a falling market with modest gains. Technology, communication services and consumer discretionary were amongst the weakest sectors.

US equities also fell in Q2. Investors were mainly focused on the evolution of inflation figures and the policy response of the US central bank for much of the period. The Federal Reserve admitted the task of bringing down inflation without triggering a recession would be challenging, although economic data continued to look quite robust. Declines affected all sectors although consumer staples and utilities were comparatively resilient. There were dramatic declines for some stocks, most notably in the media & entertainment and auto sectors.



Report of the Board of Directors

Candriam Equities L Biotechnology - Candriam Equities L Global Demography - Candriam Equities L Life Care - Candriam Equities L Meta Globe - Candriam Equities L Oncology Impact - Candriam Equities L Robotics & Innovative Technology - Candriam Equities L EMU Innovation - Candriam Equities L Europe Innovation - Candriam Equities L Europe Optimum Quality - Candriam Equities L Emerging Markets (Continued)

Q3 was the third consecutive quarter of negative performances for the US equity market. The hopes that arose on possible interest rate cuts from the Fed as of 2023 resulted in a strong market rebound in July, but those hopes were dashed by August's Jackson Hole summit of central bankers. This sent stock down. The Fed raised the federal funds rate by 75 basis points (bps) to 3.25% in September; the third consecutive 75bps increase. The communication services and real estate sectors were among the weakest sectors over the quarter. Consumer discretionary and energy proved the most resilient.

Q4 finally ended higher for US equity markets on the back of easing US inflation and a bit more visibility on the Fed's interest rate path going into 2023. Energy and materials remained among the best performing sectors over the quarter in the US, followed by industrials, and the defensive health care and consumer staples sectors. Communication services and consumer discretionary didn't participate in the market rebound and ended the quarter with negative performances.

Emerging Markets

The year 2022 proved to be one of the most challenging and volatile periods for emerging markets and the worst year since the Global Financial Crisis, where investors were faced with a confluence of global as well as EM specific factors impacting equity returns for the asset class.

The beginning of the year saw fierce headwinds for technology and long duration equities, as the FED and other global central banks embarked on one of the fastest rate hiking cycles, in an effort to control inflation. The strong USD that resulted from a risk-off environment was a strong headwind for EM equities throughout the year. Technology sector, which benefitted from a Covid related demand pull forward last year, was suddenly staring at prospects of a slowdown and inventory correction. While investors were still adapting to rising inflation and tightening liquidity conditions, Russian invasion of Ukraine, added further volatility to equity markets, with increasing geopolitical risk premium pushing equities lower. Russia which accounted for about 3% of benchmark index, was eventually excluded from emerging market indices on account of inaccessibility to markets. By mid-year, it had become clear that a combination of rising inflation, slowing demand on account of rising rates, and heightened geopolitical risks were key adversaries dominating global investing environment.

For emerging markets there were domestic challenges as well. China, the largest weight in EM index, was already struggling with a slowdown in consumer demand, and leverage problems at some of the largest real estate developers, when Covid cases continued to surge in the country. The country's adherence to Zero Covid policy in containment of large-scale outbursts of cases, came at the cost further impending consumer demand and disrupting essential supply chains of the manufacturing giant. With both China and USA facing slowdown concerns in domestic demand, export-oriented economies of South Korea and Taiwan, were not secluded from such concerns either.

In Emerging Europe, concerns around an energy crisis together with an ongoing Russia Ukraine crisis in the neighbourhood, increased risk premia for (emerging) European equities.

Amidst these uncertainties, there were only a few regions that were relatively resilient to external challenges. These included Mexico and India, both mainly defensive and domestic demand-oriented regions and both recently benefitting from supply chain reshoring efforts. The other relatively resilient markets were those benefitting from a higher commodity price environment including Indonesia in ASEAN, Brazil and South Africa. While these did relatively better for a good part of the year, it was not without uncertainties. In Brazil for instance, a very close election result saw the return of President Lula, however ensuing protests thereafter led to a market correction towards the end of the year.

The end of the year however was somewhat optimistic for Emerging Markets. Following the conclusion of the 20th party congress in China, in a sharp U turn to its previous Zero Covid policy, China decided to loosen restrictions and reopen the economy. This coincided with inflation figures in the USA to come below expectations in November, which eventually led to taking some strength off from a very strong US Dollar. The combination of the two, i.e. a weakening dollar, and China reopening were positive drivers that led to a relative recovery in Emerging market equities primarily led by Chinese equities which posted a strong rebound since November.

Candriam Equities L Australia

2022 Market Review

The Candriam Equities L - Australia portfolio generated performance for the year ending December 2022 of -1.72% (net of fees) versus the benchmark return of -7.17%, as measured by the S&P/ASX All Ordinaries Index.

At a sector level this year, the Portfolio benefited from the overweight positions in the Energy, Materials and Financials sectors. The underweight positions in the Industrials, Consumer Discretionary, Communication Services and Real Estate sectors also added value. Conversely, the overweight positions in the Health Care and Information Technology sectors detracted value. The underweight positions in the Consumer Staples and Utilities sectors also detracted value.

At a stock level, the overweight positions in IGO, Qantas, QBE Insurance, BHP, Allkem, Santos, Computershare, National Australia Bank and Webjet contributed to relative performance. The nil position in Wesfarmers also contributed to relative value. Conversely, the overweight positions in Aristocrat Leisure, Lynas Rare Earths, Xero, Block, Seek and Goodman Group detracted from relative performance. The underweight position in Woodside Energy Group and the nil positions in Westpac Bank, Fortescue Metals and Whitehaven Coal also detracted value.

The Australian economy has been markedly resilient to date, even with the rising rate environment and the energy shock the world is experiencing. However, the Ukraine invasion has triggered an energy and food inflation shock in the context of the aggressive front-loading of global and domestic interest rate rises. In response, economic activity is slowing.



Report of the Board of Directors

Candriam Equities L Australia (Continued)

We saw the economy's strength reflected in earnings for FY22, but some uncertainty is likely in FY23¹. That said, with Australia expected to outperform other advanced economies, and trading conditions still strong, we see some companies still capable of braving double-digit earnings growth, even if consensus is only expecting mid single-digit EPS growth for FY23 (S&P/ASX 200) as at mid-December.

Good Australian listed companies on average still have strong balance sheets, relatively low gearing, and enjoy an active and targeted consumer (particularly in leisure, travel and other service experiences). Australian resource companies are also benefitting from strong underlying demand for Australian commodities, from iron ore to lithium, base metals, rare earths, the energy complex, and even in soft commodities. Yes, there are inflationary pressures, and this will impact differently across sectors, though we see a range of quality leaders that are resilient in being able to pass these onto customers without impacting end demand.

Looking ahead, there are a number of secular themes driving activity and sustaining higher inflation. These include decarbonisation and the shift to renewable energy, the shift from globalisation to regionalisation, sovereign security and energy surety. These drivers, including the expected strong post-COVID Chinese recovery in 2023, are very supportive for a range of commodities in which Australia is dominant, providing a platform for higher commodity prices and hence earnings for the wider resources sector.

The relative outperformance expected for Australia's economy compared to advanced economies is also offering opportunities. Across a number of sectors, quality leaders that have relatively low elasticity of demand and can pass on the costs of inflation are offering earnings growth across the cycle. Finally, as the economy slows, there are opportunities in businesses that can deliver earnings growth across the economic cycle, be they in consumer staples, health care, specialist real estate or in companies with relatively unassailable global businesses for which there may be little competition, but significant pricing power. We are still seeing risk in sectors that are too cyclical, over-exposed to slowing economic growth, and whose earnings are adversely impacted by inflationary pressures. This includes construction and housing, and retailing and discretionary sectors generally, particularly those that are consumer facing.

Outlook

Market volatility, and concerns around inflation and rate rises remain an issue, but some clear caution in the rhetoric of central banks has given some hope that the hard steps may have already been taken in the battle against inflation. We are expecting more caution, perhaps even a pause in 2023, around rate rises as central banks look at the data for feedback on how successful they have been to date in the arrest of inflation. That said, we believe the bulk of the monetary tightening has already occurred.

We have clearly entered a period of slowing growth. However, given the relative strength of the Australian economy, the demand for our resources, low unemployment, and the current strength in the job market, Ausbil does not currently see Australia entering recession.

We think earnings growth will be hard to come by in 2023, but there will be some clear opportunities. Given the inflationary environment we are still in, resource companies generally (including energy and gold), general insurers and select diversified financials are expected to deliver positive earnings growth again in FY23, some delivering upward earnings revisions yet to be recognised in the consensus outlook. Quality leaders across the market, particularly those with relatively inelastic demand and the capacity to pass on inflationary rate costs are also expected to deliver superior earnings growth in FY23.

Conversely, we are expecting earnings downgrades in sectors where demand profile and margins are adversely impacted by higher cost inflation, rising funding costs, and a slowing economy. These include housing and construction, retailing, consumer discretionary and media.

In terms of preparing our thinking, today is when we need to be considering what sectors will benefit as inflation falls back, when central banks have ceased raising rates, and looking for the seeds of the next expansion. The complex issue is, when does this occur? Regardless, while we believe earnings growth in 2023 will undershoot the last two years, there are companies with earnings upside that are yet to be appreciated by consensus. There are also quality leaders whose earnings are immune to the vagaries of the cycle. This is where we are seeing the potential for outperformance in FY23.

¹ It is important to note that Australia reports financial years that end in 30 June each year, which is different to Europe where financials are reported on a calendar year basis ending on 31 December. For ease of reference, refers to the full year 12-months of results that are reported as at 30 June each year. Market consensus numbers also follow this pattern.



Report of the Board of Directors

Candriam Equities L Risk Arbitrage Opportunities

Despite a promising start to the year, the global volume of announced mergers and acquisitions has only reached \$3.6 billion by the end of 2022. There has been a sharp decline in activity across the three main regions, with activity at pre-pandemic levels. The decline in activity was more pronounced in the second half of the year, with the inflationary environment and geopolitical tensions contributing significantly to the slowdown.

2022 is also a year of falling equity and credit markets. As is often the case, our spreads initially reacted to de-risking movements by widening in a uniform manner, regardless of the maturity, sector or risk of the transaction. Over the summer, with the maturity of many deals, risk arbitrage spreads tightened significantly.

Deals above \$20 billion accounted for a smaller share of deal volume in 2022 than in the past decade, while deals between \$10 billion and \$20 billion and below \$10 billion were more or less in line with long-term averages. The ten largest M&A deals announced in North America in 2022 were dominated by the technology and healthcare sectors. The deal failure rate increased significantly in 2022 to about 11%. As usual, we have a failure rate well below this average.

We expect activity to rebound during 2023. Our portfolio remains well positioned and diversified on short transactions with still attractive returns in line with our management objectives.

The fund ended the year in negative territory.

None of the issuers in the portfolio has suffered a credit event.

The Board of Directors

Luxembourg, March 30, 2023.



Audit report

To the Shareholders of
Candriam Equities L

Our opinion

In our opinion, the accompanying financial statements give a true and fair view of the financial position of Candriam Equities L (the “Fund”) and of each of its sub-funds as at 31 December 2022, and of the results of their operations and changes in their net assets for the year then ended in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the financial statements.

What we have audited

The Fund’s financial statements comprise:

- the statement of net assets as at 31 December 2022;
- the statement of changes in net assets for the year then ended;
- the investment portfolio as at 31 December 2022; and
- the notes to the financial statements - Schedule of derivative instruments and the other notes to the financial statements, which include a summary of significant accounting policies.

Basis for opinion

We conducted our audit in accordance with the Law of 23 July 2016 on the audit profession (Law of 23 July 2016) and with International Standards on Auditing (ISAs) as adopted for Luxembourg by the “Commission de Surveillance du Secteur Financier” (CSSF). Our responsibilities under the Law of 23 July 2016 and ISAs as adopted for Luxembourg by the CSSF are further described in the “Responsibilities of the “Réviseur d’entreprises agréé” for the audit of the financial statements” section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

We are independent of the Fund in accordance with the International Code of Ethics for Professional Accountants, including International Independence Standards, issued by the International Ethics Standards Board for Accountants (IESBA Code) as adopted for Luxembourg by the CSSF together with the ethical requirements that are relevant to our audit of the financial statements. We have fulfilled our other ethical responsibilities under those ethical requirements.

Other information

The Board of Directors of the Fund is responsible for the other information. The other information comprises the information stated in the annual report but does not include the financial statements and our audit report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

*PricewaterhouseCoopers, Société coopérative, 2 rue Gerhard Mercator, B.P. 1443, L-1014 Luxembourg
T : +352 494848 1, F : +352 494848 2900, www.pwc.lu*

*Cabinet de révision agréé. Expert-comptable (autorisation gouvernementale n°10028256)
R.C.S. Luxembourg B 65 477 - TVA LU25482518*



In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Board of Directors of the Fund for the financial statements

The Board of Directors of the Fund is responsible for the preparation and fair presentation of the financial statements in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the financial statements, and for such internal control as the Board of Directors of the Fund determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors of the Fund is responsible for assessing the Fund's and each of its sub-funds' ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors of the Fund either intends to liquidate the Fund or close any of its sub-funds or to cease operations, or has no realistic alternative but to do so.

Responsibilities of the “Réviseur d’entreprises agréé” for the audit of the financial statements

The objectives of our audit are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an audit report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Law of 23 July 2016 and with ISAs as adopted for Luxembourg by the CSSF will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with the Law of 23 July 2016 and with ISAs as adopted for Luxembourg by the CSSF, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control;
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors of the Fund;



- conclude on the appropriateness of the Board of Directors of the Fund's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's or any of its sub-funds' ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our audit report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our audit report. However, future events or conditions may cause the Fund or any of its sub-funds to cease to continue as a going concern;
- evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

PricewaterhouseCoopers, Société coopérative
Represented by

Luxembourg, 6 April 2023

Sébastien Sadzot



Statement of net assets as at December 31, 2022

		Candriam Equities	Candriam Equities	Candriam Equities
		L Australia	L Biotechnology	L Emerging Markets
		AUD	USD	EUR
Assets				
Investment portfolio at market value	2a	226,130,392	1,736,164,766	1,180,315,615
Cash at bank and broker	12	1,857,040	36,657,009	25,332,147
Receivable on subscriptions		96,179	691,215	603,617
Receivable on CFD		0	0	0
Dividends receivable on CFD		0	0	0
Receivable on reverse repurchase agreements		0	0	0
Interest and dividends receivable, net		36,038	41,108	1,151,245
Net unrealised appreciation on forward foreign exchange contracts	2g	0	96,499	0
Net unrealised appreciation on futures	2e	0	0	0
Net unrealised appreciation on CFD	2f	0	0	0
Other assets		333	115,514	0
Total assets		228,119,982	1,773,766,111	1,207,402,624
Liabilities				
Bank overdraft		2	0	3
Payable on investments purchased		0	0	0
Payable on redemptions		280,101	776,799	293,483
Payable on CFD		0	0	0
Dividends payable on CFD		0	0	0
Net unrealised depreciation on forward foreign exchange contracts	2g	0	0	535
Management fees payable	3	239,875	1,530,953	552,933
Operating and Administrative Expenses payable	5	52,034	377,730	330,141
Performance fees payable	6	0	3,347,523	0
Subscription tax payable	7	106,052	493,644	361,363
Other liabilities		0	0	1,420,575
Total liabilities		678,064	6,526,649	2,959,033
Total net assets		227,441,918	1,767,239,462	1,204,443,591



Statement of net assets as at December 31, 2022

		Candriam Equities L EMU Innovation	Candriam Equities L Europe Innovation	Candriam Equities L Europe Optimum Quality
		EUR	EUR	EUR
Assets				
Investment portfolio at market value	2a	57,200,929	1,221,215,467	752,582,270
Cash at bank and broker	12	1,601,063	21,836,431	35,261,897
Receivable on subscriptions		0	353,420	254,003
Receivable on CFD		0	0	0
Dividends receivable on CFD		0	0	0
Receivable on reverse repurchase agreements		0	0	0
Interest and dividends receivable, net		368	412,829	144,254
Net unrealised appreciation on forward foreign exchange contracts	2g	0	0	0
Net unrealised appreciation on futures	2e	0	0	4,220,160
Net unrealised appreciation on CFD	2f	0	0	0
Other assets		135,779	585,302	1,151,914
Total assets		58,938,139	1,244,403,449	793,614,498
Liabilities				
Bank overdraft		0	0	0
Payable on investments purchased		0	0	0
Payable on redemptions		364	684,871	355,483
Payable on CFD		0	0	0
Dividends payable on CFD		0	0	0
Net unrealised depreciation on forward foreign exchange contracts	2g	0	2,153	0
Management fees payable	3	9,405	1,222,936	866,813
Operating and Administrative Expenses payable	5	10,183	282,316	184,394
Performance fees payable	6	0	0	236
Subscription tax payable	7	1,565	611,325	584,342
Other liabilities		0	0	0
Total liabilities		21,517	2,803,601	1,991,268
Total net assets		58,916,622	1,241,599,848	791,623,230



Statement of net assets as at December 31, 2022

		Candriam Equities L Global Demography	Candriam Equities L Life Care	Candriam Equities L Meta Globe
		EUR	USD	USD
Assets				
Investment portfolio at market value	2a	1,228,848,586	608,175,147	3,867,811
Cash at bank and broker	12	96,213,364	3,692,345	300,268
Receivable on subscriptions		880,262	0	0
Receivable on CFD		0	0	0
Dividends receivable on CFD		0	0	0
Receivable on reverse repurchase agreements		0	0	0
Interest and dividends receivable, net		577,167	316,723	1,187
Net unrealised appreciation on forward foreign exchange contracts	2g	0	0	0
Net unrealised appreciation on futures	2e	0	0	0
Net unrealised appreciation on CFD	2f	0	0	0
Other assets		231,433	0	0
Total assets		1,326,750,812	612,184,215	4,169,266
Liabilities				
Bank overdraft		0	0	0
Payable on investments purchased		0	314,620	0
Payable on redemptions		618,499	0	0
Payable on CFD		0	0	0
Dividends payable on CFD		0	0	0
Net unrealised depreciation on forward foreign exchange contracts	2g	0	0	0
Management fees payable	3	1,583,062	893	1
Operating and Administrative Expenses payable	5	318,019	34,198	702
Performance fees payable	6	0	0	0
Subscription tax payable	7	1,119,824	15,386	105
Other liabilities		0	0	0
Total liabilities		3,639,404	365,097	808
Total net assets		1,323,111,408	611,819,118	4,168,458



Statement of net assets as at December 31, 2022

		Candriam Equities L Oncology Impact	Candriam Equities L Risk Arbitrage Opportunities	Candriam Equities L Robotics & Innovative Technology
		USD	EUR	USD
Assets				
Investment portfolio at market value	2a	1,806,317,246	23,691,886	1,196,127,407
Cash at bank and broker	12	134,148,137	7,836,331	60,432,516
Receivable on subscriptions		2,052,862	0	250,647
Receivable on CFD		0	135,046	0
Dividends receivable on CFD		0	6,238	0
Receivable on reverse repurchase agreements		0	23,104,500	0
Interest and dividends receivable, net		840,137	38,081	302,625
Net unrealised appreciation on forward foreign exchange contracts	2g	521,941	459,189	4,890
Net unrealised appreciation on futures	2e	0	0	0
Net unrealised appreciation on CFD	2f	0	51,705	0
Other assets		0	0	966
Total assets		1,943,880,323	55,322,976	1,257,119,051
Liabilities				
Bank overdraft		0	5,210	0
Payable on investments purchased		9,981,912	0	0
Payable on redemptions		1,364,901	153,953	182,548
Payable on CFD		0	10,879	0
Dividends payable on CFD		0	5,288	0
Net unrealised depreciation on forward foreign exchange contracts	2g	0	0	0
Management fees payable	3	968,982	4,777	232,545
Operating and Administrative Expenses payable	5	330,317	10,538	120,527
Performance fees payable	6	0	77	0
Subscription tax payable	7	96,849	1,378	43,439
Other liabilities		10,756	0	0
Total liabilities		12,753,717	192,100	579,059
Total net assets		1,931,126,606	55,130,876	1,256,539,992



Statement of net assets as at December 31, 2022

		Combined
		EUR
Assets		
Investment portfolio at market value	2a	9,621,038,492
Cash at bank and broker	12	409,669,090
Receivable on subscriptions		4,958,436
Receivable on CFD		135,046
Dividends receivable on CFD		6,238
Receivable on reverse repurchase agreements		23,104,500
Interest and dividends receivable, net		3,753,993
Net unrealised appreciation on forward foreign exchange contracts	2g	1,043,241
Net unrealised appreciation on futures	2e	4,220,160
Net unrealised appreciation on CFD	2f	51,705
Other assets		2,213,780
Total assets		10,070,194,681
Liabilities		
Bank overdraft		5,214
Payable on investments purchased		9,647,723
Payable on redemptions		4,462,428
Payable on CFD		10,879
Dividends payable on CFD		5,288
Net unrealised depreciation on forward foreign exchange contracts	2g	2,688
Management fees payable	3	6,953,486
Operating and Administrative Expenses payable	5	1,977,719
Performance fees payable	6	3,136,900
Subscription tax payable	7	3,355,686
Other liabilities		1,430,653
Total liabilities		30,988,664
Total net assets		10,039,206,017



Statement of changes in net assets for the year ended December 31, 2022

		Candriam Equities L Australia	Candriam Equities L Biotechnology	Candriam Equities L Emerging Markets
		AUD	USD	EUR
Net assets at the beginning of the year		186,504,713	1,866,851,208	1,913,356,155
Income				
Dividends, net		6,630,516	8,685,511	39,218,522
Interest received on CFD		0	0	0
Interest on securities lending	9	0	127,572	43,252
Bank interest		10,259	368,937	242,821
Dividends received on CFD		0	0	0
Interest on reverse repurchase agreements		0	0	0
Other income		0	503	1,109
Total income		6,640,775	9,182,523	39,505,704
Expenses				
Management fees	3	2,645,626	16,030,115	7,469,158
Performance fees	6	0	4,808,395	0
Operating and Administrative Expenses	5	556,012	4,020,113	4,681,461
Depository fees	5	9,391	72,262	72,286
Subscription tax	7	165,046	898,102	619,282
Transaction costs	2j	99,230	702,928	7,543,057
Interest paid on CFD		0	0	0
Interest on reverse repurchase agreements		0	0	14
Bank interest		0	48,558	129,040
Other expenses		0	46	248,749
Total expenses		3,475,305	26,580,519	20,763,047
Net income / (loss) from investments		3,165,470	(17,397,996)	18,742,657
Net realised gain / (loss) on sales of investments	2b	7,986,717	(6,700,144)	(112,949,354)
Net realised gain / (loss) on options	2e	0	0	0
Net realised gain / (loss) on forward foreign exchange contracts	2g	0	(7,464,569)	(1,146,676)
Net realised gain / (loss) on futures	2e	0	0	0
Net realised gain / (loss) on CFD	2f	0	0	0
Net realised gain / (loss) on foreign exchange		(81,694)	(9,062,558)	71,689,472
Net realised gain / (loss)		11,070,493	(40,625,267)	(23,663,901)
Change in net unrealised appreciation / depreciation on investments	2a	(15,024,136)	15,834,262	(433,438,513)
Change in net unrealised appreciation / depreciation on forward foreign exchange contracts	2g	0	(713,320)	(518)
Change in net unrealised appreciation / depreciation on futures	2e	0	0	0
Change in net unrealised appreciation / depreciation on CFD	2f	0	0	0
Net increase / (decrease) in net assets as a result of operations		(3,953,643)	(25,504,325)	(457,102,932)
Evolution of the capital				
Subscriptions of shares		95,961,229	504,175,461	380,525,384
Redemptions of shares		(50,034,441)	(577,478,583)	(622,388,458)
Dividends distributed	10	(1,035,940)	(804,299)	(9,946,558)
Currency translation		0	0	0
Net assets at the end of the year		227,441,918	1,767,239,462	1,204,443,591



Statement of changes in net assets for the year ended December 31, 2022

		Candriam Equities L EMU Innovation	Candriam Equities L EuropeL Innovation	Candriam Equities L EuropeL Optimum Quality
		EUR	EUR	EUR
Net assets at the beginning of the year		87,250,657	1,986,442,269	1,041,629,101
Income				
Dividends, net		868,581	25,103,356	18,627,074
Interest received on CFD		0	0	0
Interest on securities lending	9	3,090	148,932	45,156
Bank interest		2,064	45,885	56,046
Dividends received on CFD		0	0	0
Interest on reverse repurchase agreements		0	0	0
Other income		577	1,167	2,524
Total income		874,312	25,299,340	18,730,800
Expenses				
Management fees	3	150,407	15,431,153	9,759,212
Performance fees	6	0	0	1,436
Operating and Administrative Expenses	5	103,492	3,771,717	2,214,210
Depository fees	5	2,379	66,301	36,564
Subscription tax	7	5,143	986,632	830,602
Transaction costs	2j	92,798	774,261	976,717
Interest paid on CFD		0	0	0
Interest on reverse repurchase agreements		0	0	0
Bank interest		3,258	38,089	149,982
Other expenses		2,116	33,028	24,537
Total expenses		359,593	21,101,181	13,993,260
Net income / (loss) from investments		514,719	4,198,159	4,737,540
Net realised gain / (loss) on sales of investments	2b	2,151,267	19,441,201	(2,663,891)
Net realised gain / (loss) on options	2e	0	0	25,529,309
Net realised gain / (loss) on forward foreign exchange contracts	2g	0	191,535	0
Net realised gain / (loss) on futures	2e	0	0	19,968,848
Net realised gain / (loss) on CFD	2f	0	0	0
Net realised gain / (loss) on foreign exchange		554,197	11,997,828	7,368,633
Net realised gain / (loss)		3,220,183	35,828,723	54,940,439
Change in net unrealised appreciation / depreciation on investments	2a	(17,639,449)	(487,604,554)	(174,408,114)
Change in net unrealised appreciation / depreciation on forward foreign exchange contracts	2g	0	18,892	0
Change in net unrealised appreciation / depreciation on futures	2e	0	0	8,836,560
Change in net unrealised appreciation / depreciation on CFD	2f	0	0	0
Net increase / (decrease) in net assets as a result of operations		(14,419,266)	(451,756,939)	(110,631,115)
Evolution of the capital				
Subscriptions of shares		24,581,130	312,576,867	68,954,856
Redemptions of shares		(38,495,899)	(598,932,755)	(203,573,099)
Dividends distributed	10	0	(6,729,594)	(4,756,513)
Currency translation		0	0	0
Net assets at the end of the year		58,916,622	1,241,599,848	791,623,230



Statement of changes in net assets for the year ended December 31, 2022

		Candriam Equities L Global Demography	Candriam Equities L Japan (see note 1)	Candriam Equities L Life Care
		EUR	JPY	USD
Net assets at the beginning of the year		1,416,644,708	17,547,203,150	19,087,939
Income				
Dividends, net		16,127,346	211,572,249	4,961,340
Interest received on CFD		0	0	0
Interest on securities lending	9	62,868	2,867,578	0
Bank interest		285,372	0	59,719
Dividends received on CFD		0	0	0
Interest on reverse repurchase agreements		0	0	0
Other income		9,528	0	1,295
Total income		16,485,114	214,439,827	5,022,354
Expenses				
Management fees	3	17,639,313	20,553,418	10,088
Performance fees	6	1	0	0
Operating and Administrative Expenses	5	3,715,219	14,417,705	288,004
Depository fees	5	59,630	295,002	20,060
Subscription tax	7	1,549,367	2,615,265	59,246
Transaction costs	2j	1,232,180	6,167,810	223,677
Interest paid on CFD		0	0	0
Interest on reverse repurchase agreements		0	0	0
Bank interest		252,667	50,719	10,685
Other expenses		10,050	0	118
Total expenses		24,458,427	44,099,919	611,878
Net income / (loss) from investments		(7,973,313)	170,339,908	4,410,476
Net realised gain / (loss) on sales of investments	2b	1,739,572	958,067,172	2,101,540
Net realised gain / (loss) on options	2e	0	0	(6)
Net realised gain / (loss) on forward foreign exchange contracts	2g	0	0	0
Net realised gain / (loss) on futures	2e	0	0	0
Net realised gain / (loss) on CFD	2f	0	0	0
Net realised gain / (loss) on foreign exchange		74,443,889	75,751	(5,381,116)
Net realised gain / (loss)		68,210,148	1,128,482,831	1,130,894
Change in net unrealised appreciation / depreciation on investments	2a	(292,517,191)	(1,036,144,383)	(14,559,858)
Change in net unrealised appreciation / depreciation on forward foreign exchange contracts	2g	0	0	0
Change in net unrealised appreciation / depreciation on futures	2e	0	0	0
Change in net unrealised appreciation / depreciation on CFD	2f	0	0	0
Net increase / (decrease) in net assets as a result of operations		(224,307,043)	92,338,448	(13,428,964)
Evolution of the capital				
Subscriptions of shares		381,512,028	127,445,509	624,316,114
Redemptions of shares		(245,534,856)	(17,749,409,733)	(18,155,971)
Dividends distributed	10	(5,203,429)	(17,577,374)	0
Currency translation		0	0	0
Net assets at the end of the year		1,323,111,408	0	611,819,118



Statement of changes in net assets for the year ended December 31, 2022

		Candriam Equities L Meta	Candriam Equities L Oncology Impact	Candriam Equities L Risk Arbitrage Opportunities
		USD	USD	EUR
Net assets at the beginning of the year		0	2,425,748,609	79,103,061
Income				
Dividends, net		6,075	15,035,211	229,168
Interest received on CFD		0	0	116,683
Interest on securities lending	9	0	115	169
Bank interest		1,171	1,101,615	46,841
Dividends received on CFD		0	0	3,436,948
Interest on reverse repurchase agreements		0	0	17,110
Other income		0	15	802
Total income		7,246	16,136,956	3,847,721
Expenses				
Management fees	3	5	11,004,896	72,065
Performance fees	6	0	0	5,955
Operating and Administrative Expenses	5	2,054	3,657,146	138,953
Depository fees	5	90	82,235	3,224
Subscription tax	7	205	371,539	6,818
Transaction costs	2j	1,364	450,012	119,727
Interest paid on CFD		0	0	458,491
Interest on reverse repurchase agreements		0	0	0
Bank interest		61	57,342	38,357
Other expenses		0	16,052	34,583
Total expenses		3,779	15,639,222	878,173
Net income / (loss) from investments		3,467	497,734	2,969,548
Net realised gain / (loss) on sales of investments	2b	33,430	(64,212,319)	(1,422,430)
Net realised gain / (loss) on options	2e	0	0	0
Net realised gain / (loss) on forward foreign exchange contracts	2g	3,917	(26,246,070)	(3,803,892)
Net realised gain / (loss) on futures	2e	0	0	0
Net realised gain / (loss) on CFD	2f	0	0	(1,360,605)
Net realised gain / (loss) on foreign exchange		7,584	(5,685,771)	4,438,479
Net realised gain / (loss)		48,398	(95,646,426)	821,100
Change in net unrealised appreciation / depreciation on investments	2a	115,060	(156,365,396)	(2,731,094)
Change in net unrealised appreciation / depreciation on forward foreign exchange contracts	2g	0	(1,557,110)	315,779
Change in net unrealised appreciation / depreciation on futures	2e	0	0	0
Change in net unrealised appreciation / depreciation on CFD	2f	0	0	(125,770)
Net increase / (decrease) in net assets as a result of operations		163,458	(253,568,932)	(1,719,985)
Evolution of the capital				
Subscriptions of shares		4,005,000	445,661,117	8,178,979
Redemptions of shares		0	(675,687,450)	(30,431,179)
Dividends distributed	10	0	(11,026,738)	0
Currency translation		0	0	0
Net assets at the end of the year		4,168,458	1,931,126,606	55,130,876



Statement of changes in net assets for the year ended December 31, 2022

		Candriam Equities L Robotics & Innovative Technology	Combined
		USD	EUR
Net assets at the beginning of the year		659,073,624	11,148,710,884
Income			
Dividends, net		7,596,042	139,888,245
Interest received on CFD		0	116,683
Interest on securities lending	9	43,582	484,317
Bank interest		253,333	2,357,860
Dividends received on CFD		0	3,436,948
Interest on reverse repurchase agreements		0	17,110
Other income		350	17,734
Total income		7,893,307	146,318,897
Expenses			
Management fees	3	3,762,141	81,214,439
Performance fees	6	0	4,512,798
Operating and Administrative Expenses	5	1,463,583	23,917,427
Depository fees	5	51,503	460,347
Subscription tax	7	201,024	5,554,999
Transaction costs	2j	154,012	12,281,073
Interest paid on CFD		0	458,491
Interest on reverse repurchase agreements		0	14
Bank interest		46,177	764,316
Other expenses		3,872	371,885
Total expenses		5,682,312	129,535,789
Net income / (loss) from investments		2,210,995	16,783,108
Net realised gain / (loss) on sales of investments	2b	(11,416,222)	(156,962,320)
Net realised gain / (loss) on options	2e	0	25,529,303
Net realised gain / (loss) on forward foreign exchange contracts	2g	(13,791,635)	(49,264,404)
Net realised gain / (loss) on futures	2e	0	19,968,848
Net realised gain / (loss) on CFD	2f	0	(1,360,605)
Net realised gain / (loss) on foreign exchange		(1,476,323)	150,203,896
Net realised gain / (loss)		(24,473,185)	4,897,826
Change in net unrealised appreciation / depreciation on investments	2a	(426,421,888)	(1,970,009,759)
Change in net unrealised appreciation / depreciation on forward foreign exchange contracts	2g	(1,011,985)	(2,741,429)
Change in net unrealised appreciation / depreciation on futures	2e	0	8,836,560
Change in net unrealised appreciation / depreciation on CFD	2f	0	(125,770)
Net increase / (decrease) in net assets as a result of operations		(451,907,058)	(1,959,142,572)
Evolution of the capital			
Subscriptions of shares		1,287,421,472	3,923,222,977
Redemptions of shares		(237,935,650)	(3,311,410,992)
Dividends distributed	10	(112,396)	(38,610,088)
Currency translation		0	276,435,808
Net assets at the end of the year		1,256,539,992	10,039,206,017



Statistics

Candriam Equities L Australia

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
Total net assets			AUD		227,441,918	186,504,713	171,357,828
C	LU0078775011	Capitalisation	AUD	51,749.04	1,835.48	1,867.64	1,526.57
C	LU0078775284	Distribution	AUD	34,378.61	858.41	905.55	760.40
C - EUR - Unhedged	LU0256780106	Capitalisation	EUR	69,124.84	291.47	299.13	238.74
I	LU0133348622	Capitalisation	AUD	22,433.14	2,243.37	2,256.78	1,823.76
I - EUR - Unhedged	LU0256781096	Capitalisation	EUR	33,173.86	294.72	298.95	235.84
N	LU0133347731	Capitalisation	AUD	733.91	1,634.62	1,670.95	1,372.03
N - EUR - Unhedged	LU0256780874	Capitalisation	EUR	3,946.34	273.22	281.60	225.73
R	LU0942225839	Capitalisation	AUD	11,220.07	207.10	208.87	169.22
V	LU0317020385	Capitalisation	AUD	1.00	1,723.88	1,731.85	1,397.11
Z	LU0240973742	Capitalisation	AUD	166.85	2,450.56	2,451.59	1,970.30

Candriam Equities L Biotechnology

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
Total net assets			USD		1,767,239,462	1,866,851,208	2,084,416,473
C	LU0108459040	Capitalisation	USD	464,840.81	771.93	783.64	805.04
C	LU0108459552	Distribution	USD	167,441.56	713.31	728.29	753.61
C - EUR - Hedged	LU1120766206	Capitalisation	EUR	320,936.74	185.53	195.73	203.27
C - EUR - Unhedged	LU1120766388	Capitalisation	EUR	874,412.25	204.95	195.36	186.62
I	LU0133360163	Capitalisation	USD	6,143.08	5,132.42	5,263.87	5,351.64
I - CHF - Hedged	LU2478813442	Capitalisation	CHF	181.90	1,512.61	-	-
I - EUR - Hedged	LU1006082199	Capitalisation	EUR	9,656.05	1,938.19	2,051.00	2,108.17
I - EUR - Unhedged	LU1120766032	Capitalisation	EUR	25,466.31	2,049.28	1,972.79	1,863.61
I - GBP - Unhedged	LU1269737059	Capitalisation	GBP	155.86	3,271.81	2,983.63	3,033.12
L	LU0574798848	Capitalisation	USD	14,552.33	756.03	768.69	790.97
N	LU0133359157	Capitalisation	USD	79,742.66	552.73	563.70	581.84
R	LU0942225912	Capitalisation	USD	688,456.92	242.19	243.95	248.70
R - CHF - Hedged	LU1269736754	Capitalisation	CHF	2,167.32	193.68	202.42	209.18
R - EUR - Hedged	LU1708110975	Capitalisation	EUR	50,486.61	192.25	200.07	206.27
R - EUR - Unhedged	LU1269736838	Capitalisation	EUR	40,051.62	298.55	282.20	267.39
R - GBP - Unhedged	LU1269736911	Capitalisation	GBP	1,437.48	341.80	305.75	308.83
R2	LU1397644557	Capitalisation	USD	133,372.95	205.32	206.03	209.24
R2	LU1397644631	Distribution	USD	203,057.17	222.05	223.99	229.05
R2 - EUR - Unhedged	LU1397644805	Capitalisation	EUR	857.88	233.12	219.55	207.23
S - JPY - Unhedged	LU1820816558	Capitalisation	JPY	124,035.60	255,437.00	223,650.00	203,591.00
V	LU0317020203	Capitalisation	USD	118,095.21	1,872.73	1,916.83	1,947.80
V2	LU2026682919	Capitalisation	USD	33,460.49	1,665.09	1,673.04	1,701.30
Z	LU0240982651	Capitalisation	USD	43,407.00	2,082.37	2,078.74	2,100.13

Candriam Equities L Emerging Markets

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
Total net assets			EUR		1,204,443,591	1,913,356,155	1,791,327,148
BF	LU1904319164	Capitalisation	EUR	68,118.00	1,746.28	2,293.30	2,179.06
BF	LU1397645364	Distribution	EUR	160,640.43	1,346.90	1,811.40	1,754.65
C	LU0056052961	Capitalisation	EUR	260,127.01	837.99	1,120.67	1,084.50
C	LU0056053001	Distribution	EUR	178,008.29	559.18	766.35	756.28
C - USD - Hedged	LU1293437023	Capitalisation	USD	420.00	172.29	225.74	216.58
I	LU0133355080	Capitalisation	EUR	17,805.88	982.70	1,299.12	1,242.12
I	LU1269737562	Distribution	EUR	627.00	1,599.54	2,166.05	2,112.61
I - GBP - Unhedged	LU1269737489	Capitalisation	GBP	1.00	2,479.49	3,107.94	3,196.43
L	LU0574798921	Capitalisation	EUR	8,066.23	824.53	1,103.43	1,068.88
N	LU0133352731	Capitalisation	EUR	2,363.03	753.96	1,011.59	982.01
P	LU0596238260	Capitalisation	EUR	153,316.52	1,037.57	1,365.78	1,300.79
R	LU0942226134	Capitalisation	EUR	200.47	140.74	186.54	178.90
R - GBP - Unhedged	LU1269737307	Capitalisation	GBP	4.00	252.46	317.30	327.42
R2	LU1397645018	Capitalisation	EUR	661,184.41	158.23	208.93	199.61
R2	LU1397645109	Distribution	EUR	286,417.88	156.00	210.99	205.50
V	LU0317020112	Capitalisation	EUR	2.00	1,001.61	1,320.11	1,259.74



Statistics

Candriam Equities L Emerging Markets (Continued)

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
V2	LU1397645281	Capitalisation	EUR	651.93	1,533.78	2,022.74	1,930.33
Z	LU0240980523	Capitalisation	EUR	185,082.27	1,162.68	1,526.78	1,450.63

Candriam Equities L EMU Innovation

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
Total net assets			EUR		58,916,622	87,250,657	79,641,174
C	LU0317020898	Capitalisation	EUR	2,977.64	114.59	147.53	117.33
I	LU0317021433	Capitalisation	EUR	10,675.36	1,270.96	1,618.68	1,284.39
R	LU1293437379	Capitalisation	EUR	3,488.39	167.13	213.38	168.24
S	LU0317021276	Capitalisation	EUR	5,079.67	1,695.29	2,152.60	1,687.93
Z	LU0317021359	Capitalisation	EUR	23,632.36	1,515.42	1,919.43	1,501.35

Candriam Equities L Europe Innovation

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
Total net assets			EUR		1,241,599,848	1,986,442,269	1,266,000,465
C	LU0344046155	Capitalisation	EUR	175,181.00	2,754.40	3,610.88	2,840.15
C	LU0344046239	Distribution	EUR	750,205.12	253.33	341.07	273.20
C - USD - Hedged	LU1293437882	Capitalisation	USD	9,276.98	160.22	203.13	158.36
I	LU0344046668	Capitalisation	EUR	54,805.21	2,412.31	3,127.85	2,447.64
I - USD - Hedged	LU1293437965	Capitalisation	USD	514.93	1,229.84	1,543.02	-
L	LU0654531002	Capitalisation	EUR	16,163.12	2,715.38	3,563.70	2,806.59
N	LU0344046312	Capitalisation	EUR	330,320.64	83.08	109.39	86.41
R	LU1293438005	Capitalisation	EUR	136,994.30	251.48	327.03	255.16
R2	LU1397646503	Capitalisation	EUR	80,332.43	206.64	267.71	208.08
R2	LU1397646685	Distribution	EUR	154,247.55	205.00	272.56	215.64
S	LU2026683057	Capitalisation	EUR	12,569.69	1,525.81	1,975.42	1,534.27
V	LU0344046403	Capitalisation	EUR	8,681.63	1,665.11	2,153.57	1,683.83
V2	LU2026683131	Capitalisation	EUR	44,667.98	1,981.72	2,565.69	1,992.70
Z	LU0344046585	Capitalisation	EUR	63,112.18	2,514.23	3,240.54	2,505.55

Candriam Equities L Europe Optimum Quality

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
Total net assets			EUR		791,623,230	1,041,629,101	943,704,726
C	LU0304859712	Capitalisation	EUR	2,983,529.51	142.46	161.04	136.35
C	LU0304860058	Distribution	EUR	1,760,756.04	92.35	107.17	92.55
I	LU0304860645	Capitalisation	EUR	148,301.52	214.77	239.99	199.47
I	LU1269737729	Distribution	EUR	1,029.89	1,628.06	1,866.62	1,586.42
L	LU0574799226	Capitalisation	EUR	184,842.81	140.28	158.75	134.57
N	LU0304860561	Capitalisation	EUR	10,742.68	164.12	186.29	158.39
R	LU1293438187	Capitalisation	EUR	1,564.62	195.86	219.36	184.03
R2	LU1397646842	Capitalisation	EUR	4,267.33	190.58	212.84	178.06
R2	LU1397646925	Distribution	EUR	2,132.34	180.81	207.19	176.72
V	LU0317019536	Capitalisation	EUR	1.50	1,935.67	2,159.41	1,788.88
Z	LU0317112661	Capitalisation	EUR	612,667.58	230.56	256.17	213.20

Candriam Equities L Global Demography

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
Total net assets			EUR		1,323,111,408	1,416,644,708	1,013,163,558
C	LU0654531184	Capitalisation	EUR	2,597,644.58	252.87	299.30	231.08
C	LU0654531267	Distribution	EUR	1,501,077.01	216.68	260.52	204.15
I	LU0654531341	Capitalisation	EUR	21,785.03	2,776.08	3,248.80	2,480.62
I - USD - Unhedged	LU2328285445	Capitalisation	USD	1.00	1,215.25	1,516.52	-
L	LU0654531697	Capitalisation	EUR	344,945.99	250.32	296.56	229.19
N	LU0654531424	Capitalisation	EUR	7,714.43	246.89	293.40	227.43
R	LU1598288089	Capitalisation	EUR	38,142.88	240.85	282.69	216.43
R2	LU1397647733	Capitalisation	EUR	149,923.44	226.56	264.92	202.06
R2	LU1397647816	Distribution	EUR	5,077.04	223.22	265.05	205.14



Statistics

Candriam Equities L Global Demography (Continued)

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
V2 - USD - Unhedged	LU2439121216	Capitalisation	USD	73,853.98	1,426.55	-	-
Z	LU1397647907	Capitalisation	EUR	16,809.13	2,929.80	3,408.05	2,585.83

Candriam Equities L Japan (see note 1)

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
Total net assets			JPY		-	17,547,203,150	16,955,877,561
C	LU0064109019	Capitalisation	JPY	-	-	26,018.00	24,063.00
C	LU0064109449	Distribution	JPY	-	-	20,092.00	18,984.00
I	LU0133346501	Capitalisation	JPY	-	-	31,361.00	28,667.00
R2	LU1397648111	Capitalisation	JPY	-	-	17,573.00	16,059.00
R2	LU1397648202	Distribution	JPY	-	-	17,313.00	16,158.00
V	LU0317018645	Capitalisation	JPY	-	-	15,275.00	13,865.00
Z	LU0240973403	Capitalisation	JPY	-	-	33,735.00	30,666.00

Candriam Equities L Life Care

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
Total net assets			USD		611,819,118	19,087,939	14,315,655
BF	LU2223682787	Capitalisation	USD	302,484.00	1,470.42	-	-
BF	LU2223682860	Distribution	USD	109,561.83	1,470.42	-	-
C	LU2223680658	Capitalisation	USD	3,868.02	158.38	170.25	150.13
I	LU2223680815	Capitalisation	USD	1.00	1,610.82	1,717.21	1,501.79
R	LU2223681201	Capitalisation	USD	198.63	152.76	162.99	-
R2	LU2223681896	Capitalisation	USD	1,710.00	152.42	-	-
V	LU2223682274	Capitalisation	USD	1.00	1,621.57	1,723.13	1,501.93
Z	LU2223682357	Capitalisation	USD	3,027.00	1,662.43	1,757.91	1,524.78

Candriam Equities L Meta Globe

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
Total net assets			USD		4,168,458	-	-
C	LU2476793240	Capitalisation	USD	10.00	141.76	-	-
I	LU2476792861	Capitalisation	USD	1.00	1,419.07	-	-
R	LU2476792432	Capitalisation	USD	10.00	141.89	-	-
V	LU2476791467	Capitalisation	USD	1.00	1,419.41	-	-
Z	LU2476791384	Capitalisation	USD	2,666.00	1,561.43	-	-

Candriam Equities L Oncology Impact

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
Total net assets			USD		1,931,126,606	2,425,748,609	1,983,560,019
BF - EUR - Unhedged	LU1940963215	Capitalisation	EUR	121,989.64	2,589.38	2,667.77	2,376.98
BF - EUR - Unhedged	LU1940963306	Distribution	EUR	113,938.72	2,488.13	2,605.47	2,360.76
C	LU1864481467	Capitalisation	USD	568,388.94	253.04	282.79	275.90
C	LU1864481541	Distribution	USD	10,858.04	225.49	256.89	254.83
C - EUR - Hedged	LU1864481624	Capitalisation	EUR	640,593.01	197.73	228.44	225.30
C - EUR - Unhedged	LU1864484214	Capitalisation	EUR	246,362.07	230.42	241.68	219.15
I	LU1864482358	Capitalisation	USD	106,165.31	2,624.19	2,905.31	2,808.85
I	LU1864482432	Distribution	USD	34,337.95	1,473.86	1,801.74	1,986.68
I - EUR - Hedged	LU2015349330	Capitalisation	EUR	52,911.37	1,984.36	2,271.08	2,219.30
I - GBP - Unhedged	LU1864482515	Capitalisation	GBP	3,477.23	2,158.43	2,121.89	2,032.69
N - EUR - Hedged	LU1864482606	Capitalisation	EUR	144,507.14	198.33	230.04	227.84
PI	LU1864483836	Capitalisation	USD	9,311.99	2,319.95	2,557.07	2,461.19
R	LU1864482788	Capitalisation	USD	21,472.66	261.40	289.69	280.35
R	LU1864482861	Distribution	USD	9,240.00	180.40	203.79	200.48
R - EUR - Hedged	LU1864483083	Capitalisation	EUR	126,197.31	182.53	209.04	204.57
R - EUR - Unhedged	LU1864483166	Capitalisation	EUR	151,658.86	241.32	250.99	225.76
R - GBP - Unhedged	LU1864482945	Capitalisation	GBP	1,808.84	152.94	150.53	-
R2	LU1864483240	Capitalisation	USD	1,755.00	139.33	153.86	-
R2	LU1864483323	Distribution	USD	176,732.38	234.60	264.05	258.84



Statistics

Candriam Equities L Oncology Impact (Continued)

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
R2 - EUR - Hedged	LU1864483596	Distribution	EUR	492.00	168.65	196.26	194.53
SF2 - EUR - Unhedged	LU2295688928	Capitalisation	EUR	120,665.68	1,035.15	1,068.42	-
S - JPY - Asset Hedged	LU2015349090	Distribution	JPY	31,364.50	20,794.00	23,085.00	22,266.00
S - JPY - Unhedged	LU2015348522	Distribution	JPY	100,986.80	25,545.00	24,980.00	21,933.00
V - GBP - Unhedged	LU2425425506	Capitalisation	GBP	12,312.63	1,772.47	-	-
V	LU1864483752	Capitalisation	USD	29,440.78	2,174.91	2,400.14	2,312.99
Z	LU1864483919	Capitalisation	USD	35,270.23	2,432.36	2,671.42	2,562.09

Candriam Equities L Risk Arbitrage Opportunities

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
Total net assets			EUR		55,130,876	79,103,061	-
C	LU2223682944	Capitalisation	EUR	7.00	145.77	151.65	-
I	LU2223683082	Capitalisation	EUR	1.00	1,472.90	1,522.70	-
PI	LU2223683678	Capitalisation	EUR	13,144.00	147.88	152.11	-
R	LU2223683322	Capitalisation	EUR	7.00	146.85	152.08	-
S	LU2223683751	Capitalisation	EUR	6,666.67	1,497.47	1,536.52	-
V	LU2223683835	Capitalisation	EUR	1.00	1,478.11	1,524.75	-
Z	LU2223683918	Capitalisation	EUR	28,866.00	1,496.54	1,531.65	-

Candriam Equities L Robotics & Innovative Technology

Name	ISIN	Share type	Currency	Number of shares outstanding	Net asset value per share as at 31.12.2022	Net asset value per share as at 31.12.2021	Net asset value per share as at 31.12.2020
Total net assets			USD		1,256,539,992	659,073,624	473,479,656
BF	LU2226954738	Capitalisation	USD	584,230.20	1,196.13	-	-
BF	LU2226954902	Distribution	USD	162,577.23	1,196.13	-	-
C	LU1502282558	Capitalisation	USD	52,179.21	276.14	408.44	348.02
C	LU1502282715	Distribution	USD	21,380.21	258.89	390.30	337.45
C - EUR - Hedged	LU1806526718	Capitalisation	EUR	15,091.49	175.73	271.45	234.08
C - EUR - Unhedged	LU1502282632	Capitalisation	EUR	201,722.15	258.72	359.14	284.42
I	LU1502282806	Capitalisation	USD	10,192.44	2,911.08	4,265.59	3,600.44
I - EUR - Unhedged	LU1613213971	Capitalisation	EUR	36,988.97	2,494.29	3,430.07	2,690.88
N - EUR - Hedged	LU1806526809	Capitalisation	EUR	19,324.49	183.38	284.12	245.94
R	LU1502282988	Capitalisation	USD	14,619.40	289.28	424.30	358.49
R	LU1708110629	Distribution	USD	1,704.62	196.35	293.45	251.46
R - EUR - Hedged	LU1613220596	Capitalisation	EUR	33,791.03	177.62	271.91	232.46
R - EUR - Unhedged	LU1598284849	Capitalisation	EUR	89,506.77	284.38	391.46	307.41
R - GBP - Hedged	LU1613217964	Capitalisation	GBP	829.40	214.55	324.78	276.25
Z	LU1502283010	Capitalisation	USD	37,564.24	3,048.62	4,431.45	3,710.55



Candriam Equities L Australia

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in AUD)	% net assets
Transferable securities admitted to an official stock exchange listing or dealt in another regulated market				
Shares				
Australia				
29METALS --- REGISTERED SHS	634,022	AUD	1,210,982	0.53
ALLKEM LIMITED	349,688	AUD	3,930,493	1.73
ALTIUM	34,306	AUD	1,203,454	0.53
ANZ BANKING GROUP	290,259	AUD	6,867,528	3.02
ARISTOCRAT LEISURE	174,041	AUD	5,311,731	2.34
BHP GROUP LTD	485,931	AUD	22,173,032	9.75
BLUESCOPE STEEL	255,208	AUD	4,297,703	1.89
COMMONWEALTH BANK OF AUSTRALIA	165,206	AUD	16,950,136	7.45
COMPUTERSHARE LIMITED	174,681	AUD	4,576,642	2.01
CSL LTD	73,064	AUD	21,024,897	9.24
EVOLUTION MINING	961,554	AUD	2,865,431	1.26
GOODMAN GROUP - STAPLED SECURITY	342,334	AUD	5,942,918	2.61
IDP EDUCATION	127,777	AUD	3,472,979	1.53
IGO NL	389,176	AUD	5,238,309	2.30
LYNAS RARE EARTHS LTD	790,935	AUD	6,208,840	2.73
MACQUARIE GROUP	59,635	AUD	9,956,660	4.38
NAT. AUSTRALIA BANK	489,592	AUD	14,717,136	6.47
NEXTDC LTD	205,818	AUD	1,872,944	0.82
OZ MINERALS	306,755	AUD	8,558,464	3.76
QBE INSURANCE GROUP	521,577	AUD	7,004,779	3.08
QUANTAS AIRWAYS LTD	1,040,054	AUD	6,250,725	2.75
RAMSAY HEALTH CARE LTD	58,200	AUD	3,765,540	1.66
RESMED - CDI RATIO OF 10 CDIS PER ORD SH	152,696	AUD	4,727,468	2.08
RIO TINTO	50,192	AUD	5,842,851	2.57
SANTOS LTD	1,109,918	AUD	7,924,815	3.48
SEEK LTD	136,206	AUD	2,853,516	1.25
SUNCORP GROUP	312,967	AUD	3,768,123	1.66
TELSTRA CORP	1,505,170	AUD	6,005,628	2.64
TREASURY WINE ESTATES LTD	371,168	AUD	5,051,596	2.22
WEBJET LTD	461,284	AUD	2,850,735	1.25
WOODSIDE ENERGY SHARES	125,291	AUD	4,440,313	1.95
WOOLWORTHS GRP - REGISTERED	169,348	AUD	5,683,319	2.50
WORLEY LTD	319,665	AUD	4,794,975	2.11
			217,344,662	95.56
Ireland				
JAMES HARDIES IND/CHESS UNITS OF FOR SEC	85,453	AUD	2,255,959	0.99
			2,255,959	0.99
New Zealand				
XERO	50,119	AUD	3,521,862	1.55
			3,521,862	1.55
United States of America				
BLOCK --- SHS CHESS DEPOSITORY INTERESTS	32,716	AUD	3,007,909	1.32
			3,007,909	1.32
Total Shares			226,130,392	99.42
Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market			226,130,392	99.42
Total investment portfolio			226,130,392	99.42
Acquisition cost			191,059,468	

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Australia

Geographical and economic breakdown of investments as at December 31, 2022

Geographical breakdown (in % of net assets)

Australia	95.56
New Zealand	1.55
United States of America	1.32
Ireland	0.99
	99.42

Economic breakdown (in % of net assets)

Banks and other financial institutions	22.98
Coal mining and steel industry & Chemicals	17.13
Biotechnology	9.24
Petroleum	7.54
Precious metals and stones	6.83
Internet and internet services	4.91
Retail trade and department stores	3.75
Healthcare	3.18
Insurance	3.08
Transportation	2.75
Communication	2.64
Real estate	2.61
Non ferrous metals	2.57
Hotels and restaurants	2.34
Tobacco and alcoholic drinks	2.22
Pharmaceuticals	2.08
Miscellaneous services	1.32
Miscellaneous consumer goods	1.25
Building materials	0.99
	99.42



Candriam Equities L Biotechnology

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in USD)	% net assets
Transferable securities admitted to an official stock exchange listing or dealt in another regulated market				
Shares				
Belgium				
UCB	118,186	EUR	9,278,418	0.53
			9,278,418	0.53
Canada				
XENON PHARMA --- REGISTERED SHS	735,884	USD	29,015,906	1.64
			29,015,906	1.64
Cayman Islands				
BEIGENE - REG SHS	938,572	HKD	16,137,977	0.91
LEGEND BIOTECH CORP	116,026	USD	5,792,018	0.33
			21,929,995	1.24
Denmark				
GENMAB AS	74,380	DKK	31,394,365	1.78
ZEALAND PHARMA	404,583	DKK	11,694,121	0.66
			43,088,486	2.44
France				
INVENTIVA SA	654,265	EUR	3,124,733	0.18
SANOFI	166,550	EUR	15,969,104	0.90
			19,093,837	1.08
Germany				
BIONTECH --- SHS SPONSORED ADR	142,303	USD	21,376,757	1.21
MORPHOSYS	149,931	EUR	2,113,783	0.12
			23,490,540	1.33
Ireland				
ALKERMES	332,779	USD	8,695,515	0.49
HORIZON THERAPEUTICS PLC	350,161	USD	39,848,322	2.25
JAZZ PHARMACEUTICALS PLC	161,633	USD	25,749,753	1.46
			74,293,590	4.20
Japan				
EISAI	255,500	JPY	16,854,538	0.95
			16,854,538	0.95
Luxembourg				
AKERO THERAPEUTICS INC	210,000	USD	11,508,000	0.65
KARUNA THERAPEUTICS INC	82,201	USD	16,152,496	0.91
REVOLUTION MEDICINES INC	303,556	USD	7,230,704	0.41
			34,891,200	1.97
Netherlands				
ARGENX SE	61,094	EUR	22,710,056	1.29
MERUS - REGISTERED	431,151	USD	6,669,906	0.38
			29,379,962	1.66
Switzerland				
CRISPR THERAP --- NAMEN-AKT	193,675	USD	7,872,889	0.45
			7,872,889	0.45
United Kingdom				
ASTRAZENECA PLC	279,025	GBP	37,651,190	2.13
ASTRAZENECA PLC ADR REPR 1SHS	372,056	USD	25,225,397	1.43
BICYCLE THERAPEUTICS PLC	467,295	USD	13,831,932	0.78
			76,708,519	4.34
United States of America				
ADICET BIO INC	396,002	USD	3,540,258	0.20
ALNYLAM PHARMACEUTICALS INC	300,326	USD	71,372,474	4.04
ALTIMMUNE - REGISTERED SHS	200,000	USD	3,290,000	0.19
AMGEN INC	393,648	USD	103,387,711	5.85
AMICUS THERAPEUTICS	693,879	USD	8,472,263	0.48
APELLIS PHARMA	278,507	USD	14,401,597	0.81
ARROWHEAD PHARMACEUTICALS INC	358,054	USD	14,522,670	0.82
ARVINAS --- REGISTERED SHS	149,282	USD	5,106,937	0.29
ASCENDIS PHARMA ADR REP 1SHS	190,375	USD	23,250,499	1.32

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Biotechnology

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in USD)	% net assets
AVIDITY BIOSCI --- REGISTERED SHS	211,067	USD	4,683,577	0.27
AXSOME THERAPEUTICS INC	160,084	USD	12,347,279	0.70
BEAM THERAPEUTICS INC	79,665	USD	3,115,698	0.18
BIOATLA	814,417	USD	6,718,940	0.38
BIOGEN IDEC INC	263,114	USD	72,861,529	4.12
BIOMARIN PHARMACEUTICAL INC	304,796	USD	31,543,338	1.78
BLUEPRINT MEDICINES CORP	117,156	USD	5,132,604	0.29
BRUKER BIOSCIENCES	315,628	USD	21,573,174	1.22
CELLEX THERAPEUTICS INC	488,509	USD	21,772,846	1.23
CEREVEL THERAPEUTICS HOLDINGS INC	327,221	USD	10,320,550	0.58
CHINOOK THERAPEUTICS	926,155	USD	24,265,261	1.37
CINCOR PHARMA --- REGISTERED SHS	175,000	USD	2,150,750	0.12
CYTOKINETICS INC	503,240	USD	23,058,457	1.30
DANAHER CORP	89,467	USD	23,746,331	1.34
DENALI THRPTCS --- REGISTERED SHS	357,878	USD	9,952,587	0.56
DICE THERAPEUTICS INC	210,000	USD	6,552,000	0.37
DYNE THERAPEUTICS INC	633,624	USD	7,343,702	0.42
EDGEWISE THERAPE	298,000	USD	2,664,120	0.15
ENANTA PHARM	100,507	USD	4,675,586	0.26
EXELIXIS	769,968	USD	12,350,287	0.70
FATE THERAPEUTICS	215,492	USD	2,174,314	0.12
GILEAD SCIENCES INC	1,351,375	USD	116,015,544	6.56
GUARDANT HEALTH --- REGISTERED SHS	180,000	USD	4,896,000	0.28
HALOZYME THERAPEUT -SHS-	185,997	USD	10,583,229	0.60
ILLUMINA INC	160,760	USD	32,505,672	1.84
IMMUNOGEN INC	1,299,681	USD	6,446,418	0.36
INCYTE CORP	357,823	USD	28,740,343	1.63
INHIBRX --- REGISTERED SHS	187,069	USD	4,609,380	0.26
INSMED	1,052,200	USD	21,022,956	1.19
INTELLIA THERAPEUTICS INC	91,275	USD	3,184,585	0.18
IONIS PHARMACEUTICALS NEW	319,067	USD	12,051,161	0.68
IOVANCE BIOTHERAPEUTICS INC	786,367	USD	5,024,885	0.28
ITEOS THERAPEUTICS INC	265,115	USD	5,177,696	0.29
IVERIC BIO - REGISTERED SHS	1,135,832	USD	24,318,163	1.38
KEROS THERAPEUTICS INC	367,065	USD	17,626,461	1.00
KURA ONCOLOGY - REGISTERED	224,402	USD	2,784,829	0.16
KYMERA THERAPEUTICS INC	210,476	USD	5,253,481	0.30
MERSANA THERAPEUTICS INC	972,494	USD	5,698,815	0.32
MIRATI THERAPEUTICS INC	354,018	USD	16,040,556	0.91
MODERNA INC	364,625	USD	65,493,942	3.71
MORPHIC HLDG	344,933	USD	9,226,958	0.52
NEKTAR THERAPEUTICS	595,938	USD	1,346,820	0.08
NEUROCRINE BIOSCIENCES	233,616	USD	27,903,095	1.58
NGM BIOPHARMACEUTICALS INC	217,187	USD	1,090,279	0.06
NURIX THERAPETC --- REGISTERED SHS	319,992	USD	3,513,512	0.20
PACIRA PHARMACEUTICALS INC	179,901	USD	6,945,978	0.39
PIERIS PHARMACEUTICALS INC	941,834	USD	979,507	0.06
PROMETHEUS BIOSCIENCES INC	75,000	USD	8,250,000	0.47
PTC THERAPEUTICS	202,652	USD	7,735,227	0.44
RAPT THERAPEUTICS INC	313,262	USD	6,202,588	0.35
REGENERON PHARMACEUTICALS INC	168,260	USD	121,397,907	6.87
RELAY THERAPTCS - REGISTERED SHS	537,641	USD	8,032,357	0.45
RELMADA THERAP --- REGISTERED SHS	92,186	USD	321,729	0.02
ROCKET PHARMCTC	50,000	USD	978,500	0.06
SAREPTA THERAPEUTICS	94,000	USD	12,180,520	0.69
SCHRODINGER INC	140,000	USD	2,616,600	0.15
SEAGEN INC	376,047	USD	48,325,800	2.73
SUTRO BIOPHARMA INC	582,812	USD	4,709,121	0.27

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Biotechnology

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in USD)	% net assets
THERMO FISHER SCIENT SHS	46,755	USD	25,747,511	1.46
TWIST BIOSCIENCE CORPORATION	129,360	USD	3,080,062	0.17
ULTRAGENYX PHARMACEUTICAL INC	49,480	USD	2,292,408	0.13
VERTEX PHARMACEUTICALS INC	329,220	USD	95,072,152	5.38
XENCOR INC	326,298	USD	8,496,800	0.48
			1,350,266,886	76.41
Total Shares			1,736,164,766	98.24
Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market			1,736,164,766	98.24
Total investment portfolio			1,736,164,766	98.24
Acquisition cost			1,643,299,091	



Candriam Equities L Biotechnology

Geographical and economic breakdown of investments as at December 31, 2022

Geographical breakdown (in % of net assets)

United States of America	76.41
United Kingdom	4.34
Ireland	4.20
Denmark	2.44
Luxembourg	1.97
Netherlands	1.66
Canada	1.64
Germany	1.33
Cayman Islands	1.24
France	1.08
Japan	0.95
Belgium	0.53
Switzerland	0.45
	98.24

Economic breakdown (in % of net assets)

Biotechnology	50.90
Pharmaceuticals	40.66
Banks and other financial institutions	2.51
Electronics and semiconductors	1.46
Machine and apparatus construction	1.34
Miscellaneous services	0.78
Healthcare	0.60
	98.24

Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Emerging Markets

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in EUR)	% net assets
Transferable securities admitted to an official stock exchange listing or dealt in another regulated market				
Shares				
Bermuda				
CREDICORP	56,000	USD	7,129,328	0.59
			7,129,328	0.59
Brazil				
AREZZO INDUSTRIA E COMERCIO SA	360,000	BRL	5,003,286	0.42
B3 - REGISTERED SHS	2,600,000	BRL	6,100,208	0.51
BB SEGURIDADE	1,960,000	BRL	11,735,005	0.97
HYPERA SA	1,040,000	BRL	8,349,111	0.69
ITAUUNIBANCO PFD SHS	2,600,000	BRL	11,544,678	0.96
LOCALIZA RENT A CAR SA	760,000	BRL	7,181,145	0.60
PETRO RIO - REGISTERED SHS	2,080,000	BRL	13,746,479	1.14
SLC AGRICOLA SA	260,000	BRL	2,166,243	0.18
WEG SA	2,100,000	BRL	14,363,533	1.19
			80,189,688	6.66
Cayman Islands				
AIRTAC INTL	204,579	TWD	5,818,508	0.48
ALCHIP TECHNOLOGIES LIMITED	220,000	TWD	5,296,022	0.44
ALIBABA GROUP	4,160,000	HKD	43,209,133	3.59
JD HEALTH INTERNATIONAL INC	1,720,000	HKD	14,779,017	1.23
JD.COM INC - CL A	1,020,000	HKD	27,048,339	2.25
LI NING CO	520,000	HKD	4,242,636	0.35
MEITUAN - SHS 114A/REG S	1,580,000	HKD	33,240,926	2.76
NETEASE INC	500,000	HKD	6,894,434	0.57
PINDUODUO	90,000	USD	6,962,918	0.58
TENCENT HOLDINGS LTD	1,320,000	HKD	53,093,764	4.41
			200,585,697	16.65
Hong Kong				
BYD ELECTRONIC -RC-	3,200,000	HKD	9,672,680	0.80
CSPC PHARMACEUTICAL	4,800,000	HKD	4,739,999	0.39
			14,412,679	1.20
India				
ABB SHS	292,000	INR	8,888,450	0.74
APOLLO HOSPITALS	124,000	INR	6,299,259	0.52
ASIAN PAINTS LTD	340,000	INR	11,911,451	0.99
AXIS BANK	1,760,000	INR	18,645,147	1.55
BAJAJ FINANCE LTD	156,000	INR	11,637,403	0.97
BHARTI AIRTEL LTD(DEMATERIALIZED)	2,080,000	INR	19,077,091	1.58
EICHER MOTORS - REGISTERED SHS	350,000	INR	12,817,120	1.06
HDFC BANK - REGISTERED SHS	1,120,000	INR	20,688,784	1.72
ICICI BANK	1,050,000	INR	10,612,468	0.88
INFOSYS TECHNOLOGIES DEMATERIALIZED	1,020,000	INR	17,453,464	1.45
JUBILANT FOODWOR SHARES	840,000	INR	4,870,406	0.40
RELIANCE INDUSTRIES DEMATERIALIZED	720,000	INR	20,807,412	1.73
SBI CARDS & PAYMENT SERVICES LTD	820,000	INR	7,396,578	0.61
TORRENT PHARMACEUTICALS DEMATERIALIZED	330,000	INR	5,803,208	0.48
			176,908,241	14.69
Indonesia				
ANEKA TAMBANG SHS	47,994,000	IDR	5,744,062	0.48
BANK CENTRAL ASIA DEP	38,000,000	IDR	19,589,412	1.63
SUMBER ALFARIA TRIJAYA TBK	48,000,000	IDR	7,669,354	0.64
TELKOM INDONESIA -B-	20,000,000	IDR	4,522,025	0.38
			37,524,853	3.12
Luxembourg				
GINLONG TECHNOLOGIES CO LT-A	76,754	CNY	1,865,995	0.15
GLOBANT REG SHS	34,000	USD	5,377,375	0.45
JAFRON BIOMEDICAL CO LTD	559,853	CNY	2,341,162	0.19

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Emerging Markets

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in EUR)	% net assets
JIUMAOJIU INTERNATIONAL HOLDINGS LIMITED	6,200,000	HKD	15,567,571	1.29
PROYA COSMETICS CO	379,698	CNY	8,586,527	0.71
PT MERDEKA COPPER GOLD TBK	18,000,000	IDR	4,471,378	0.37
SHANGHAI BAOSIGHT SOFTWARE CO LTD	930,533	CNY	5,628,933	0.47
VARUN BEVERAGES LTD	760,000	INR	11,403,764	0.95
VOLTRONIC POWER TECHNOLOGY CORP	202,000	TWD	9,534,124	0.79
YADEA GROUP HOLDINGS LTD	7,599,700	HKD	11,952,610	0.99
			76,729,439	6.37
Mexico				
AMERICA MOVIL -L-	15,200,000	MXN	13,128,571	1.09
GRUMA SHS-B-	680,000	MXN	8,731,673	0.72
GRUPO AEROPORTUARIO DEL PACIFICO SAB-B-	760,000	MXN	10,537,271	0.87
GRUPO FINANCIERO BANORTE -O-	2,320,000	MXN	16,057,498	1.33
			48,455,013	4.02
People's Republic of China				
AIER EYE HOSPITAL GROUP CO LTD	1,679,542	CNY	7,046,094	0.59
BANK OF JIANGSU CO LTD	15,199,917	CNY	14,961,841	1.24
BJ UNITED --- REGISTERED SHS -A-	240,345	CNY	2,870,120	0.24
BYD COMPANY LTD -H-	600,000	HKD	13,916,520	1.16
CHINA TOURISM -H	460,000	HKD	12,741,155	1.06
CONTEMPORARY AMPEREX TECHN-A	137,939	CNY	7,327,567	0.61
GANFENG LIT GRP --- REGISTERED SHS -H-	1,020,000	HKD	7,161,300	0.59
LONGI GREEN ENE - REGISTERED SHS -A-	539,779	CNY	3,080,078	0.26
LONGSHINE TECHNOLOGY GROUP CO LTD	1,699,937	CNY	5,045,182	0.42
MING YANG SMART/REGSH	2,459,804	CNY	8,389,772	0.70
NARI TECHNOLOGY -A-	1,999,827	CNY	6,588,682	0.55
NINGBO DEYE TECHNOLOGY CO -A	79,891	CNY	3,572,765	0.30
NINGBO ORIENT WIRES CABLES CO LTD	540,878	CNY	4,953,788	0.41
NONGFU SPRING - REGISTERED SHS -H- UNI	1,880,000	HKD	9,984,345	0.83
PING AN INS (GRP) CO -H-	4,499,600	HKD	27,987,709	2.32
SZ INNOVANCE TECHNOLOGY -A-	1,199,768	CNY	11,258,962	0.93
TONGFANG GUOXIN -A-	189,908	CNY	3,380,188	0.28
ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD	1,000,000	CNY	5,729,139	0.48
ZIJIN MINING CORP CO LTD -H-	2,600,000	HKD	3,312,700	0.28
			159,307,907	13.23
Poland				
DINA POLSKA S.A.	170,000	PLN	13,659,322	1.13
			13,659,322	1.13
South Africa				
CAPITEC BANK HOLDINGS LTD	58,000	ZAR	6,006,872	0.50
FIRSTRAND LTD	2,640,000	ZAR	9,037,490	0.75
GOLD FIELDS	586,000	ZAR	5,986,660	0.50
SHOPRITE HOLDINGS LTD (SHP)	860,000	ZAR	10,877,670	0.90
			31,908,692	2.65
South Korea				
KAKAOBANK CORP	260,000	KRW	4,706,741	0.39
KB FINANCIAL GROUP INC	330,000	KRW	11,923,298	0.99
L & F CO LTD	70,000	KRW	9,047,701	0.75
LG CHEM	22,000	KRW	9,833,647	0.82
SAMSUNG BIOLOGICS CO LTD	32,000	KRW	19,571,938	1.62
SAMSUNG ELECTRONICS CO LTD	590,000	KRW	24,306,244	2.02
SAMSUNG ENGINEERING	580,000	KRW	9,613,880	0.80
SAMSUNG SDI CO LTD	49,000	KRW	21,573,682	1.79
SK HYNIX INC	190,000	KRW	10,615,869	0.88
			121,193,000	10.06
Taiwan				
ACCTON TECHNOLOGY CORPORATION	1,320,000	TWD	9,456,223	0.79
CHAILEASE HOLDING COMPANY LTD	2,700,525	TWD	17,902,301	1.49
DELTA ELECTRONIC INCS	1,700,000	TWD	14,879,025	1.24

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Emerging Markets

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in EUR)	% net assets
E.SUN FINANCIAL HOLDING	800,635	TWD	588,235	0.05
PRIME VIEW INTERNATIONAL CO LTD	970,000	TWD	4,770,880	0.40
TAIWAN SEMICONDUCTOR CO	5,500,000	TWD	75,357,427	6.26
			122,954,091	10.21
Thailand				
AIRPORTS THAILAND-UNITS NON-VOT DEP REC	3,400,000	THB	6,933,549	0.58
BANGKOK DUSIT MEDICAL SERVICES PUBLIC	14,000,000	THB	11,039,298	0.92
C.P.ALL-UNITS NON-VOTING DEPOSIT.RECEIPT	6,000,000	THB	11,134,465	0.92
ENERGY ABSOLUTE NVDR	5,400,000	THB	14,242,326	1.18
KASIKORNBANK UNITS NVDR	2,200,000	THB	8,823,282	0.73
			52,172,920	4.33
Turkey				
BIM BIRLESIK MAGAZALAR	1,180,000	TRY	8,078,706	0.67
			8,078,706	0.67
United States of America				
COUPANG INC	500,000	USD	6,881,337	0.57
MERCADOLIBRE	20,400	USD	16,590,417	1.38
SOQUIMICH SPONSORED ADR REPR 1 -B- PEF	76,000	USD	5,627,938	0.47
			29,099,692	2.42
Total Shares			1,180,309,268	98.00
Rights				
Brazil				
LOCALIZA RENT A CAR 31.01.23 RIGHT	3,321	BRL	6,347	0.00
			6,347	0.00
Total Rights			6,347	0.00
Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market			1,180,315,615	98.00
Other transferable securities				
Shares				
Russia				
MAGNIT SHS	169,180	USD	0	0.00
			0	0.00
Total Shares			0	0.00
Total Other transferable securities			0	0.00
Total investment portfolio			1,180,315,615	98.00
Acquisition cost			1,231,170,794	

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Emerging Markets

Geographical and economic breakdown of investments as at December 31, 2022

Geographical breakdown (in % of net assets)

Cayman Islands	16.65
India	14.69
People's Republic of China	13.23
Taiwan	10.21
South Korea	10.06
Brazil	6.66
Luxembourg	6.37
Thailand	4.33
Mexico	4.02
Indonesia	3.12
South Africa	2.65
United States of America	2.42
Hong Kong	1.20
Poland	1.13
Turkey	0.67
Bermuda	0.59
Russia	0.00
	98.00

Economic breakdown (in % of net assets)

Banks and other financial institutions	17.35
Electronics and semiconductors	14.23
Internet and internet services	11.66
Foods and non alcoholic drinks	6.00
Retail trade and department stores	5.00
Machine and apparatus construction	4.18
Chemicals	4.00
Electrical engineering	3.97
Pharmaceuticals	3.70
Miscellaneous services	3.59
Insurance	3.30
Communication	3.05
Biotechnology	2.81
Road vehicles	2.65
Transportation	1.93
Healthcare	1.81
Office supplies and computing	1.18
Petroleum	1.14
Miscellaneous consumer goods	1.11
Non ferrous metals	1.06
Precious metals and stones	0.97
Utilities	0.70
Coal mining and steel industry & Chemicals	0.65
Non Classifiable Institutions	0.61
Aeronautic and astronautic Industry	0.58
Graphic art and publishing	0.58
Agriculture and fishery	0.18
	98.00

Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L EMU Innovation

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in EUR)	% net assets
Transferable securities admitted to an official stock exchange listing or dealt in another regulated market				
Shares				
Belgium				
KBC GROUPE SA	29,187	EUR	1,753,555	2.98
SOLVAY	9,581	EUR	905,021	1.54
			2,658,576	4.51
Denmark				
CHRISTIAN HANSEN	12,989	DKK	872,809	1.48
GENMAB AS	2,016	DKK	797,297	1.35
SIMCORP A/S	13,957	DKK	897,503	1.52
			2,567,609	4.36
Finland				
KONE -B-	20,161	EUR	973,776	1.65
			973,776	1.65
France				
BIOMERIEUX SA	27,298	EUR	2,673,020	4.54
DASSAULT SYST.	69,350	EUR	2,322,878	3.94
ESSILORLUXOTTICA SA	10,211	EUR	1,727,701	2.93
L'OREAL SA	5,449	EUR	1,817,786	3.09
SANOFI	20,209	EUR	1,815,577	3.08
SCHNEIDER ELECTRIC SE	19,311	EUR	2,524,334	4.28
SOMFY SA NI	7,986	EUR	1,141,998	1.94
			14,023,294	23.80
Germany				
BEIERSDORF AG	16,686	EUR	1,788,739	3.04
CARL ZEISS MEDITEC AG	20,866	EUR	2,460,101	4.18
DUERR AG	35,630	EUR	1,123,058	1.91
INFINEON TECHNOLOGIES REG SHS	28,104	EUR	798,997	1.36
NEMETSCHEK	33,959	EUR	1,619,505	2.75
RATIONAL NAMEN	1,508	EUR	836,940	1.42
SIEMENS AG REG	13,154	EUR	1,705,285	2.89
SIEMENS HEALTHINEERS	35,728	EUR	1,669,569	2.83
STRATEC N NAMEN-AKT	19,829	EUR	1,608,132	2.73
SYMRISE AG	24,002	EUR	2,439,803	4.14
			16,050,129	27.24
Ireland				
KERRY GROUP -A-	30,778	EUR	2,592,739	4.40
KINGSPAN GROUP	33,751	EUR	1,707,126	2.90
			4,299,865	7.30
Italy				
FINECOBANK	143,529	EUR	2,227,570	3.78
ILLIMITY BANK SPA - BEARER SHS	62,918	EUR	434,134	0.74
			2,661,704	4.52
Luxembourg				
GRAND CITY PROPERTIES	151,378	EUR	1,391,164	2.36
			1,391,164	2.36
Netherlands				
ADYEN --- PARTS SOCIALES	1,208	EUR	1,556,387	2.64
ASML HOLDING NV	4,701	EUR	2,368,364	4.02
CORBION	14,843	EUR	472,601	0.80
DSM KONINKLIJKE	21,791	EUR	2,490,711	4.23
			6,888,063	11.69
Norway				
TOMRA SYSTEMS ASA	48,657	NOK	766,405	1.30
			766,405	1.30
Spain				
AMADEUS IT GROUP SA -A-	32,316	EUR	1,568,942	2.66
INDITEX SHARE FROM SPLIT	69,462	EUR	1,726,131	2.93
			3,295,073	5.59

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L EMU Innovation

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in EUR)	% net assets
Sweden				
ASSA ABLOY -B- NEW I	42,188	SEK	848,673	1.44
HEXAGON --- REGISTERED SHS -B-	79,229	SEK	776,598	1.32
			1,625,271	2.76
Total Shares			57,200,929	97.09
Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market			57,200,929	97.09
Total investment portfolio			57,200,929	97.09
Acquisition cost			59,500,894	



Candriam Equities L EMU Innovation

Geographical and economic breakdown of investments as at December 31, 2022

Geographical breakdown (in % of net assets)

Germany	27.24
France	23.80
Netherlands	11.69
Ireland	7.30
Spain	5.59
Italy	4.52
Belgium	4.51
Denmark	4.36
Sweden	2.76
Luxembourg	2.36
Finland	1.65
Norway	1.30
	97.09

Economic breakdown (in % of net assets)

Pharmaceuticals	23.68
Internet and internet services	10.88
Electrical engineering	10.54
Machine and apparatus construction	10.35
Banks and other financial institutions	10.14
Chemicals	9.90
Electronics and semiconductors	5.38
Foods and non alcoholic drinks	5.20
Retail trade and department stores	2.93
Building materials	2.90
Biotechnology	2.83
Real estate	2.36
	97.09



Candriam Equities L Europe Innovation

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in EUR)	% net assets
Transferable securities admitted to an official stock exchange listing or dealt in another regulated market				
Shares				
Belgium				
SOLVAY	104,275	EUR	9,849,816	0.79
			9,849,816	0.79
Denmark				
CHRISTIAN HANSEN	355,170	DKK	23,866,018	1.92
GENMAB AS	51,271	DKK	20,276,881	1.63
SIMCORP A/S	294,268	DKK	18,922,867	1.52
			63,065,766	5.08
Finland				
KONE -B-	193,131	EUR	9,328,227	0.75
			9,328,227	0.75
France				
BIOMERIEUX SA	573,491	EUR	56,156,239	4.52
DASSAULT SYST.	1,239,421	EUR	41,514,406	3.34
ESSILORLUXOTTICA SA	155,131	EUR	26,248,165	2.11
L'OREAL SA	61,114	EUR	20,387,630	1.64
SANOFI	240,110	EUR	21,571,482	1.74
SCHNEIDER ELECTRIC SE	306,315	EUR	40,041,497	3.22
			205,919,419	16.59
Germany				
BEIERSDORF AG	187,190	EUR	20,066,768	1.62
CARL ZEISS MEDITEC AG	266,756	EUR	31,450,532	2.53
DUERR AG	289,039	EUR	9,110,509	0.73
INFINEON TECHNOLOGIES REG SHS	366,131	EUR	10,409,104	0.84
NEMETSCHEK	328,715	EUR	15,676,418	1.26
SIEMENS AG REG	160,722	EUR	20,836,000	1.68
SIEMENS HEALTHINEERS	511,934	EUR	23,922,676	1.93
STRATEC N NAMEN-AKT	226,118	EUR	18,338,170	1.48
SYMRISE AG	464,376	EUR	47,203,820	3.80
			197,013,997	15.87
Ireland				
KERRY GROUP -A-	523,764	EUR	44,121,879	3.55
KINGSPAN GROUP	388,279	EUR	19,639,152	1.58
			63,761,031	5.14
Italy				
FINECOBANK	2,732,431	EUR	42,407,329	3.42
ILLIMITY BANK SPA - BEARER SHS	1,152,209	EUR	7,950,242	0.64
			50,357,571	4.06
Luxembourg				
GRAND CITY PROPERTIES	1,912,625	EUR	17,577,024	1.42
MIPS AB	258,610	SEK	9,997,656	0.81
			27,574,680	2.22
Netherlands				
ADYEN --- PARTS SOCIALES	15,771	EUR	20,319,356	1.64
ASML HOLDING NV	81,926	EUR	41,274,319	3.32
CORBION	257,439	EUR	8,196,858	0.66
DSM KONINKLIJKE	340,870	EUR	38,961,441	3.14
			108,751,974	8.76
Norway				
TOMRA SYSTEMS ASA	2,299,930	NOK	36,226,605	2.92
			36,226,605	2.92
Spain				
AMADEUS IT GROUP SA -A-	355,001	EUR	17,235,299	1.39
INDITEX SHARE FROM SPLIT	873,174	EUR	21,698,374	1.75
			38,933,673	3.14
Sweden				
ASSA ABLOY -B- NEW I	1,969,863	SEK	39,626,659	3.19

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Europe Innovation

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in EUR)	% net assets
CELLAVISION	477,465	SEK	9,832,466	0.79
HEXAGON --- REGISTERED SHS -B-	4,094,842	SEK	40,137,387	3.23
THULE CORP	328,466	SEK	6,430,345	0.52
			96,026,857	7.73
Switzerland				
NESTLE SA REG SHS	412,794	CHF	44,788,849	3.61
ROCHE HOLDING LTD	64,326	CHF	18,924,202	1.52
SCHINDLER HOLDING SA	98,496	CHF	17,346,149	1.40
SIKA - REGISTERED SHS	86,471	CHF	19,414,270	1.56
TECAN GROUP NAM.AKT	82,866	CHF	34,608,272	2.79
VAT GROUP SA	34,616	CHF	8,862,145	0.71
			143,943,887	11.59
United Kingdom				
ADMIRAL GROUP PLC	812,565	GBP	19,571,163	1.58
ASTRAZENECA PLC	166,464	GBP	21,046,978	1.70
CRODA INTL - REGISTERED SHS	258,756	GBP	19,259,787	1.55
HALMA PLC	1,673,974	GBP	37,243,445	3.00
JOHNSON MATTHEY	962,657	GBP	23,077,728	1.86
RECKITT BENCKISER GROUP PLC	297,657	GBP	19,303,673	1.55
SPIRAX-SARCO ENGIN	258,771	GBP	30,959,190	2.49
			170,461,964	13.73
Total Shares			1,221,215,467	98.36
Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market			1,221,215,467	98.36
Total investment portfolio			1,221,215,467	98.36
Acquisition cost			1,219,407,414	



Candriam Equities L Europe Innovation

Geographical and economic breakdown of investments as at December 31, 2022

Geographical breakdown (in % of net assets)

France	16.59
Germany	15.87
United Kingdom	13.73
Switzerland	11.59
Netherlands	8.76
Sweden	7.73
Ireland	5.14
Denmark	5.08
Italy	4.06
Spain	3.14
Norway	2.92
Luxembourg	2.22
Belgium	0.79
Finland	0.75
	98.36

Economic breakdown (in % of net assets)

Pharmaceuticals	22.10
Machine and apparatus construction	16.19
Chemicals	10.85
Foods and non alcoholic drinks	7.82
Internet and internet services	7.52
Electronics and semiconductors	7.16
Banks and other financial institutions	6.41
Electrical engineering	4.90
Biotechnology	4.35
Miscellaneous consumer goods	2.07
Precious metals and stones	1.86
Retail trade and department stores	1.75
Building materials	1.58
Insurance	1.58
Real estate	1.42
Miscellaneous services	0.81
	98.36

Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Europe Optimum Quality

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in EUR)	% net assets
Transferable securities admitted to an official stock exchange listing or dealt in another regulated market				
Shares				
Belgium				
AEDIFICA SA	104,391	EUR	7,912,838	1.00
ANHEUSER-BUSCH INBEV	327,993	EUR	18,456,166	2.33
KBC GROUPE SA	360,615	EUR	21,665,749	2.74
SOLVAY	79,607	EUR	7,519,677	0.95
WAREHOUSES DE PAUW SCA - REGISTERED SHS	22,645	EUR	604,622	0.08
			56,159,052	7.09
Czech Republic				
KOMERCNI BANKA AS	441,799	CZK	11,980,556	1.51
			11,980,556	1.51
Denmark				
CHRISTIAN HANSEN	233,310	DKK	15,677,508	1.98
COLOPLAST -B-	11,143	DKK	1,216,725	0.15
GENMAB AS	45,450	DKK	17,974,766	2.27
ORSTED	144,018	DKK	12,226,071	1.54
SIMCORP A/S	169,880	DKK	10,924,112	1.38
TOPDANMARK AS	166,440	DKK	8,178,254	1.03
TRYG A/S	746,164	DKK	16,591,010	2.10
			82,788,446	10.46
Finland				
KONE -B-	180,011	EUR	8,694,531	1.10
			8,694,531	1.10
France				
AIR LIQUIDE SA	187,277	EUR	24,795,475	3.13
BIOMERIEUX SA	234,654	EUR	22,977,320	2.90
BUREAU VERITAS SA	655,800	EUR	16,139,238	2.04
DASSAULT SYST.	475,966	EUR	15,942,481	2.01
ESSILORLUXOTTICA SA	112,188	EUR	18,982,210	2.40
L'OREAL SA	63,197	EUR	21,082,519	2.66
SANOFI	198,533	EUR	17,836,205	2.25
SCHNEIDER ELECTRIC SE	161,453	EUR	21,105,136	2.67
			158,860,584	20.07
Germany				
BEIERSDORF AG	191,009	EUR	20,476,165	2.59
CARL ZEISS MEDITEC AG	68,917	EUR	8,125,314	1.03
HANNOVER RUECK SE	43,948	EUR	8,152,354	1.03
SAP AG	84,643	EUR	8,158,739	1.03
SIEMENS HEALTHINEERS	350,903	EUR	16,397,697	2.07
SYMRISE AG	185,786	EUR	18,885,147	2.39
			80,195,416	10.13
Ireland				
KERRY GROUP -A-	277,393	EUR	23,367,586	2.95
			23,367,586	2.95
Italy				
FINECOBANK	772,213	EUR	11,984,746	1.51
			11,984,746	1.51
Luxembourg				
GRAND CITY PROPERTIES	690,110	EUR	6,342,111	0.80
SHURGARD SELF STORAGE SA ORDSHR	33,676	EUR	1,443,017	0.18
			7,785,128	0.98
Netherlands				
AKZO NOBEL NV	89,565	EUR	5,603,186	0.71
DSM KONINKLIJKE	173,513	EUR	19,832,536	2.51
			25,435,722	3.21
Norway				
TOMRA SYSTEMS ASA	248,677	NOK	3,916,955	0.49
			3,916,955	0.49

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Europe Optimum Quality

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in EUR)	% net assets
Spain				
AMADEUS IT GROUP SA -A-	164,894	EUR	8,005,604	1.01
BANKINTER SA REGS	946,159	EUR	5,930,525	0.75
INDITEX SHARE FROM SPLIT	657,418	EUR	16,336,837	2.06
			30,272,966	3.82
Switzerland				
BACHEM HOLDING LTD SHARES	58,045	CHF	4,693,800	0.59
GIVAUDAN SA REG.SHS	1,163	CHF	3,336,654	0.42
KARDEX HOLDING AG	32,945	CHF	5,071,285	0.64
LONZA GROUP (CHF)	32,395	CHF	14,864,727	1.88
NESTLE SA REG SHS	221,314	CHF	24,012,944	3.03
ROCHE HOLDING LTD	34,680	CHF	10,202,582	1.29
SCHINDLER HOLDING SA	87,184	CHF	15,353,990	1.94
SGS SA REG SHS	3,699	CHF	8,053,927	1.02
SIG COMBIBLOC GROUP AG	534,994	CHF	10,944,229	1.38
TECAN GROUP NAM.AKT	53,321	CHF	22,269,057	2.81
			118,803,195	15.01
United Kingdom				
ADMIRAL GROUP PLC	455,178	GBP	10,963,262	1.38
ASTRAZENECA PLC	101,774	GBP	12,867,858	1.63
COMPASS GROUP	572,687	GBP	12,376,752	1.56
GRAINGER PLC	2,791,424	GBP	7,928,305	1.00
HALMA PLC	165,579	GBP	3,683,888	0.47
INTERTEK GROUP PLC	232,702	GBP	10,580,106	1.34
PRUDENTIAL PLC	645,938	GBP	8,208,454	1.04
RECKITT BENCKISER GROUP PLC	306,290	GBP	19,863,541	2.51
RELX PLC	616,501	GBP	15,898,048	2.01
RENTOKIL INITIAL PLC	969,132	GBP	5,548,820	0.70
SPIRAX-SARCO ENGIN	36,121	GBP	4,321,492	0.55
UNILEVER	91,538	EUR	4,290,386	0.54
UNILEVER	335,349	GBP	15,806,475	2.00
			132,337,387	16.72
Total Shares			752,582,270	95.07
Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market			752,582,270	95.07
Total investment portfolio			752,582,270	95.07
Acquisition cost			793,955,832	

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Europe Optimum Quality

Geographical and economic breakdown of investments as at December 31, 2022

Geographical breakdown (in % of net assets)

France	20.07
United Kingdom	16.72
Switzerland	15.01
Denmark	10.46
Germany	10.13
Belgium	7.09
Spain	3.82
Netherlands	3.21
Ireland	2.95
Czech Republic	1.51
Italy	1.51
Finland	1.10
Luxembourg	0.98
Norway	0.49
	95.07

Economic breakdown (in % of net assets)

Pharmaceuticals	21.78
Chemicals	11.98
Foods and non alcoholic drinks	8.52
Banks and other financial institutions	8.49
Insurance	6.58
Internet and internet services	5.44
Machine and apparatus construction	4.72
Biotechnology	4.25
Miscellaneous services	3.76
Real estate	3.06
Electrical engineering	2.67
Miscellaneous consumer goods	2.51
Tobacco and alcoholic drinks	2.33
Retail trade and department stores	2.06
Graphic art and publishing	2.01
Hotels and restaurants	1.56
Utilities	1.54
Textiles and garments	1.34
Electronics and semiconductors	0.47
	95.07

Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Global Demography

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in EUR)	% net assets
Transferable securities admitted to an official stock exchange listing or dealt in another regulated market				
Shares				
Belgium				
KBC GROUPE SA	341,490	EUR	20,516,719	1.55
SOLVAY	142,726	EUR	13,481,898	1.02
			33,998,617	2.57
Canada				
ROYAL BANK OF CANADA	173,995	CAD	15,317,287	1.16
			15,317,287	1.16
Finland				
KONE -B-	257,074	EUR	12,416,674	0.94
			12,416,674	0.94
France				
ESSILORLUXOTTICA SA	63,832	EUR	10,800,374	0.82
LVMH MOET HENNESSY LOUIS VUITTON SE	37,829	EUR	25,719,937	1.94
PERNOD RICARD SA	84,230	EUR	15,477,262	1.17
TOTALENERGIESSE	366,654	EUR	21,504,257	1.63
VINCI SA	139,739	EUR	13,036,251	0.99
			86,538,081	6.54
Hong Kong				
AIA GROUP LTD	1,779,289	HKD	18,540,824	1.40
			18,540,824	1.40
Ireland				
TRANE TECH - REGISTERED SHS	73,924	USD	11,642,900	0.88
			11,642,900	0.88
Japan				
DAIKIN INDUSTRIES LTD	90,700	JPY	13,010,667	0.98
HOYA CORP	149,300	JPY	13,470,241	1.02
SHIMANO INC	56,700	JPY	8,423,365	0.64
UNI CHARM	177,100	JPY	6,373,765	0.48
			41,278,038	3.12
Netherlands				
ASML HOLDING NV	27,370	EUR	13,789,006	1.04
			13,789,006	1.04
Spain				
IBERDROLA SA	1,125,314	EUR	12,299,682	0.93
			12,299,682	0.93
Switzerland				
NESTLE SA REG SHS	253,155	CHF	27,467,747	2.08
ROCHE HOLDING LTD	62,102	CHF	18,269,918	1.38
TE CONNECTIVITY LTD REG SHS	114,151	USD	12,278,786	0.93
			58,016,451	4.38
United Kingdom				
ASTRAZENECA PLC	151,079	GBP	19,101,766	1.44
DIAGEO PLC	319,350	GBP	13,137,532	0.99
RELX PLC	646,353	EUR	16,701,762	1.26
SHELL PLC	510,008	EUR	13,505,012	1.02
UNILEVER	295,876	EUR	13,867,708	1.05
			76,313,780	5.77
United States of America				
ABBOTT LABORATORIES	196,739	USD	20,238,908	1.53
ADOBE INC	56,161	USD	17,708,935	1.34
ADVANCED MICRO DEVICES INC	182,996	USD	11,105,787	0.84
AIR PRODUCTS & CHEMICALS INC	44,698	USD	12,910,382	0.98
ALLSTATE CORP	149,928	USD	19,049,179	1.44
ALPHABET INC -A-	570,620	USD	47,173,392	3.57
AMAZON.COM INC	361,852	USD	28,480,270	2.15
ANALOG DEVICES INC	98,504	USD	15,139,481	1.14
APPLE INC	347,561	USD	42,313,048	3.20

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Global Demography

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in EUR)	% net assets
BANK OF AMERICA CORP	788,463	USD	24,468,395	1.85
CISCO SYSTEMS INC	423,884	USD	18,921,372	1.43
COCA-COLA CO	349,439	USD	20,827,186	1.57
CONSOLIDATED EDISON INC	155,889	USD	13,921,556	1.05
DANAHER CORP	93,770	USD	23,320,153	1.76
ELI LILLY & CO	32,758	USD	11,229,034	0.85
EXXON MOBIL CORP	154,948	USD	16,013,834	1.21
FORTIVE CORP	212,485	USD	12,791,906	0.97
HOME DEPOT INC	28,669	USD	8,484,788	0.64
IQVIA HOLDINGS INC	62,307	USD	11,961,660	0.90
JOHNSON & JOHNSON	233,664	USD	38,675,798	2.92
MASTERCARD INC -A-	63,267	USD	20,613,571	1.56
MCDONALD'S CORP	83,868	USD	20,709,050	1.57
MERCK & CO INC	257,543	USD	26,773,854	2.02
METLIFE INC	182,267	USD	12,359,487	0.93
MICROSOFT CORP	355,972	USD	79,989,885	6.05
MONDELEZ INTERNATIONAL INC	217,814	USD	13,602,533	1.03
MORGAN STANLEY	271,207	USD	21,605,078	1.63
NIKE INC	109,212	USD	11,973,667	0.90
OTIS WORLDWIDE CORPORATION	225,810	USD	16,568,921	1.25
PAYPAL HOLDINGS	160,400	USD	10,703,854	0.81
PROCTER & GAMBLE CO	292,072	USD	41,477,098	3.13
REPUBLIC SERVICES -A-	140,608	USD	16,994,168	1.28
S&P GLOBAL INC	58,913	USD	18,488,939	1.40
STARBUCKS CORP	208,236	USD	19,355,363	1.46
STRYKER CORP	72,931	USD	16,707,332	1.26
TJX COS INC	189,028	USD	14,098,504	1.07
UNITEDHEALTH GROUP INC	45,094	USD	22,401,440	1.69
VISA INC -A-	154,460	USD	30,068,503	2.27
WALT DISNEY CO	200,915	USD	16,355,582	1.24
			845,581,893	63.91
Total Shares			1,225,733,233	92.64
Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market			1,225,733,233	92.64
Undertakings for Collective Investment				
Shares/Units in investment funds				
Luxembourg				
CANDRIAM EQUITIES L LIFE CARE Z C	2,000	USD	3,115,353	0.24
			3,115,353	0.24
Total Shares/Units in investment funds			3,115,353	0.24
Total Undertakings for Collective Investment			3,115,353	0.24
Total investment portfolio			1,228,848,586	92.88
Acquisition cost			1,223,264,266	

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Global Demography

Geographical and economic breakdown of investments as at December 31, 2022

Geographical breakdown (in % of net assets)

United States of America	63.91
France	6.54
United Kingdom	5.77
Switzerland	4.38
Japan	3.12
Belgium	2.57
Hong Kong	1.40
Canada	1.16
Netherlands	1.04
Finland	0.94
Spain	0.93
Ireland	0.88
Luxembourg	0.24
	92.88

Economic breakdown (in % of net assets)

Pharmaceuticals	13.13
Internet and internet services	10.95
Banks and other financial institutions	8.68
Machine and apparatus construction	5.82
Foods and non alcoholic drinks	5.73
Electronics and semiconductors	5.01
Office supplies and computing	4.63
Graphic art and publishing	3.90
Petroleum	3.86
Retail trade and department stores	3.86
Insurance	3.78
Miscellaneous consumer goods	3.62
Miscellaneous services	3.08
Hotels and restaurants	3.03
Textiles and garments	2.85
Tobacco and alcoholic drinks	2.16
Chemicals	1.99
Utilities	1.98
Healthcare	1.69
Environmental services and recycling	1.28
Building materials	0.99
Road vehicles	0.64
Investments funds	0.24
	92.88

Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Life Care

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in USD)	% net assets
Transferable securities admitted to an official stock exchange listing or dealt in another regulated market				
Shares				
Belgium				
ION BEAM APPLICATIONS	53,000	EUR	880,140	0.14
UCB	24,829	EUR	1,949,248	0.32
			2,829,388	0.46
Cayman Islands				
BEIGENE - REG SHS	195,000	HKD	3,352,865	0.55
JACOBIO PHARMACEUTICALS GROUP CO LTD	574,438	HKD	384,923	0.06
			3,737,788	0.61
Denmark				
BAVARIAN NORDIC	55,000	DKK	1,684,448	0.28
NOVO NORDISK	122,517	DKK	16,493,001	2.70
ZEALAND PHARMA	55,000	DKK	1,589,727	0.26
			19,767,176	3.23
France				
BIOMERIEUX SA	12,000	EUR	1,254,061	0.20
SANOFI	52,890	EUR	5,071,185	0.83
			6,325,246	1.03
Germany				
BIONTECH --- SHS SPONSORED ADR	10,080	USD	1,514,218	0.25
MERCK KGAA	31,592	EUR	6,099,326	1.00
SIEMENS HEALTHINEERS	44,621	EUR	2,225,365	0.36
			9,838,909	1.61
Ireland				
MEDTRONIC HLD	223,228	USD	17,349,280	2.84
			17,349,280	2.84
Japan				
BML INC	236,300	JPY	6,008,462	0.98
DAIICHI SANKYO CO LTD	154,900	JPY	4,989,390	0.82
EISAI	105,700	JPY	6,972,699	1.14
HOYA CORP	60,000	JPY	5,777,407	0.94
OLYMPUS CORP	130,000	JPY	2,317,329	0.38
SHIMADZU CORPORATION	90,800	JPY	2,577,180	0.42
SHINOBI CO LTD	55,000	JPY	2,745,311	0.45
TAKEDA PHARMACEUTICAL	155,660	JPY	4,849,886	0.79
TERUMO CORP.	100,000	JPY	2,839,062	0.46
			39,076,726	6.39
Netherlands				
MERUS - REGISTERED	23,504	USD	363,607	0.06
QIAGEN - REGISTERED	50,000	EUR	2,508,571	0.41
			2,872,178	0.47
South Africa				
ASPEN PHARMACARE HOLDINGS PLC	185,000	ZAR	1,482,284	0.24
			1,482,284	0.24
Spain				
ALMIRALL - BEARER SHS	246,738	EUR	2,380,513	0.39
			2,380,513	0.39
Sweden				
BIOTAGE	30,000	SEK	534,093	0.09
SURGICAL SCIENCE SWEDEN AB	50,000	SEK	790,342	0.13
			1,324,435	0.22
Switzerland				
ALCON - REGISTERED SHS	30,000	CHF	2,048,575	0.33
BACHEM HOLDING LTD SHARES	18,000	CHF	1,553,454	0.25
NOVARTIS AG REG SHS	130,000	CHF	11,744,884	1.92
POLYPEPTIDE GROUP AG	21,000	CHF	574,691	0.09
ROCHE HOLDING LTD	70,835	CHF	22,240,528	3.64
SONOVA HOLDING NAM-AKT	27,085	CHF	6,419,756	1.05

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Life Care

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in USD)	% net assets
TECAN GROUP NAM.AKT	4,198	CHF	1,871,165	0.31
			46,453,053	7.59
United Kingdom				
ASTRAZENECA PLC	96,572	GBP	13,031,272	2.13
CONVATEC GROUP REGD	1,877,647	GBP	5,253,440	0.86
GSK --- REGISTERED SHS	253,938	GBP	4,391,227	0.72
HIKMA PHARMACEUTICALS PLC	100,000	GBP	1,866,861	0.31
			24,542,800	4.01
United States of America				
ABBOTT LABORATORIES	168,256	USD	18,472,826	3.02
ABBVIE INC	96,588	USD	15,609,587	2.55
AGILENT TECHNOLOGIES	19,999	USD	2,992,850	0.49
AKOYA BIOSCIENCES INC	162,300	USD	1,553,211	0.25
ALIGN TECHNOLOGY INC	14,000	USD	2,952,600	0.48
ALNYLAM PHARMACEUTICALS INC	6,490	USD	1,542,348	0.25
AMEDISYS INC	14,000	USD	1,169,560	0.19
AMGEN INC	49,158	USD	12,910,857	2.11
ANDEM DIABETES - REGISTERED SHS	18,587	USD	835,486	0.14
ANTHEM INC	31,694	USD	16,258,071	2.66
AVANTOR - REGISTERED SHS	55,000	USD	1,159,950	0.19
BECTON DICKINSON	15,704	USD	3,993,527	0.65
BIO RAD LABORATORIES -A-	10,590	USD	4,452,989	0.73
BIOGEN IDEC INC	9,239	USD	2,558,464	0.42
BIOMARIN PHARMACEUTICAL INC	20,000	USD	2,069,800	0.34
BOSTON SCIENTIF CORP	230,000	USD	10,642,100	1.74
BRISTOL-MYERS SQUIBB CO	113,262	USD	8,149,201	1.33
BRUKER BIOSCIENCES	72,558	USD	4,959,339	0.81
CATALENT	30,000	USD	1,350,300	0.22
COOPER COMPANIES INC	6,990	USD	2,311,383	0.38
CTI BIOPHARMA CORP	90,000	USD	540,900	0.09
CVS HEALTH	124,380	USD	11,590,972	1.89
DANAHER CORP	63,802	USD	16,934,327	2.77
DENTSPLY SIRONA INC	64,000	USD	2,037,760	0.33
EDWARDS LIFESCIENCES CORP	66,966	USD	4,996,333	0.82
ELI LILLY & CO	63,284	USD	23,151,819	3.78
EXELIXIS	180,000	USD	2,887,200	0.47
GILEAD SCIENCES INC	79,499	USD	6,824,989	1.12
GLOBUS MEDICAL -A-	33,940	USD	2,520,724	0.41
GUARDANT HEALTH --- REGISTERED SHS	55,225	USD	1,502,120	0.25
HCA INC	16,975	USD	4,073,321	0.67
HOLOGIC INC	37,000	USD	2,767,970	0.45
HUMANA INC	19,990	USD	10,238,678	1.67
ILLUMINA INC	11,276	USD	2,280,007	0.37
INSULET	6,000	USD	1,766,340	0.29
INTUITIVE SURGICAL	20,108	USD	5,335,658	0.87
IQVIA HOLDINGS INC	18,000	USD	3,688,020	0.60
ITEOS THERAPEUTICS INC	33,000	USD	644,490	0.11
JOHNSON & JOHNSON	140,317	USD	24,786,998	4.05
KARM THES INC	200,000	USD	680,000	0.11
KURA ONCOLOGY - REGISTERED	85,000	USD	1,054,850	0.17
LABORATORY CORP OF AMERICA HOLDINGS	22,586	USD	5,318,551	0.87
MARAVAI LIFESCIENCES HOLDINGS INC -SH	130,000	USD	1,860,300	0.30
MERCK & CO INC	162,043	USD	17,978,671	2.94
MIRATI THERAPEUTICS INC	35,000	USD	1,585,850	0.26
MODERNA INC	15,000	USD	2,694,300	0.44
NATERA	55,000	USD	2,209,350	0.36
NURIX THERAPETC --- REGISTERED SHS	51,712	USD	567,798	0.09
ORTHOPEDIATRICS CORP	70,842	USD	2,814,553	0.46
OUTSET MEDICAL INC ORDSHR	83,455	USD	2,154,808	0.35

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Life Care

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in USD)	% net assets
PACIRA PHARMACEUTICALS INC	45,000	USD	1,737,450	0.28
PENUMBRA INC	15,000	USD	3,336,900	0.55
PFIZER INC	340,000	USD	17,421,600	2.85
QUEST DIAGNOSTICS	10,000	USD	1,564,400	0.26
REGENERON PHARMACEUTICALS INC	11,271	USD	8,131,914	1.33
RELAY THERAPTCS - REGISTERED SHS	60,000	USD	896,400	0.15
RESMED	20,980	USD	4,366,567	0.71
SEAGEN INC	20,246	USD	2,601,813	0.43
SEER INC	25,000	USD	145,000	0.02
SHOCKWAVE MED --- REGISTERED SHS	10,000	USD	2,056,100	0.34
STRYKER CORP	35,965	USD	8,793,083	1.44
TELADOC HEALTH	18,871	USD	446,299	0.07
THERMO FISHER SCIENT SHS	39,445	USD	21,721,967	3.55
TREACE MEDICAL CONCEPTS INC	105,000	USD	2,413,950	0.39
TWIST BIOSCIENCE CORPORATION	80,000	USD	1,904,800	0.31
UNITEDHEALTH GROUP INC	95,276	USD	50,513,430	8.26
VEEVA SYSTEMS -A-	29,922	USD	4,828,812	0.79
VERTEX PHARMACEUTICALS INC	18,701	USD	5,400,475	0.88
ZIMMER BIOMET HLDGS SHS	38,942	USD	4,965,105	0.81
ZOETIS INC -A-	24,000	USD	3,517,200	0.57
Total Shares			430,195,371	70.31
Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market			608,175,147	99.40
Total investment portfolio			608,175,147	99.40
Acquisition cost			621,346,787	



Candriam Equities L Life Care

Geographical and economic breakdown of investments as at December 31, 2022

Geographical breakdown (in % of net assets)

United States of America	70.31
Switzerland	7.59
Japan	6.39
United Kingdom	4.01
Denmark	3.23
Ireland	2.84
Germany	1.61
France	1.03
Cayman Islands	0.61
Netherlands	0.47
Belgium	0.46
Spain	0.39
South Africa	0.24
Sweden	0.22
	99.40

Economic breakdown (in % of net assets)

Pharmaceuticals	64.06
Healthcare	14.25
Biotechnology	8.96
Electronics and semiconductors	4.92
Machine and apparatus construction	2.77
Banks and other financial institutions	2.23
Miscellaneous services	0.86
Internet and internet services	0.79
Photographic and optics	0.38
Chemicals	0.19
	99.40

Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Meta Globe

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in USD)	% net assets
Transferable securities admitted to an official stock exchange listing or dealt in another regulated market				
Shares				
Cayman Islands				
XIAOMI CORP - REGISTERED SHS -B-	52,675	HKD	73,833	1.77
			73,833	1.77
France				
DASSAULT SYST.	1,783	EUR	63,738	1.53
			63,738	1.53
Germany				
SIEMENS AG REG	621	EUR	85,920	2.06
			85,920	2.06
Japan				
CAPCOM CO LTD	1,200	JPY	38,289	0.92
RENESAS ELECTRONICS	6,900	JPY	61,891	1.48
SONY CORP	800	JPY	60,844	1.46
			161,024	3.86
Luxembourg				
CLOUDFLARE INC	825	USD	37,298	0.89
GLOBANT REG SHS	169	USD	28,419	0.68
PINTEREST REGISTERED SHS -A-	2,571	USD	62,424	1.50
SNOWFLAKE INC-CLASS A	349	USD	50,095	1.20
			178,236	4.28
Netherlands				
UNIVERSAL MUSIC GROUP N.V.	3,266	EUR	78,462	1.88
			78,462	1.88
People's Republic of China				
GOERTEK INC. -A-	15,148	CNY	36,673	0.88
			36,673	0.88
South Korea				
NAVER	436	KRW	61,202	1.47
NCISOFT	141	KRW	49,955	1.20
			111,157	2.67
Sweden				
HEXAGON --- REGISTERED SHS -B-	6,638	SEK	69,441	1.67
SURGICAL SCIENCE SWEDEN AB	2,571	SEK	40,639	0.97
			110,080	2.64
Switzerland				
LOGITECH NAMEN AKT	726	CHF	44,773	1.07
			44,773	1.07
United States of America				
ADOBE INC	457	USD	153,794	3.69
ADVANCED MICRO DEVICES INC	1,983	USD	128,439	3.08
AKAMAI TECHNOLOGIES	1,094	USD	92,224	2.21
ALPHABET INC -A-	1,305	USD	115,140	2.76
ANSYS INC	312	USD	75,376	1.81
APPLE INC	892	USD	115,898	2.78
ARISTA NETWORKS INC	519	USD	62,981	1.51
AUTODESK INC	314	USD	58,677	1.41
BENTLEY SYSTEMS --- REGISTERED SHS -B-	2,064	USD	76,285	1.83
BROADCOM INC - REGISTERED SHS	282	USD	157,675	3.78
CADENCE DESIGN SYSTEMS INC	361	USD	57,991	1.39
CROWDSTRIKE HOLDINGS INC	578	USD	60,858	1.46
ELECTRONIC ARTS - REGISTERED	518	USD	63,289	1.52
EQUINIX INC	120	USD	78,604	1.89
GENERAL ELECTRI	950	USD	79,600	1.91
IBM CORP	1,045	USD	147,230	3.53
INTUITIVE SURGICAL	314	USD	83,320	2.00
KEYSIGHT TECHNOLOGIES	375	USD	64,151	1.54
LIVE NATION ENT	792	USD	55,234	1.33

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Meta Globe

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in USD)	% net assets
MICRON TECHNOLOGY INC	1,192	USD	59,576	1.43
MICROSOFT CORP	592	USD	141,973	3.41
NVIDIA CORP	904	USD	132,111	3.17
OKTA -A-	560	USD	38,265	0.92
PAYPAL HOLDINGS	1,434	USD	102,129	2.45
PTC INC	564	USD	67,703	1.62
QUALCOMM INC	1,107	USD	121,704	2.92
SEA -A- ADR REPR1 SHS	1,112	USD	57,857	1.39
SKYWORKS SOLUTIONS INC	678	USD	61,786	1.48
TAIWAN SEMICONDUCTOR CO ADR (REPR 5 SHS)	1,851	USD	137,881	3.31
TAKE TWO INTERACTIVE SOFTWARE INC	549	USD	57,167	1.37
UNITY SOFTWARE INC	1,432	USD	40,941	0.98
WALT DISNEY CO	1,305	USD	113,378	2.72
ZSCALER INC	578	USD	64,678	1.55
			2,923,915	70.14
Total Shares			3,867,811	92.79
Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market			3,867,811	92.79
Total investment portfolio			3,867,811	92.79
Acquisition cost			3,752,753	



Candriam Equities L Meta Globe

Geographical and economic breakdown of investments as at December 31, 2022

Geographical breakdown (in % of net assets)

United States of America	70.14
Luxembourg	4.28
Japan	3.86
South Korea	2.67
Sweden	2.64
Germany	2.06
Netherlands	1.88
Cayman Islands	1.77
France	1.53
Switzerland	1.07
People's Republic of China	0.88
	92.79

Economic breakdown (in % of net assets)

Internet and internet services	41.31
Electronics and semiconductors	15.41
Office supplies and computing	11.17
Electrical engineering	6.39
Communication	2.92
Graphic art and publishing	2.72
Banks and other financial institutions	2.56
Miscellaneous services	2.45
Pharmaceuticals	2.00
Real estate	1.89
Machine and apparatus construction	1.67
Hotels and restaurants	1.33
Healthcare	0.97
	92.79



Candriam Equities L Oncology Impact

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in USD)	% net assets
Transferable securities admitted to an official stock exchange listing or dealt in another regulated market				
Shares				
Cayman Islands				
BEIGENE - REG SHS	934,215	HKD	16,063,062	0.83
			16,063,062	0.83
Denmark				
GENMAB AS	130,583	DKK	55,116,568	2.85
			55,116,568	2.85
Germany				
MERCK KGAA	392,742	EUR	75,824,940	3.93
MORPHOSYS	178,796	EUR	2,520,733	0.13
SIEMENS HEALTHINEERS	1,501,212	EUR	74,869,334	3.88
			153,215,007	7.93
Japan				
DAIICHI SANKYO CO LTD	2,132,400	JPY	68,685,438	3.56
OLYMPUS CORP	1,019,600	JPY	18,174,991	0.94
			86,860,429	4.50
Jersey				
NOVOCURE --- REGISTERED SHS	84,525	USD	6,199,909	0.32
			6,199,909	0.32
Luxembourg				
IGM BIOSCIENCES INC	105,000	USD	1,786,050	0.09
REVOLUTION MEDICINES INC	395,376	USD	9,417,856	0.49
SPRINGWORKS THERAPEUTICS INC	150,619	USD	3,917,600	0.20
			15,121,506	0.78
Netherlands				
MERUS - REGISTERED	688,076	USD	10,644,536	0.55
			10,644,536	0.55
Switzerland				
LONZA GROUP (CHF)	42,748	CHF	20,934,419	1.08
ROCHE HOLDING LTD	433,697	CHF	136,170,679	7.05
TECAN GROUP NAM.AKT	55,799	CHF	24,871,165	1.29
			181,976,263	9.42
United Kingdom				
ASTRAZENECA PLC	1,182,508	GBP	159,565,750	8.26
BICYCLE THERAPEUTICS PLC	652,934	USD	19,326,846	1.00
IMMUNOCORE HOLDINGS PLC-ADR	110,000	USD	6,277,700	0.33
			185,170,296	9.59
United States of America				
ADICET BIO INC	769,847	USD	6,882,432	0.36
AGILENT TECHNOLOGIES	179,660	USD	26,886,119	1.39
AMGEN INC	296,468	USD	77,864,356	4.03
ARCELLX INC	390,000	USD	12,082,200	0.63
ARVINAS --- REGISTERED SHS	333,254	USD	11,400,619	0.59
BIO RAD LABORATORIES -A-	45,012	USD	18,927,096	0.98
BIOATLA	913,642	USD	7,537,546	0.39
BLUEPRINT MEDICINES CORP	130,063	USD	5,698,060	0.30
COGENT BIOSCIENCES INC	922,449	USD	10,663,510	0.55
DANAHER CORP	304,878	USD	80,920,719	4.19
ELI LILLY & CO	187,160	USD	68,470,614	3.55
EXELIXIS	1,191,641	USD	19,113,922	0.99
FATE THERAPEUTICS	225,529	USD	2,275,588	0.12
GUARDANT HEALTH --- REGISTERED SHS	191,123	USD	5,198,546	0.27
HALOZYME THERAPEUT -SHS-	431,138	USD	24,531,752	1.27
HOLOGIC INC	914,424	USD	68,408,059	3.54
IDEAYA BIOSCIENCES INC	260,000	USD	4,724,200	0.24
ILLUMINA INC	38,235	USD	7,731,117	0.40
IMMUNOGEN INC	1,282,876	USD	6,363,065	0.33
INCYTE CORP	347,120	USD	27,880,678	1.44

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Oncology Impact

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in USD)	% net assets
IOVANCE BIOTHERAPEUTICS INC	711,403	USD	4,545,865	0.24
IQVIA HOLDINGS INC	213,883	USD	43,822,488	2.27
ITEOS THERAPEUTICS INC	406,411	USD	7,937,207	0.41
KARM THES INC	1,235,630	USD	4,201,142	0.22
KEROS THERAPEUTICS INC	240,981	USD	11,571,908	0.60
KURA ONCOLOGY - REGISTERED	466,996	USD	5,795,420	0.30
KYMERA THERAPEUTICS INC	277,815	USD	6,934,262	0.36
MERCK & CO INC	1,398,089	USD	155,117,975	8.03
MERSANA THERAPEUTICS INC	1,592,915	USD	9,334,482	0.48
MIRATI THERAPEUTICS INC	349,720	USD	15,845,813	0.82
NURIX THERAPETC --- REGISTERED SHS	443,096	USD	4,865,194	0.25
NUVALENT INC-A SHARES	240,000	USD	7,147,200	0.37
REGENERON PHARMACEUTICALS INC	170,834	USD	123,255,023	6.38
RELAY THERAPTCS - REGISTERED SHS	593,400	USD	8,865,396	0.46
REPLIMUNE GRP --- REGISTERED SHS	612,162	USD	16,650,806	0.86
SEAGEN INC	366,015	USD	47,036,588	2.44
SUTRO BIOPHARMA INC	1,055,369	USD	8,527,382	0.44
THERMO FISHER SCIENT SHS	161,082	USD	88,706,247	4.59
VERACYTE - REGISTERED SHS	555,898	USD	13,191,460	0.68
VIEWRAY - REGISTERED SHS	1,670,497	USD	7,483,827	0.39
XENCOR INC	351,667	USD	9,157,409	0.47
ZENTALIS PH --- REGISTERED SHS	118,986	USD	2,396,378	0.12
			1,095,949,670	56.75
Total Shares			1,806,317,246	93.54
Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market			1,806,317,246	93.54
Total investment portfolio			1,806,317,246	93.54
Acquisition cost			1,757,562,010	

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Oncology Impact

Geographical and economic breakdown of investments as at December 31, 2022

Geographical breakdown (in % of net assets)

United States of America	56.75
United Kingdom	9.59
Switzerland	9.42
Germany	7.93
Japan	4.50
Denmark	2.85
Cayman Islands	0.83
Luxembourg	0.78
Netherlands	0.55
Jersey	0.32
	93.54

Economic breakdown (in % of net assets)

Pharmaceuticals	51.04
Biotechnology	25.43
Electronics and semiconductors	4.98
Banks and other financial institutions	4.38
Machine and apparatus construction	4.19
Chemicals	1.08
Miscellaneous services	1.00
Photographic and optics	0.94
Healthcare	0.49
	93.54



Candriam Equities L Risk Arbitrage Opportunities

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in EUR)	% net assets
Transferable securities admitted to an official stock exchange listing or dealt in another regulated market				
Shares				
Canada				
HOME CAPITAL GROUP -B- SUB.VOTING	25,903	CAD	762,733	1.38
SHAW COMMUNICATIONS -B- NON.VOTING	11,275	CAD	304,165	0.55
			1,066,898	1.94
Finland				
CAVERION OYJ	2,531	EUR	17,540	0.03
			17,540	0.03
Ireland				
HORIZON THERAPEUTICS PLC	3,250	USD	346,545	0.63
			346,545	0.63
Israel				
TOWER SEMICONDUCTOR	18,805	USD	761,186	1.38
			761,186	1.38
Italy				
AUTOGRILL SPA	85,685	EUR	553,696	1.00
			553,696	1.00
Marshall Islands				
ATLAS CORP	929	USD	13,353	0.02
			13,353	0.02
New Zealand				
PUSHPAY - REGISTERED SHS DEFERRED DELIV	145,892	NZD	110,662	0.20
			110,662	0.20
United States of America				
1LIFE HEALTHCARE INC	45,679	USD	715,199	1.30
ACTIVISION BLIZZARD	9,727	USD	697,683	1.27
ALTRA HOLDINGS INC	11,964	USD	669,805	1.21
ATLAS AIR WORLDWIDE HOLDINGS INC	22,914	USD	2,164,189	3.93
AVEO PHARMACEUTICALS INC	150	USD	2,101	0.00
COWEN GROUP INC-A-REG	8,691	USD	314,497	0.57
EVO PAYMENTS - REGISTERED SHS -A-	83,071	USD	2,633,987	4.78
FIRST HORIZON CORPORATION	89,443	USD	2,053,271	3.72
FORGEROCK INC	96,463	USD	2,058,058	3.73
IAA SPINCO - REGISTERED SHS W/I	36,019	USD	1,349,974	2.45
IMAGO BIOSCIENCES-REGS	19,696	USD	663,454	1.20
IROBOT	45,571	USD	2,055,125	3.73
LHC GROUP	4,613	USD	698,877	1.27
MONEYGRAM INTERNATIONAL	136,670	USD	1,394,553	2.53
SIGNIFY HEALTH INC	13,523	USD	363,148	0.66
STORE CAPITAL CORP	23,148	USD	695,362	1.26
TEGNA	77,459	USD	1,537,930	2.79
UMPQUA HOLDINGS	45,129	USD	754,793	1.37
			20,822,006	37.77
Total Shares			23,691,886	42.97
Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market			23,691,886	42.97
Total investment portfolio			23,691,886	42.97
Acquisition cost			25,270,693	

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Risk Arbitrage Opportunities

Geographical and economic breakdown of investments as at December 31, 2022

Geographical breakdown (in % of net assets)

United States of America	37.77
Canada	1.94
Israel	1.38
Italy	1.00
Ireland	0.63
New Zealand	0.20
Finland	0.03
Marshall Islands	0.02
	42.97

Economic breakdown (in % of net assets)

Internet and internet services	10.43
Banks and other financial institutions	9.41
Transportation	3.95
Miscellaneous consumer goods	3.73
Graphic art and publishing	2.79
Healthcare	2.56
Road vehicles	2.45
Electronics and semiconductors	1.38
Non Classifiable Institutions	1.38
Real estate	1.26
Biotechnology	1.20
Hotels and restaurants	1.00
Pharmaceuticals	0.63
Communication	0.55
Office supplies and computing	0.20
Building materials	0.03
	42.97

Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Robotics & Innovative Technology

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in USD)	% net assets
Transferable securities admitted to an official stock exchange listing or dealt in another regulated market				
Shares				
Cayman Islands				
AMBARELLA INC	232,785	USD	19,141,911	1.52
			19,141,911	1.52
France				
SCHNEIDER ELECTRIC SE	256,310	EUR	35,758,044	2.85
			35,758,044	2.85
Germany				
SAP AG	223,651	EUR	23,007,477	1.83
SIEMENS AG REG	360,283	EUR	49,848,140	3.97
			72,855,617	5.80
Japan				
DAIFUKU CO	398,500	JPY	18,664,823	1.49
FANUC CORP SHS	132,600	JPY	19,933,465	1.59
KEYENCE CORP	77,000	JPY	30,007,503	2.39
NABTESCO CORP	937,500	JPY	23,909,110	1.90
NIDEC CORP	461,900	JPY	23,941,295	1.91
ROHM CO LTD	163,300	JPY	11,794,680	0.94
SMC CORP	60,600	JPY	25,526,909	2.03
			153,777,785	12.24
Jersey				
APTIV PLC	258,702	USD	24,092,917	1.92
			24,092,917	1.92
Luxembourg				
TENABLE HOLDINGS INC	501,554	USD	19,134,285	1.52
			19,134,285	1.52
Netherlands				
ASML HOLDING NV	73,731	EUR	39,643,725	3.15
STMICROELECTRONICS NV	1,001,746	EUR	35,282,302	2.81
			74,926,027	5.96
Switzerland				
TECAN GROUP NAM.AKT	48,753	CHF	21,730,567	1.73
			21,730,567	1.73
United States of America				
ADOBE INC	58,451	USD	19,670,515	1.57
ADVANCED MICRO DEVICES INC	467,355	USD	30,270,583	2.41
ALPHABET INC -A-	583,946	USD	51,521,556	4.10
ANALOG DEVICES INC	246,431	USD	40,422,077	3.22
ANSYS INC	84,357	USD	20,379,808	1.62
APPLIED MATERIALS INC	410,617	USD	39,985,883	3.18
AUTODESK INC	146,195	USD	27,319,460	2.17
CERENCE INC	520,072	USD	9,636,934	0.77
CROWDSTRIKE HOLDINGS INC	177,970	USD	18,738,461	1.49
DATADOG INC	153,863	USD	11,308,930	0.90
EMERSON ELECTRIC CO	605,374	USD	58,152,226	4.63
INTUITIVE SURGICAL	112,222	USD	29,778,108	2.37
KEYSIGHT TECHNOLOGIES	114,437	USD	19,576,738	1.56
MICROSOFT CORP	172,135	USD	41,281,416	3.29
MONGODB INC	84,490	USD	16,631,012	1.32
NVIDIA CORP	116,380	USD	17,007,773	1.35
ON SEMICONDUCTOR CORP	275,580	USD	17,187,925	1.37
PALO ALTO NETWORKS	200,991	USD	28,046,284	2.23
PAYPAL HOLDINGS	199,137	USD	14,182,537	1.13
PTC INC	369,100	USD	44,306,764	3.53
QUALCOMM INC	192,321	USD	21,143,771	1.68
ROCKWELL AUTOMATION	159,332	USD	41,039,143	3.27
SALESFORCE.COM INC	126,770	USD	16,808,434	1.34
SERVICENOW INC	79,269	USD	30,777,775	2.45

The accompanying notes form an integral part of the financial statements.
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Robotics & Innovative Technology

Investment portfolio as at December 31, 2022

Description	Quantity	Currency	Market value (in USD)	% net assets
SILICON LABORATORIES INC	233,702	USD	31,706,350	2.52
TAIWAN SEMICONDUCTOR CO ADR (REPR 5 SHS)	164,934	USD	12,285,934	0.98
TRIMBLE	514,497	USD	26,012,968	2.07
UNIVERSAL DISPLAY	186,250	USD	20,122,450	1.60
VARONIS SYSTEMS INC	767,168	USD	18,366,002	1.46
			773,667,817	61.57
Total Shares			1,195,084,970	95.11
Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market			1,195,084,970	95.11
Undertakings for Collective Investment				
Shares/Units in investment funds				
Luxembourg				
CANDRIAM EQUITIES L META GLOBE Z C	666	USD	1,042,437	0.08
			1,042,437	0.08
Total Shares/Units in investment funds			1,042,437	0.08
Total Undertakings for Collective Investment			1,042,437	0.08
Total investment portfolio			1,196,127,407	95.19
Acquisition cost			1,427,615,513	



Candriam Equities L Robotics & Innovative Technology

Geographical and economic breakdown of investments as at December 31, 2022

Geographical breakdown (in % of net assets)

United States of America	61.57
Japan	12.24
Netherlands	5.96
Germany	5.80
France	2.85
Jersey	1.92
Switzerland	1.73
Luxembourg	1.61
Cayman Islands	1.52
	95.19

Economic breakdown (in % of net assets)

Electronics and semiconductors	32.19
Internet and internet services	30.82
Electrical engineering	17.85
Machine and apparatus construction	5.42
Pharmaceuticals	4.10
Road vehicles	1.92
Communication	1.68
Miscellaneous services	1.13
Investments funds	0.08
	95.19



Notes to the financial statements - Schedule of derivative instruments

hForward foreign exchange contracts

As at December 31, 2022, the following forward foreign exchange contracts were outstanding:

Candriam Equities L Biotechnology

Currency purchased	Quantity purchased	Currency sold	Quantity sold	Maturity date	Counterparty	Unrealised (in USD)
CHF	759,147	USD	823,063	17/01/2023	CACEIS Bank, Lux. Branch	(1,285)
EUR	96,471,938	USD	102,916,502	17/01/2023	CACEIS Bank, Lux. Branch	145,229
USD	70,551	CHF	65,421	17/01/2023	CACEIS Bank, Lux. Branch	(267)
USD	9,228,157	EUR	8,682,317	17/01/2023	CACEIS Bank, Lux. Branch	(47,178)
						96,499

Candriam Equities L Emerging Markets

Currency purchased	Quantity purchased	Currency sold	Quantity sold	Maturity date	Counterparty	Unrealised (in EUR)
EUR	3,751	USD	4,001	17/01/2023	CACEIS Bank, Lux. Branch	(2)
USD	76,100	EUR	71,905	17/01/2023	CACEIS Bank, Lux. Branch	(533)
						(535)

Candriam Equities L Europe Innovation

Currency purchased	Quantity purchased	Currency sold	Quantity sold	Maturity date	Counterparty	Unrealised (in EUR)
EUR	161,011	USD	171,193	17/01/2023	CACEIS Bank, Lux. Branch	765
USD	2,318,400	EUR	2,173,081	17/01/2023	CACEIS Bank, Lux. Branch	(2,918)
						(2,153)

Candriam Equities L Oncology Impact

Currency purchased	Quantity purchased	Currency sold	Quantity sold	Maturity date	Counterparty	Unrealised (in USD)
CHF	84,143	JPY	12,224,487	06/01/2023	J.P. Morgan SE	(1,713)
CHF	40,000	JPY	5,859,050	06/01/2023	BNP Paribas Paris	(1,176)
DKK	114,670	JPY	2,209,600	06/01/2023	J.P. Morgan SE	(292)
DKK	228,726	JPY	4,453,045	06/01/2023	BNP Paribas Paris	(929)
EUR	54,308	JPY	7,864,010	06/01/2023	J.P. Morgan SE	(1,652)
EUR	70,397	JPY	10,089,496	06/01/2023	BNP Paribas Paris	(1,351)
EUR	5,582	JPY	795,276	06/01/2023	Société Générale	(71)
EUR	304,891,221	USD	325,310,857	17/01/2023	CACEIS Bank, Lux. Branch	406,834
GBP	38,586	JPY	6,402,109	06/01/2023	J.P. Morgan SE	(2,122)
GBP	21,974	JPY	3,701,186	06/01/2023	BNP Paribas Paris	(1,628)
GBP	22,708	JPY	3,713,831	06/01/2023	Société Générale	(841)
HKD	115,695	JPY	2,026,669	06/01/2023	J.P. Morgan SE	(541)
JPY	79,939,471	CHF	545,244	06/01/2023	J.P. Morgan SE	16,598
JPY	27,965,497	DKK	1,449,596	06/01/2023	J.P. Morgan SE	3,944
JPY	72,061,408	EUR	502,086	06/01/2023	BNP Paribas Paris	10,400
JPY	5,165,990	EUR	36,881	06/01/2023	Société Générale	(201)
JPY	69,199,366	GBP	416,717	06/01/2023	BNP Paribas Paris	23,362
JPY	2,443,962	GBP	15,325	06/01/2023	Société Générale	95
JPY	719,215	HKD	41,377	06/01/2023	J.P. Morgan SE	151
JPY	7,451,779	HKD	421,699	06/01/2023	BNP Paribas Paris	2,464
JPY	528,023,319	USD	3,808,185	06/01/2023	J.P. Morgan SE	195,211
JPY	46,261,582	USD	346,656	06/01/2023	BNP Paribas Paris	4,098
USD	21,688,214	EUR	20,394,196	17/01/2023	CACEIS Bank, Lux. Branch	(98,955)
USD	324,278	JPY	44,168,758	06/01/2023	J.P. Morgan SE	(10,605)
USD	529,953	JPY	71,893,212	06/01/2023	BNP Paribas Paris	(15,136)
USD	118,322	JPY	16,133,819	06/01/2023	Société Générale	(4,003)
						521,941



Notes to the financial statements - Schedule of derivative instruments

Candriam Equities L Risk Arbitrage Opportunities

Currency purchased	Quantity purchased	Currency sold	Quantity sold	Maturity date	Counterparty	Unrealised (in EUR)
EUR	1,184,890	CAD	1,700,000	06/01/2023	UBS Europe SE	9,510
EUR	2,780,879	JPY	400,000,000	06/01/2023	UBS Europe SE	(60,201)
EUR	120,700	NZD	200,000	06/01/2023	J.P. Morgan SE	2,202
EUR	28,583,943	USD	30,000,000	06/01/2023	J.P. Morgan SE	480,422
JPY	400,000,000	EUR	2,784,697	06/01/2023	UBS Europe SE	56,384
USD	6,200,000	EUR	5,837,204	06/01/2023	UBS Europe SE	(29,128)
						459,189

Candriam Equities L Robotics & Innovative Technology

Currency purchased	Quantity purchased	Currency sold	Quantity sold	Maturity date	Counterparty	Unrealised (in USD)
EUR	13,744,175	USD	14,664,420	17/01/2023	CACEIS Bank, Lux. Branch	18,590
GBP	199,009	USD	246,668	17/01/2023	CACEIS Bank, Lux. Branch	(7,192)
USD	1,596,302	EUR	1,500,493	17/01/2023	CACEIS Bank, Lux. Branch	(6,678)
USD	24,743	GBP	20,421	17/01/2023	CACEIS Bank, Lux. Branch	170
						4,890

Please refer to Note 13 for collateral received/posted in relation with the forward foreign exchange contracts. These operations on forward foreign exchange contracts are mainly allocated to the classes of shares hedged against exchange risk.



Notes to the financial statements - Schedule of derivative instruments

Futures

As at December 31, 2022, the following futures contracts were outstanding:

Candriam Equities L Europe Optimum Quality

Quantity (purchase/(sale))	Description	Currency	Commitment (in EUR) (in absolute value)	Counterparty	Unrealised (in EUR)
Futures on index					
(6,500)	DJ EURO STOX /202303	EUR	246,585,300	J.P. Morgan SE	4,220,160
					4,220,160

Please refer to Note 12 about Cash at broker related to futures.



Notes to the financial statements - Schedule of derivative instruments

Contracts for difference

As at December 31, 2022, the following CFD contracts were outstanding:

Candriam Equities L Risk Arbitrage Opportunities

Quantity	Long / Short position	Currency	Underlying	Counterparty	Commitment (in EUR) (in absolute value)	Unrealised (in EUR)
128,624	Long	GBP	MICRO FOCUS INT	BARCLAYS BANK IRELAND PLC	767,467	10,438
26,887	Short	USD	COLUMBIA BANKING SYSTEM INC	UBS FRANCFORT	759,059	91,198
190,843	Long	GBP	DEVRO INTERNATIONAL PLC	J.P. MORGAN SE	662,492	12,906
328,403	Long	GBP	MEDICLINIC INTERNATIONAL PLC	J.P. MORGAN SE	1,843,276	2,961
52,349	Long	GBP	HOMESERVE SHS	J.P. MORGAN SE	706,247	4,130
20,905	Short	USD	RITCHIE BROTHERS AUCTIONEERS	J.P. MORGAN SE	1,132,758	(69,928)
257,401	Long	EUR	EDF SA	CITIGROUP GLOBAL MARKETS DEUTSCHLAND AG	3,088,812	0
						51,705

Please refer to Note 12 about Cash at broker related to CFD contracts.



Other notes to the financial statements

Note 1 - General Information

Candriam Equities L (hereafter the "SICAV" or "the Fund") was incorporated for an indefinite period on April 27, 1994 under the name "BIL Equities" in the form of a Société d'Investissement à Capital Variable (SICAV) in accordance with the provisions of the part I of the law of December 17, 2010, as amended, relating to undertakings for collective investment and the Law of August 10, 1915, as amended, on commercial undertakings. Its minimum capital is EUR 1,250,000.

The Articles of Incorporation of the SICAV were published in the "Mémorial, Recueil des Sociétés et Associations" dated June 9, 1994. They have been modified several times, in particular, for the last time on April 6, 2020. The corresponding modifications were published in the "Recueil Electronique des Sociétés et Associations" ("RESA"). The SICAV is registered in the Luxembourg Commercial and Companies Register under the number B-47449.

During the year, the following sub-fund has been closed:

<u>Sub-funds</u>	<u>Closing date</u>
Candriam Equities L Japan	May 23, 2022

The following sub-funds are currently available to investors:

<u>Sub-funds</u>	<u>Reference currency</u>
Candriam Equities L Australia	AUD
Candriam Equities L Biotechnology	USD
Candriam Equities L Emerging Markets	EUR
Candriam Equities L EMU Innovation	EUR
Candriam Equities L Europe Innovation	EUR
Candriam Equities L Europe Optimum Quality	EUR
Candriam Equities L Global Demography	EUR
Candriam Equities L Life Care	USD
Candriam Equities L Meta Globe (launched on 01.07.2022)	USD
Candriam Equities L Oncology Impact	USD
Candriam Equities L Risk Arbitrage Opportunities	EUR
Candriam Equities L Robotics & Innovative Technology	USD

The structure of multiple sub-funds offers investors not only the advantage of being able to choose between different sub-funds but also of being able to switch between these sub-funds if allowed. Within each sub-fund, the SICAV may issue different share classes which differ in particular in terms of the fees and commissions payable or in terms of their distribution policy.

The issued share classes are the following:

- The **BF class** is reserved for Belgian-law feeder UCIs approved by the Management Company and managed by an entity of the Candriam group.
- The **C class** is offered to individuals and companies.
- The **CB class** is reserved only for certain bank distributors approved by the Management Company.
- The **I class** is restricted exclusively to institutional investors whose initial minimum subscription is EUR 250,000. This minimum may be modified at the discretion of the Board of Directors, on condition that equal treatment of shareholders is ensured on the same valuation day. For the sub-fund Candriam Equities L Oncology Impact, the Board of Directors decided to close the share class I Distribution (ISIN: LU1864482432) with effect from July 11, 2022, since no further commercial interest has been identified for such a share class.
- The **I2 class** is a share class with no performance fee that is reserved solely for institutional investors with a minimum initial subscription of EUR 250,000, or the equivalent in foreign currencies for the classes denominated in foreign currencies (the Board of Directors may adjust this minimum at its discretion provided all shareholders are treated equally on a given valuation day).
- The **LOCK class** (hereinafter "L class") is a share class linked to a mechanism aimed at limiting the capital risk taken. This mechanism is offered only by Belfius Banque S.A., the sole distributor authorized to distribute these shares. By investing in this class, the investor agrees that the shares be automatically sold as soon as the net asset value has reached a predetermined amount (activation price). Thus when Belfius Banque S.A. ascertains that the net asset value is equal to or lower than the activation price, a redemption order is automatically generated and executed as soon as possible. The sale order will be globalized at the first cut-off date (closing date for receipt of orders) following the date on which the net asset value that gave rise to the automatic triggering of the redemption order was calculated. Given the specific nature of this class, potential investors are invited, before subscribing, to obtain information from their financial adviser at Belfius Banque S.A. in order to familiarize themselves with the technical and operational requirements related to this mechanism.
- The **N class** is restricted to distributors especially authorised by the Management Company.



Other notes to the financial statements

Note 1 - General Information (Continued)

- The **P class** is reserved for (i) occupational retirement pension institutions and/or similar investment vehicles, established at the initiative of one or more employers for the benefit of their employees and (ii) groups of one or more employers investing the funds that they hold in order to provide retirement benefits to their employees. The minimum initial subscription is EUR 15,000,000.
- The **PI class** is reserved for institutional investors which subscribe before the sub-fund has reached a critical size in terms of assets under management. The minimum initial subscription is EUR 1,000,000, or the equivalent amount in the relevant currency for classes denominated in other currencies (the Board of Directors may adjust this minimum at its discretion provided all shareholders are treated equally on a given valuation day). This class will remain open to subscriptions until one of the following events occurs: (i) the period set by the Board of Directors has expired; (ii) the sub-fund has reached a critical size in terms of assets under management, as defined by the Board of Directors; (iii) the Board of Directors has decided, on justified grounds, to close this class to subscriptions. The Board of Directors has the option of re-opening this share class at its discretion, without being obliged to inform investors beforehand.
- The **R class** is reserved for financial intermediaries (including distributors and platforms) which:
 - have separate arrangements with their clients for the provision of investment services related to the sub-fund, and
 - are not entitled to accept and retain from the Management Company and to retain, on account of their applicable laws and regulations or further to agreements with their clients, any fees, commissions or other monetary benefits in connection with the provision of the above-mentioned investment service.
- The **R2 class** is reserved:
 - for distributors and/or intermediaries approved by the Management Company and which do not receive, for investments in this class, any form of remuneration from an entity of the Candriam Group when the final investments in the shares are made in the context of a mandate.
 - for UCIs approved by the Management Company.
- The **S class** is a share class reserved exclusively for institutional investors which have been especially approved by the Management Company.
- The **SF2 class** is reserved for feeder funds approved by the Management Company and managed by delegation by an entity of the Candriam group. The minimum holding in this class is EUR 200,000,000 or the equivalent in foreign currencies for classes denominated in foreign currencies. This amount may be changed at the discretion of the Board of Directors provided that shareholders are treated equally.
- The **V class** is restricted exclusively to institutional investors whose initial minimum subscription is EUR 15,000,000 or its equivalent in foreign currencies for the classes denominated in foreign currencies (this minimum amount may be modified at the discretion of the Board of Directors, on condition that equal treatment of shareholders is ensured on the same valuation day).
- The **V2 class** is a share class with no performance fee and is restricted to institutional/professional investors, distributors and/or intermediaries approved by the Management Company, and whose initial minimum subscription is EUR 15,000,000 or the equivalent in foreign currencies for the classes denominated in foreign currencies (this amount can be reviewed at the directors' discretion; in this case, equal treatment of shareholders must be ensured on the same valuation day).
- The **Y class** is a share class reserved exclusively for institutional investors which have been especially approved by the Management Company.
- The **Z class** is reserved:
 - for institutional/professional investors approved by the Management Company. Since the portfolio management activity for this class is remunerated directly via the contract concluded with the investor, no portfolio management fee will be charged on the assets of this class.
 - for UCIs approved by the Management Company and managed by an entity of the Candriam Group.
- The **ZF class** is reserved for feeder UCIs approved by the Management Company and managed by an entity of the Candriam group.

The assets of the various classes are pooled within a single account.

Furthermore, a currency hedging process may be applied to the share classes:

- **Base currency hedged share classes:**
These hedged share classes aim to reduce the effect of exchange rate fluctuations between the base currency of the sub-fund and the currency in which the hedged share class is denominated.
The aim of this type of hedging is for the performance of the hedged share class to be reasonably comparable (after adjusting for the difference in interest rates between the two currencies) to the performance of a share class denominated in the sub-fund's base currency. This type of hedging is identified with the suffix H added in the denomination of the share class.
- **Asset hedged share classes:**
These hedged share classes aim to reduce the effect of exchange rate fluctuations between the currencies in which a sub-fund's investments are held and the currency of the hedged share class. This type of hedging is identified with the suffix AH added in the denomination of the share class.

The shares issued are described in detail in the section "Statistics" of the various sub-funds.

In the frame of the Sustainable Finance Disclosure Regulation (SFDR), information on environmental and/or social characteristics and/or sustainable investments is available in the relevant annexes under the (unaudited) Sustainable Finance Disclosure Regulation section.



Other notes to the financial statements

Note 2 - Principal accounting policies

The financial statements of the SICAV are prepared in accordance with Luxembourg regulations relating to Undertakings for Collective Investment. Some small discrepancies might appear in some totals or sub-totals in the financial statements due to rounding rules.

The net asset values used for the purpose of the financial statements are dated:

- Sub-fund Candriam Equities L Australia: the net asset value has been calculated on December 31, 2022 on the basis of the closing stock market prices dated December 30, 2022;
- Sub-fund Candriam Equities L Emerging Markets : the net asset values has been calculated on December 31, 2022 on the basis of the stock market prices dated December 31, 2022 for Asian markets opened at that date and on the basis of the stock market prices dated December 30, 2022;
- For the other sub-funds of the SICAV, the net asset values dated December 31, 2022 have been calculated on January 2, 2023 on the basis of the last known prices at the time of the valuation.

This annual report is prepared on the basis of the last unofficial technical net asset values, calculated for the purpose of the financial statements as at December 31, 2022.

a) Valuation of each sub-fund's portfolio

The valuation of any security admitted for trading to an official listing or any other normally operating regulated market which is recognised and open to the public is based on the last price known in Luxembourg on the valuation date or, if this stock is traded on several markets, on the last known price on the principal market on which it is traded. If the last known price is not representative, the valuation shall be based on the probable realisation value as estimated by the Board of Directors with prudence and good faith. Securities which are neither quoted nor traded on a stock market or any other normally operating regulated market which is recognised and open to the public shall be valued on the basis of the probable realisation value as estimated with due prudence and good faith. All other assets shall be valued by the directors on the basis of the probable realisation value which must be estimated in good faith and according to generally accepted principles and procedures.

b) Net realised profits or losses on sales of investments

The realised profits or losses realised on sales of investments from each sub-fund are calculated based on the average cost of the investments sold.

c) Foreign currency translation

The values expressed in a currency other than the reference currency of each sub-fund are translated into that currency at the exchange rate prevailing at closing date.

Income and expenses in a currency other than the reference currency of each sub-fund are translated into that currency at the exchange rates prevailing at the transaction date.

The acquisition cost of securities in each sub-fund expressed in a currency other than the reference currency of the sub-fund is translated into that currency at the exchange rates prevailing at the day of purchase.

For the sub-funds Candriam Equities L Biotechnology, Candriam Equities L EMU Innovation, Candriam Equities L Europe Innovation, Candriam Equities L Europe Optimum Quality, Candriam Equities L Global Demography, Candriam Equities L Life Care, Candriam Equities L Oncology Impact, Candriam Equities L Robotics & Innovative Technology, Candriam Equities L Risk Arbitrage Opportunities, Candriam Equities L Meta Globe, the exchange rates used as at December 31, 2022 are as follows:

1 EUR =	1.573750	AUD	1 EUR =	7.436450	DKK	1 EUR =	10.513500	NOK	1 EUR =	1.067250	USD
1 EUR =	1.446050	CAD	1 EUR =	0.887250	GBP	1 EUR =	1.687500	NZD	1 EUR =	18.159250	ZAR
1 EUR =	0.987450	CHF	1 EUR =	8.329850	HKD	1 EUR =	4.681250	PLN			
1 EUR =	24.154000	CZK	1 EUR =	140.818300	JPY	1 EUR =	11.120250	SEK			

For the sub-funds Candriam Equities L Australia, Candriam Equities L Emerging Markets, the exchange rates used as at December 31, 2022 are as follows:

1 EUR =	1.570410	AUD	1 EUR =	0.882790	GBP	1 EUR =	20.759000	MXN	1 EUR =	1.065200	USD
1 EUR =	5.630300	BRL	1 EUR =	8.303800	HKD	1 EUR =	4.688300	PLN	1 EUR =	18.052800	ZAR
1 EUR =	1.443570	CAD	1 EUR =	400.130000	HUF	1 EUR =	1.430400	SGD			
1 EUR =	0.985090	CHF	1 EUR =	16585.490000	IDR	1 EUR =	36.777700	THB			
1 EUR =	7.406000	CNY	1 EUR =	88.140900	INR	1 EUR =	19.937600	TRY			
1 EUR =	24.178000	CZK	1 EUR =	1342.330000	KRW	1 EUR =	32.734000	TWD			



Other notes to the financial statements

Note 2 - Principal accounting policies (Continued)

d) Combined financial statements of the SICAV

The combined statement of the SICAV's net assets and the combined statement of changes in net assets which are expressed in EUR are the sum of the statement of net assets, the statement of changes in net assets of each sub-fund converted into the currency of the SICAV using exchange rates prevailing at the closing date.

The investments made by certain sub-funds of the SICAV in other sub-funds of the SICAV have not been eliminated from the combined statement of net assets as of December 31, 2022. As of December 31, 2022, the total of intra-SICAV investments amounted to EUR 3,895,797. Therefore, the combined net assets at the closing date would amount to EUR 10,035,310,220 if these intra-SICAV investments were eliminated.

Sub-funds	Intra-SICAV Investments	Amount (in EUR)
Candriam Equities L Global Demography	CANDRIAM EQUITIES L LIFE CARE Z CAPITALISATION	2,919,047
Candriam Equities L Robotics & Innovative Technology	CANDRIAM EQUITIES L META GLOBE Z CAPITALISATION	976,750

e) Valuation of options and futures

The valuation of options and futures admitted to an official listing or any other organised market is based on the last known price or, if the option is traded on more than one market, on the basis of the last known price in the market on which the contract was concluded by the SICAV.

Options and futures that are not traded on a stock exchange or any other organised market will be valued at their probable market value estimated conservatively and in good faith. The market value of options is included in the statement of net assets under the heading "options (long position) / (short position) at market value".

The realised gains / (losses) and change in unrealised appreciation / depreciation on options are disclosed in the statement of changes in net assets respectively under the headings "Net realised gain / (loss) on options" and "Change in net unrealised appreciation / depreciation on options".

The unrealised appreciation / (depreciation) on future contracts is disclosed in the statement of net assets under "Net unrealised appreciation / (depreciation) on futures". Changes in the market value of open future contracts are recorded as unrealised appreciation / (depreciation) in the statement of changes in net assets under "Change in net unrealised appreciation / depreciation on futures". Realised gains or losses, representing the difference between the value of the contract at the time it was opened and the value at the time it was closed, are reported at the closing or expiration of futures contracts in the statement of changes in net assets under "Net realised gain / (loss) on futures".

For the details of outstanding options or financial futures, if any, please refer to the section "Notes to the financial statements - Schedule of derivative instruments".

f) Valuation of Contracts for difference ("CFD")

Contracts for difference are valued at fair value based respectively on the last known spread curve, rates curve and last known closing price of the underlying asset.

The unrealised appreciation / (depreciation) on CFD is disclosed in the statement of net assets under "Net unrealised appreciation / (depreciation) on CFD". Realised gains / (losses) and change in unrealised appreciation / depreciation resulting there from are included in the statement of changes in net assets respectively under "Net realised gain / (loss) on CFD" and "Change in net unrealised appreciation / depreciation on CFD".

For the details of outstanding CFD contracts, if any, please refer to the section "Notes to the report - Schedule of derivative instruments".

g) Valuation of forward foreign exchange contracts

The forward foreign exchange contracts are valued on the basis of forward exchange rates prevailing at the closing date and applicable to the remaining period until the expiration date. The unrealised appreciation / (depreciation) on forward foreign exchange contracts is disclosed in the statement of net assets under "Net unrealised appreciation / (depreciation) on forward foreign exchange contracts".

Realised gains / (losses) and change in unrealised appreciation / depreciation resulting there from are included in the statement of changes in net assets respectively under "Net realised gain / (loss) on forward foreign exchanges contracts" and "Change in net unrealised appreciation / depreciation on forward foreign exchange contracts".

For the details of outstanding forward foreign exchange contracts, if any, please refer to the section "Notes to the financial statements - Schedule of derivative instruments".

h) Repurchase agreements

Each sub-fund may enter into repurchase agreements, which involve the sale and purchase of securities whose terms grant the seller the right to repurchase the securities at a price and terms stipulated by the parties at the time the contract is established.

i) Formation expenses

Formation expenses are amortised using the straight-line method over 5 years at 20% per annum.

j) Transaction costs

For the year ended December 31, 2022, the SICAV incurred transaction costs and broker's charges related to the purchase and sale of transferable securities, money market instruments, other eligible assets and derivatives instruments. Those charges are disclosed in the statement of changes in net assets under the heading "Transaction costs".

k) Income

Interest income is accrued pursuant to the terms of the underlying investment. Income is recorded net of respective withholding taxes, if any. Dividends are recognised on ex-date.



Other notes to the financial statements

Note 2 - Principal accounting policies (Continued)

l) Abbreviations used in investment portfolios

A: Annual
 FL.R: Floating Rate Notes
 Q: Quarterly
 S: Semi-Annual
 XX: Perpetual Bonds
 ZCP or U: Zero Coupon

Note 3 - Management fees

Candriam (hereinafter referred to as the "Management Company"), a partnership limited by shares under Luxembourg law was established in Luxembourg on July 10, 1991, has been appointed as Management Company of the SICAV on the basis of an agreement concluded between the SICAV and Candriam applicable on December 30, 2005.

The Management Company, having its registered office at SERENITY - Bloc B, 19-21, Route d'Arlon, L-8009 Strassen, is a subsidiary of Candriam Group, an entity of the New York Life Insurance Company Group.

It is authorised as a Management Company of Chapter 15 of the law of December 17, 2010, concerning UCITS and is authorised to exercise the activities of collective portfolio management, investment portfolio management and to provide investment advisory services.

The Management Company is vested with the widest powers to carry out all actions relating to the management and administration of the SICAV within the scope of this purpose, in accordance with its articles of association. It is responsible for the portfolio management activities, administration activities (Administrative Agent, Transfer Agent (including the Register holding business)) and marketing activities (distribution).

In accordance with the law of December 17, 2010, the Management Company is authorised to delegate its functions, powers and obligations or a part thereof to any person or company whom/which it deems appropriate. However, the Management Company retains full responsibility for the acts accomplished by this (these) representative(s).

Until June 30, 2022, the Management Company delegated, under its supervision and responsibility and at its own expense, the portfolio management of certain sub-funds of the SICAV to its Belgian subsidiary Candriam Belgium, whose registered office is at Avenue des Arts 58, B-1000 Brussels via a delegation agreement entered into for an unlimited term. This agreement may be terminated by either party subject to advance written notice of 90 days or by the Manager with immediate effect when the investors' interests are involved.

All the sub-funds of the SICAV were affected by this delegation, except the Candriam Equities L Australia sub-fund and Candriam Equities L Risk Arbitrage Opportunities.

Since July 1, 2022, the portfolio management function is no more delegated and is performed directly by Candriam and/or by one or more of its branches : Candriam-Belgian Branch, Candriam – Succursale française, Candriam – UK Establishment.

The Management Company delegated, under its supervision, responsibility and expense, the implementation of portfolio management for the Candriam Equities L Australia sub-fund to Ausbil Management Limited via a delegation agreement entered into for an unlimited term. This agreement may be terminated by either party subject to advance written notice of 90 days.

The Management Company receives management fees as payment for its services, expressed as an annual percentage of the average net asset value.

These fees are payable by the SICAV at the end of each month.

The rates applicable as at December 31, 2022 are as follows:

Sub-funds	Share class	Share type	ISIN	Management fee
Candriam Equities L Australia	C	Capitalisation	LU0078775011	1.50%
	C	Distribution	LU0078775284	1.50%
	C - EUR - Unhedged	Capitalisation	LU0256780106	1.50%
	I	Capitalisation	LU0133348622	0.55%
	I - EUR - Unhedged	Capitalisation	LU0256781096	0.55%
	N	Capitalisation	LU0133347731	2.00%
	N - EUR - Unhedged	Capitalisation	LU0256780874	2.00%
	R	Capitalisation	LU0942225839	0.70%
	V	Capitalisation	LU0317020385	0.35%
	Z	Capitalisation	LU0240973742	0.00%
Candriam Equities L Biotechnology	C	Capitalisation	LU0108459040	1.60%
	C	Distribution	LU0108459552	1.60%
	C - EUR - Hedged	Capitalisation	LU1120766206	1.60%
	C - EUR - Unhedged	Capitalisation	LU1120766388	1.60%
	I	Capitalisation	LU0133360163	0.60%
	I - CHF - Hedged	Capitalisation	LU2478813442	0.60%
	I - EUR - Hedged	Capitalisation	LU1006082199	0.60%
	I - EUR - Unhedged	Capitalisation	LU1120766032	0.60%
	I - GBP - Unhedged	Capitalisation	LU1269737059	0.60%
	L	Capitalisation	LU0574798848	1.60%
	N	Capitalisation	LU0133359157	2.00%
R	Capitalisation	LU0942225912	0.80%	



Other notes to the financial statements

Note 3 - Management fees (Continued)

Sub-funds	Share class	Share type	ISIN	Management fee
	R - CHF - Hedged	Capitalisation	LU1269736754	0.80%
	R - EUR - Hedged	Capitalisation	LU1708110975	0.80%
	R - EUR - Unhedged	Capitalisation	LU1269736838	0.80%
	R - GBP - Unhedged	Capitalisation	LU1269736911	0.80%
	R2	Capitalisation	LU1397644557	0.38%
	R2	Distribution	LU1397644631	0.38%
	R2 - EUR - Unhedged	Capitalisation	LU1397644805	0.38%
	S - JPY - Unhedged	Capitalisation	LU1820816558	0.50%
	V	Capitalisation	LU0317020203	0.45%
	V2	Capitalisation	LU2026682919	0.65%
	Z	Capitalisation	LU0240982651	0.00%
Candriam Equities L Emerging Markets	BF	Capitalisation	LU1904319164	0.00%
	BF	Distribution	LU1397645364	0.00%
	C	Capitalisation	LU0056052961	1.60%
	C	Distribution	LU0056053001	1.60%
	C - USD - Hedged	Capitalisation	LU1293437023	1.60%
	I	Capitalisation	LU0133355080	0.65%
	I	Distribution	LU1269737562	0.65%
	I - GBP - Unhedged	Capitalisation	LU1269737489	0.65%
	L	Capitalisation	LU0574798921	1.60%
	N	Capitalisation	LU0133352731	2.00%
	P	Capitalisation	LU0596238260	0.25%
	R	Capitalisation	LU0942226134	0.85%
	R - GBP - Unhedged	Capitalisation	LU1269737307	0.85%
	R2	Capitalisation	LU1397645018	0.40%
	R2	Distribution	LU1397645109	0.40%
	V	Capitalisation	LU0317020112	0.35%
	V2	Capitalisation	LU1397645281	0.44%
	Z	Capitalisation	LU0240980523	0.00%
Candriam Equities L EMU Innovation	C	Capitalisation	LU0317020898	1.50%
	I	Capitalisation	LU0317021433	0.55%
	R	Capitalisation	LU1293437379	0.70%
	S	Capitalisation	LU0317021276	0.25%
	Z	Capitalisation	LU0317021359	0.00%
Candriam Equities L Europe Innovation	C	Capitalisation	LU0344046155	1.60%
	C	Distribution	LU0344046239	1.60%
	C - USD - Hedged	Capitalisation	LU1293437882	1.60%
	I	Capitalisation	LU0344046668	0.60%
	I - USD - Hedged	Capitalisation	LU1293437965	0.60%
	L	Capitalisation	LU0654531002	1.60%
	N	Capitalisation	LU0344046312	2.00%
	R	Capitalisation	LU1293438005	0.80%
	R2	Capitalisation	LU1397646503	0.38%
	R2	Distribution	LU1397646685	0.38%
	S	Capitalisation	LU2026683057	0.45%
	V	Capitalisation	LU0344046403	0.35%
	V2	Capitalisation	LU2026683131	0.45%
	Z	Capitalisation	LU0344046585	0.00%
Candriam Equities L Europe Optimum Quality	C	Capitalisation	LU0304859712	1.60%
	C	Distribution	LU0304860058	1.60%
	I	Capitalisation	LU0304860645	0.55%
	I	Distribution	LU1269737729	0.55%
	L	Capitalisation	LU0574799226	1.60%
	N	Capitalisation	LU0304860561	2.00%
	R	Capitalisation	LU1293438187	0.70%
	R2	Capitalisation	LU1397646842	0.38%
	R2	Distribution	LU1397646925	0.38%
	V	Capitalisation	LU0317019536	0.35%
	Z	Capitalisation	LU0317112661	0.00%
Candriam Equities L Global Demography	C	Capitalisation	LU0654531184	1.60%
	C	Distribution	LU0654531267	1.60%
	I	Capitalisation	LU0654531341	0.60%
	I - USD - Unhedged	Capitalisation	LU2328285445	0.60%
	L	Capitalisation	LU0654531697	1.60%
	N	Capitalisation	LU0654531424	2.00%
	R	Capitalisation	LU1598288089	0.80%
	R2	Capitalisation	LU1397647733	0.38%
	R2	Distribution	LU1397647816	0.38%
	V2 - USD - Unhedged	Capitalisation	LU2439121216	0.35%
	Z	Capitalisation	LU1397647907	0.00%
Candriam Equities L Japan (see note 1)	C	Capitalisation	LU0064109019	1.50%
	C	Distribution	LU0064109449	1.50%
	I	Capitalisation	LU0133346501	0.55%
	R2	Capitalisation	LU1397648111	0.38%
	R2	Distribution	LU1397648202	0.38%
	V	Capitalisation	LU0317018645	0.35%
	Z	Capitalisation	LU0240973403	0.00%



Other notes to the financial statements

Note 3 - Management fees (Continued)

Sub-funds	Share class	Share type	ISIN	Management fee
Candriam Equities L Life Care	BF	Capitalisation	LU2223682787	0.00%
	BF	Distribution	LU2223682860	0.00%
	C	Capitalisation	LU2223680658	1.50%
	I	Capitalisation	LU2223680815	0.80%
	R	Capitalisation	LU2223681201	0.80%
	R2	Capitalisation	LU2223681896	0.40%
	V	Capitalisation	LU2223682274	0.48%
	Z	Capitalisation	LU2223682357	0.00%
Candriam Equities L Meta Globe	C	Capitalisation	LU2476793240	1.60%
	I	Capitalisation	LU2476792861	0.80%
	R	Capitalisation	LU2476792432	0.80%
	V	Capitalisation	LU2476791467	0.48%
	Z	Capitalisation	LU2476791384	0.00%
Candriam Equities L Oncology Impact	BF - EUR - Unhedged	Capitalisation	LU1940963215	0.00%
	BF - EUR - Unhedged	Distribution	LU1940963306	0.00%
	C	Capitalisation	LU1864481467	1.60%
	C	Distribution	LU1864481541	1.60%
	C - EUR - Hedged	Capitalisation	LU1864481624	1.60%
	C - EUR - Unhedged	Capitalisation	LU1864482414	1.60%
	I	Capitalisation	LU1864482358	0.80%
	I	Distribution	LU1864482432	0.80%
	I - EUR - Hedged	Capitalisation	LU2015349330	0.80%
	I - GBP - Unhedged	Capitalisation	LU1864482515	0.80%
	N - EUR - Hedged	Capitalisation	LU1864482606	2.00%
	PI	Capitalisation	LU1864483836	0.40%
	R	Capitalisation	LU1864482788	0.80%
	R	Distribution	LU1864482861	0.80%
	R - EUR - Hedged	Capitalisation	LU1864483083	0.80%
	R - EUR - Unhedged	Capitalisation	LU1864483166	0.80%
	R - GBP - Unhedged	Capitalisation	LU1864482945	0.80%
	R2	Capitalisation	LU1864483240	0.40%
	R2	Distribution	LU1864483323	0.40%
	R2 - EUR - Hedged	Distribution	LU1864483596	0.40%
	S - JPY - Asset Hedged	Distribution	LU2015349090	0.38%
	S - JPY - Unhedged	Distribution	LU2015348522	0.50%
	SF2 - EUR - Unhedged	Capitalisation	LU2295688928	0.18%
	V	Capitalisation	LU1864483752	0.48%
	V - GBP - Unhedged	Capitalisation	LU2425425506	0.48%
Z	Capitalisation	LU1864483919	0.00%	
Candriam Equities L Risk Arbitrage Opportunities	C	Capitalisation	LU2223682944	1.50%
	I	Capitalisation	LU2223683082	1.00%
	PI	Capitalisation	LU2223683678	0.50%
	R	Capitalisation	LU2223683322	1.00%
	S	Capitalisation	LU2223683751	0.25%
	V	Capitalisation	LU2223683835	0.80%
	Z	Capitalisation	LU2223683918	0.00%
	Candriam Equities L Robotics & Innovative Technology	BF	Capitalisation	LU2226954738
BF		Distribution	LU2226954902	0.00%
C		Capitalisation	LU1502282558	1.60%
C		Distribution	LU1502282715	1.60%
C - EUR - Hedged		Capitalisation	LU1806526718	1.60%
C - EUR - Unhedged		Capitalisation	LU1502282632	1.60%
I		Capitalisation	LU1502282806	0.80%
I - EUR - Unhedged		Capitalisation	LU1613213971	0.80%
N - EUR - Hedged		Capitalisation	LU1806526809	2.00%
R		Capitalisation	LU1502282988	0.80%
R		Distribution	LU1708110629	0.80%
R - EUR - Hedged		Capitalisation	LU1613220596	0.80%
R - EUR - Unhedged		Capitalisation	LU1598284849	0.80%
R - GBP - Hedged		Capitalisation	LU1613217964	0.80%
Z		Capitalisation	LU1502283010	0.00%

The table hereafter reflects the maximum Management fee's annual rate applied to UCITS invested into by Candriam Equities L different sub-funds as at December 31, 2022.

Target fund	Maximum rate
CANDRIAM EQUITIES L LIFE CARE Z	0.00%
CANDRIAM EQUITIES L META GLOBE Z	0.00%



Other notes to the financial statements

Note 4 - Distribution fees

The rates of the specific distribution fee for the Lock share class are as follows:

Sub-funds	Share class	Share type	ISIN	Annual rate
Candriam Equities L Global Demography	L	Capitalisation	LU0654531697	0.10%
Candriam Equities L Europe Optimum Quality	L	Capitalisation	LU0574799226	0.10%
Candriam Equities L Europe Innovation	L	Capitalisation	LU0654531002	0.10%
Candriam Equities L Emerging Markets	L	Capitalisation	LU0574798921	0.10%
Candriam Equities L Biotechnology	L	Capitalisation	LU0574798848	0.10%

Note 5 - Operating and Administrative Expenses

The SICAV bears the current operating and administrative expenses incurred to cover all the overheads and variable expenses, the charges, fees and other expenses, as defined below ("Operating and Administrative Expenses").

The Operating and Administrative Expenses cover, but are not limited to, the following expenses:

a) the expenditures incurred directly by the SICAV, including, inter alia, the Depositary Bank's fees and charges, the fees and expenses of the approved independent auditors, the cost of share class hedging, including that invoiced by the Management Company, the fees paid to the Directors and the reasonable expenses and outlays incurred by or for the Directors;

b) a "service fee" paid to the Management Company and including the remaining sum of the Operating and Administrative Expenses after deduction of the expenses detailed in section (a) above, that is, inter alia, the fees and expenses of the Domiciliary Agent, the Administrative Agent, the Transfer Agent and Registrar Holding and the Principal Paying Agent, the costs related to registration and maintenance of the registration in all the jurisdictions (such as the fees charged by the supervisory authorities concerned, the translation expenses and the remuneration of the Representatives abroad and the local paying agents), the stock exchange registration and renewal expenses, the cost of publishing the share prices, the postal and telecommunication charges, preparation cost, printing, translating and distributing the prospectuses, key investor information documents, notices to shareholders, financial reports or of any other document intended for the shareholders, the legal fees and expenses, the charges and expenses related to the taking out of any subscription/licence or any other use of fee-paying information or data, the expenses incurred by the use of a registered trademark by the SICAV, the expenses and fees payable to the Management Company and/or its delegates and/or to any other agent appointed by the SICAV itself and/or to the independent experts.

The Operating and Administrative Expenses are expressed as an annual percentage of the average net asset value of each share class and are payable monthly.

At the end of a given period, if the actual charges and expenses were to be higher than the percentage of Operating and Administrative Expenses set for a share class, then the Management Company would pay for the difference itself. Conversely, if the actual charges and expenses were to turn out to be lower than the percentage of Operating and Administrative Expenses set for a share class, then the Management Company would retain the difference.

The Management Company shall be entitled to instruct the SICAV to proceed to settle all or part of the expenses as listed above directly from its assets.

In such a case, the amount of the Operating and Administrative Expenses would be reduced accordingly.

The maximum rates applicable as at December 31, 2022 are as follows:

Sub-funds	Share class	Share type	ISIN	Maximum rate
Candriam Equities L Australia	C	Capitalisation	LU0078775011	0.40%
	C	Distribution	LU0078775284	0.40%
	C - EUR - Unhedged	Capitalisation	LU0256780106	0.40%
	I	Capitalisation	LU0133348622	0.30%
	I - EUR - Unhedged	Capitalisation	LU0256781096	0.30%
	N	Capitalisation	LU0133347731	0.40%
	N - EUR - Unhedged	Capitalisation	LU0256780874	0.40%
	R	Capitalisation	LU0942225839	0.40%
	V	Capitalisation	LU0317020385	0.30%
	Z	Capitalisation	LU0240973742	0.30%
Candriam Equities L Biotechnology	C	Capitalisation	LU0108459040	0.40%
	C	Distribution	LU0108459552	0.40%
	C - EUR - Hedged	Capitalisation	LU1120766206	0.40%
	C - EUR - Unhedged	Capitalisation	LU1120766388	0.40%
	I	Capitalisation	LU0133360163	0.30%
	I - CHF - Hedged	Capitalisation	LU2478813442	0.30%
	I - EUR - Hedged	Capitalisation	LU1006082199	0.30%
	I - EUR - Unhedged	Capitalisation	LU1120766032	0.30%
	I - GBP - Unhedged	Capitalisation	LU1269737059	0.30%
	L	Capitalisation	LU0574798848	0.40%
	N	Capitalisation	LU0133359157	0.40%
	R	Capitalisation	LU0942225912	0.40%
	R - CHF - Hedged	Capitalisation	LU1269736754	0.40%
	R - EUR - Hedged	Capitalisation	LU1708110975	0.40%
	R - EUR - Unhedged	Capitalisation	LU1269736838	0.40%
	R - GBP - Unhedged	Capitalisation	LU1269736911	0.40%
	R2	Capitalisation	LU1397644557	0.40%
	R2	Distribution	LU1397644631	0.40%



Other notes to the financial statements

Note 5 - Operating and Administrative Expenses (Continued)

Sub-funds	Share class	Share type	ISIN	Maximum rate	
Candriam Equities L Biotechnology (Continued)	R2 - EUR - Unhedged	Capitalisation	LU1397644805	0.40%	
	S - JPY - Unhedged	Capitalisation	LU1820816558	0.30%	
	V	Capitalisation	LU0317020203	0.30%	
	V2	Capitalisation	LU2026682919	0.40%	
	Z	Capitalisation	LU0240982651	0.30%	
Candriam Equities L Emerging Markets	BF	Capitalisation	LU1904319164	0.46%	
	BF	Distribution	LU1397645364	0.46%	
	C	Capitalisation	LU0056052961	0.55%	
	C	Distribution	LU0056053001	0.55%	
	C - USD - Hedged	Capitalisation	LU1293437023	0.55%	
	I	Capitalisation	LU0133355080	0.46%	
	I	Distribution	LU1269737562	0.46%	
	I - GBP - Unhedged	Capitalisation	LU1269737489	0.46%	
	L	Capitalisation	LU0574798921	0.55%	
	N	Capitalisation	LU0133352731	0.55%	
	P	Capitalisation	LU0596238260	0.46%	
	R	Capitalisation	LU0942226134	0.55%	
	R - GBP - Unhedged	Capitalisation	LU1269737307	0.55%	
	R2	Capitalisation	LU1397645018	0.55%	
	R2	Distribution	LU1397645109	0.55%	
	V	Capitalisation	LU0317020112	0.46%	
	V2	Capitalisation	LU1397645281	0.46%	
Z	Capitalisation	LU0240980523	0.46%		
Candriam Equities L EMU Innovation	C	Capitalisation	LU0317020898	0.40%	
	I	Capitalisation	LU0317021433	0.30%	
	R	Capitalisation	LU1293437379	0.40%	
	S	Capitalisation	LU0317021276	0.30%	
	Z	Capitalisation	LU0317021359	0.30%	
Candriam Equities L Europe Innovation	C	Capitalisation	LU0344046155	0.40%	
	C	Distribution	LU0344046239	0.40%	
	C - USD - Hedged	Capitalisation	LU1293437882	0.40%	
	I	Capitalisation	LU0344046668	0.30%	
	I - USD - Hedged	Capitalisation	LU1293437965	0.30%	
	L	Capitalisation	LU0654531002	0.40%	
	N	Capitalisation	LU0344046312	0.40%	
	R	Capitalisation	LU1293438005	0.40%	
	R2	Capitalisation	LU1397646503	0.40%	
	R2	Distribution	LU1397646685	0.40%	
	S	Capitalisation	LU2026683057	0.40%	
	V	Capitalisation	LU0344046403	0.30%	
	V2	Capitalisation	LU2026683131	0.40%	
	Z	Capitalisation	LU0344046585	0.30%	
Candriam Equities L Europe Optimum Quality	C	Capitalisation	LU0304859712	0.40%	
	C	Distribution	LU0304860058	0.40%	
	I	Capitalisation	LU0304860645	0.30%	
	I	Distribution	LU1269737729	0.30%	
	L	Capitalisation	LU0574799226	0.40%	
	N	Capitalisation	LU0304860561	0.40%	
	R	Capitalisation	LU1293438187	0.40%	
	R2	Capitalisation	LU1397646842	0.40%	
	R2	Distribution	LU1397646925	0.40%	
	V	Capitalisation	LU0317019536	0.30%	
	Z	Capitalisation	LU0317112661	0.30%	
	Candriam Equities L Global Demography	C	Capitalisation	LU0654531184	0.40%
		C	Distribution	LU0654531267	0.40%
I		Capitalisation	LU0654531341	0.30%	
I - USD - Unhedged		Capitalisation	LU2328285445	0.00%	
L		Capitalisation	LU0654531697	0.40%	
N		Capitalisation	LU0654531424	0.40%	
R		Capitalisation	LU1598288089	0.40%	
R2		Capitalisation	LU1397647733	0.40%	
R2		Distribution	LU1397647816	0.40%	
V2 - USD - Unhedged		Capitalisation	LU2439121216	0.30%	
Z		Capitalisation	LU1397647907	0.30%	
Candriam Equities L Japan (see note 1)		C	Capitalisation	LU0064109019	0.40%
	C	Distribution	LU0064109449	0.40%	
	I	Capitalisation	LU0133346501	0.30%	
	R2	Capitalisation	LU1397648111	0.40%	
	R2	Distribution	LU1397648202	0.40%	
	V	Capitalisation	LU0317018645	0.30%	
	Z	Capitalisation	LU0240973403	0.30%	
Candriam Equities L Life Care	BF	Capitalisation	LU2223682787	0.30%	
	BF	Distribution	LU2223682860	0.20%	
	C	Capitalisation	LU2223680658	0.20%	
	I	Capitalisation	LU2223680815	0.30%	
	R	Capitalisation	LU2223681201	0.30%	
	R2	Capitalisation	LU2223681896	0.20%	
	V	Capitalisation	LU2223682274	0.20%	
	Z	Capitalisation	LU2223682357	0.10%	



Other notes to the financial statements

Note 5 - Operating and Administrative Expenses (Continued)

Sub-funds	Share class	Share type	ISIN	Maximum rate
Candriam Equities L Meta Globe	C	Capitalisation	LU2476793240	0.40%
	I	Capitalisation	LU2476792861	0.30%
	R	Capitalisation	LU2476792432	0.40%
	V	Capitalisation	LU2476791467	0.30%
	Z	Capitalisation	LU2476791384	0.30%
Candriam Equities L Oncology Impact	BF - EUR - Unhedged	Capitalisation	LU1940963215	0.30%
	BF - EUR - Unhedged	Distribution	LU1940963306	0.10%
	C	Capitalisation	LU1864481467	0.40%
	C	Distribution	LU1864481541	0.40%
	C - EUR - Hedged	Capitalisation	LU1864481624	0.40%
	C - EUR - Unhedged	Capitalisation	LU1864484214	0.40%
	I	Capitalisation	LU1864482358	0.30%
	I	Distribution	LU1864482432	0.30%
	I - EUR - Hedged	Capitalisation	LU2015349330	0.10%
	I - GBP - Unhedged	Capitalisation	LU1864482515	0.30%
	N - EUR - Hedged	Capitalisation	LU1864482606	0.40%
	PI	Capitalisation	LU1864483836	0.30%
	R	Capitalisation	LU1864482788	0.40%
	R	Distribution	LU1864482861	0.40%
	R - EUR - Hedged	Capitalisation	LU1864483083	0.40%
	R - EUR - Unhedged	Capitalisation	LU1864483166	0.40%
	R - GBP - Unhedged	Capitalisation	LU1864482945	0.40%
	R2	Capitalisation	LU1864483240	0.40%
	R2	Distribution	LU1864483323	0.40%
	R2 - EUR - Hedged	Distribution	LU1864483596	0.40%
	S - JPY - Asset Hedged	Distribution	LU2015349090	0.10%
	S - JPY - Unhedged	Distribution	LU2015348522	0.05%
	SF2 - EUR - Unhedged	Capitalisation	LU2295688928	0.30%
V	Capitalisation	LU1864483752	0.30%	
V - GBP - Unhedged	Capitalisation	LU2425425506	0.30%	
Z	Capitalisation	LU1864483919	0.30%	
Candriam Equities L Risk Arbitrage Opportunities	C	Capitalisation	LU2223682944	0.40%
	I	Capitalisation	LU2223683082	0.30%
	PI	Capitalisation	LU2223683678	0.30%
	R	Capitalisation	LU2223683322	0.40%
	S	Capitalisation	LU2223683751	0.30%
	V	Capitalisation	LU2223683835	0.30%
	Z	Capitalisation	LU2223683918	0.30%
Candriam Equities L Robotics & Innovative Technology	BF	Capitalisation	LU2226954738	0.00%
	BF	Distribution	LU2226954902	0.00%
	C	Capitalisation	LU1502282558	0.40%
	C	Distribution	LU1502282715	0.40%
	C - EUR - Hedged	Capitalisation	LU1806526718	0.40%
	C - EUR - Unhedged	Capitalisation	LU1502282632	0.40%
	I	Capitalisation	LU1502282806	0.30%
	I - EUR - Unhedged	Capitalisation	LU1613213971	0.30%
	N - EUR - Hedged	Capitalisation	LU1806526809	0.40%
	R	Capitalisation	LU1502282988	0.40%
	R	Distribution	LU1708110629	0.40%
	R - EUR - Hedged	Capitalisation	LU1613220596	0.40%
	R - EUR - Unhedged	Capitalisation	LU1598284849	0.40%
	R - GBP - Hedged	Capitalisation	LU1613217964	0.40%
	Z	Capitalisation	LU1502283010	0.30%



Other notes to the financial statements

Note 6 - Performance fees

In payment for its portfolio management activity, the Management Company also receives performance fees on certain share classes of certain sub-funds (see table below with concerned share classes and related index).

The method of calculating the performance commission is detailed in the various technical specifications attached to the Prospectus of the SICAV in force at the time.

Since January 01, 2022, the following sub-funds are subject to performance fees, the conditions of which are set out in the prospectus:

Candriam Equities L Biotechnology

Share class	Class type	Currency	Performance fee rate	Amount of performance fee charged for the year	% on the Share Class NAV of performance fee charges for the year
I	Capitalisation	USD	20.00%	693,748	2.27%
I - CHF - H	Capitalisation	CHF	20.00%	0	0.00%
I - EUR - H	Capitalisation	EUR	20.00%	428,139	2.19%
I - EUR - U	Capitalisation	EUR	20.00%	1,459,165	2.36%
I - GBP - U	Capitalisation	GBP	20.00%	10,085	1.97%
V	Capitalisation	USD	20.00%	2,217,258	1.65%

The performance fee charged during the year ended December 31, 2022 amounted to USD 4,808,395.

Candriam Equities L Emerging Markets

Share class	Class type	Currency	Performance fee rate	Amount of performance fee charged for the year	% on the Share Class NAV of performance fee charges for the year
I	Capitalisation	EUR	20.00%	0	0.00%
I	Distribution	EUR	20.00%	0	0.00%
I - GBP - U	Capitalisation	GBP	20.00%	0	0.00%
V	Capitalisation	EUR	20.00%	0	0.00%

No performance was charged during the year ended December 31, 2022.

Candriam Equities L EMU Innovation

Share class	Class type	Currency	Performance fee rate	Amount of performance fee charged for the year	% on the Share Class NAV of performance fee charges for the year
I	Capitalisation	EUR	20.00%	0	0.00%

No performance was charged during the year ended December 31, 2022.

Candriam Equities L Europe Innovation

Share class	Class type	Currency	Performance fee rate	Amount of performance fee charged for the year	% on the Share Class NAV of performance fee charges for the year
I	Capitalisation	EUR	20.00%	0	0.00%
I - USD - H	Capitalisation	USD	20.00%	0	0.00%
V	Capitalisation	EUR	20.00%	0	0.00%

No performance was charged during the year ended December 31, 2022.

Candriam Equities L Europe Optimum Quality

Share class	Class type	Currency	Performance fee rate	Amount of performance fee charged for the year	% on the Share Class NAV of performance fee charges for the year
I	Capitalisation	EUR	20.00%	1,436	0.00%
I	Distribution	EUR	20.00%	0	0.00%
V	Capitalisation	EUR	20.00%	0	0.00%

The performance fee charged during the year ended December 31, 2022 amounted to EUR 1,436.

Candriam Equities L Global Demography

Share class	Class type	Currency	Performance fee rate	Amount of performance fee charged for the year	% on the Share Class NAV of performance fee charges for the year
I	Capitalisation	EUR	20.00%	1	0.00%
I - USD - U	Capitalisation	USD	20.00%	0	0.00%

The performance fee charged during the year ended December 31, 2022 amounted to EUR 1.

Candriam Equities L Risk Arbitrage Opportunities

Share class	Class type	Currency	Performance fee rate	Amount of performance fee charged for the year	% on the Share Class NAV of performance fee charges for the year
C	Capitalisation	EUR	20.00%	0	0.00%
I	Capitalisation	EUR	20.00%	0	0.00%
PI	Capitalisation	EUR	20.00%	1,910	0.02%
R	Capitalisation	EUR	20.00%	0	0.00%
V	Capitalisation	EUR	20.00%	0	0.00%
Z	Capitalisation	EUR	20.00%	4,045	0.01%

The performance fee charged during the year ended December 31, 2022 amounted to EUR 5,955.



Other notes to the financial statements

Note 7 - Subscription tax

The SICAV is governed by the Luxembourg tax laws.

By virtue of the legislation and regulations currently in force, the SICAV is subject in Luxembourg to an annual tax of 0.05% of the net asset value of the SICAV; this rate is reduced to 0.01% for the classes reserved for institutional investors. This tax is payable quarterly on the basis of the net assets value of the SICAV calculated at the end of the quarter to which the tax relates.

The Belgian government enacted a law to tax once a year the net asset value of foreign investment funds registered in Belgium. This annual tax is calculated on the net amounts defined as invested in Belgium by Belgian financial intermediaries. In the absence of a sufficient declaration relating to these figures, the tax authority will be entitled to calculate the tax on the entirety of the assets of these sub-funds. The Belgian law of June 17, 2013 comprising fiscal and financial provisions and provisions relating to sustainable development set the rate of the annual tax for Undertakings for Collective Investment at 0.0925% with effect from January 1, 2014.

As a precautionary measure, the SICAV filed a claim with the Belgian tax authority and the Brussels Court of First Instance for the tax to be refunded. At this stage, it is not possible to prejudge the outcome of the dispute or any reimbursement in favour of the SICAV. In a similar case, the Belgian State appealed to the Court of Cassation against the Court of Appeal's rulings in favour of the plaintiff.

The management company was informed that the Court of Cassation ruled against the plaintiff on March 25, 2022. The Court of Cassation (French-speaking chamber) considers that the Brussels Court of Appeal wrongly qualified the Belgian subscription tax as a wealth tax covered by the double taxation convention between Belgium and Luxembourg (which convention attributes the right to tax Luxembourg SICAVs only by Luxembourg and not by Belgium, which justified the claim for reimbursement of the Belgian subscription tax).

The case is referred back to the Court of Appeal of Liège which will be bound by the assessment taken by the Court of Cassation.

Another decision of the Court of Cassation (Dutch-speaking chamber) of April 21, 2022 does not dispute that the Belgian subscription tax is a wealth tax, but considers that the double taxation convention between Belgium and Luxembourg (unlike the one signed with the Netherlands) does not cover in its scope a wealth tax levied in Belgium.

The prospect of a refund is therefore limited and will in any case not be possible in the short term.

Note 8 - Reverse repurchase agreements

As at December 31, 2022, the following reverse repurchase agreements were outstanding:

Candriam Equities L Risk Arbitrage Opportunities

Currency	Nominal	Maturity date	Description	Counterparty	Receivable on reverse repurchase agreements (in EUR)
EUR	5,300,000	15/07/25	NETHERLANDS 0.25 15-25 15/07A	CACEIS Bank, Lux. Branch	5,088,000
EUR	6,300,000	15/07/25	NETHERLANDS 0.25 15-25 15/07A	CACEIS Bank, Lux. Branch	6,016,500
EUR	6,307,556	25/05/32	FRANCE (GOVT OF) 0.0000 22-32 25/05A	CACEIS Bank, Lux. Branch	5,000,000
EUR	8,750,000	25/05/32	FRANCE (GOVT OF) 0.0000 22-32 25/05A	CACEIS Bank, Lux. Branch	7,000,000
TOTAL					23,104,500



Other notes to the financial statements

Note 9 - Securities lending

By a delegation contract dated February 18, 2014, the Management Company delegated the implementation of the securities lending and borrowing transactions, under its supervision and responsibility, to Candriam France, a simplified joint-stock company, whose registered office is at 40, rue Washington, F-75408 Paris Cedex 08. This contract may be terminated by either party giving 90 days' notice in writing.

As at December 31, 2022, the composition of the securities lent was as follows:

Sub-funds	Currency	Market value of securities lent	Collateral Securities
Candriam Equities L Biotechnology	USD	107,232,280	189,608,947
Candriam Equities L Emerging Markets	EUR	195,701	499,157
Candriam Equities L EMU Innovation	EUR	3,149,903	3,332,244
Candriam Equities L Europe Innovation	EUR	143,865,296	157,560,476
Candriam Equities L Europe Optimum Quality	EUR	66,369,061	72,070,800

The types of financial guarantees permitted are as follows:

- cash denominated in the reference currency of the sub-fund concerned;
- good-quality debt securities (rated at least BBB-/Baa3 or equivalent by one of the rating agencies) issued by a public-sector issuer of an OECD country (states, supranationals, etc.) and whose issue size is a minimum of EUR 250 million;
- good-quality debt securities (rated at least BBB-/Baa3 or equivalent by one of the rating agencies) issued by a private-sector issuer of an OECD country and whose issue size is a minimum of EUR 250 million;
- shares listed or traded on a regulated market of a Member State of the European Union or on a securities exchange of a State belonging to the OECD, provided that these shares are included in a major index;
- shares or units of undertakings for collective investment offering adequate liquidity and investing in money market instruments, good-quality bonds or in shares that meet the conditions listed above.

The securities lent are valued on the basis of the last-known price. The securities and the related interest receivable are shown in the Statement of net assets.

The amounts of the interest received in connection with this securities lending are included in the item "Interest on securities lending" of the statement of changes in net assets.

The counterparties related to the open positions of securities lending are BNP Paribas Securities Services SCA, Natixis SA, Goldman Sachs Bank Europe SE EQ., Crédit Agricole Corporate and Investment Bank, Morgan Stanley Europe S.E., Barclays Bank PLC - Ireland - LC, Unicredit AG and Scotiabank and Société Générale S.A..

The following items of income were recorded in the accounts during the year ended December 31, 2022:

Sub-funds	Currency	Total gross amount of securities lending income	Direct-indirect costs and fees deducted from gross securities lending income	Total net amount of securities lending income
Candriam Equities L Biotechnology	USD	212,620	85,048	127,572
Candriam Equities L Emerging Markets	EUR	72,087	28,835	43,252
Candriam Equities L EMU Innovation	EUR	5,150	2,060	3,090
Candriam Equities L Europe Innovation	EUR	248,220	99,288	148,932
Candriam Equities L Europe Optimum Quality	EUR	75,260	30,104	45,156
Candriam Equities L Global Demography	EUR	104,780	41,912	62,868
Candriam Equities L Japan (see note 1)	JPY	4,779,297	1,911,719	2,867,578
Candriam Equities L Oncology Impact	EUR	192	77	115
Candriam Equities L Risk Arbitrage Opportunities	EUR	282	113	169
Candriam Equities L Robotics & Innovative Technology	USD	72,637	29,055	43,582

The Income net of cost and fees, and agent's commissions are received by the SICAV.

Direct and indirect costs and fees received by Candriam France and Candriam amount to respectively 19% and 1% for all the sub-funds. The commissions received by CACEIS Bank, Luxembourg Branch amount to 20% of the gross income.

Candriam – Succursale française and Candriam are related parties of the SICAV.

Note 10 - Dividends

The SICAV distributed the following dividends during the year ended December 31, 2022:

Sub-funds	Share class	Currency	Dividend	Ex-date
Candriam Equities L Australia	C	AUD	31.80	28/04/2022
Candriam Equities L Biotechnology	C	USD	3.44	28/04/2022
Candriam Equities L Biotechnology	R2	USD	1.04	28/04/2022
Candriam Equities L Emerging Markets	BF	EUR	38.27	28/04/2022
Candriam Equities L Emerging Markets	C	EUR	16.49	28/04/2022
Candriam Equities L Emerging Markets	I	EUR	46.04	28/04/2022
Candriam Equities L Emerging Markets	R2	EUR	4.48	28/04/2022
Candriam Equities L Europe Innovation	C	EUR	7.48	28/04/2022



Other notes to the financial statements

Note 10 - Dividends (Continued)

Sub-funds	Share class	Currency	Dividend	Ex-date
Candriam Equities L Europe Innovation	R2	EUR	5.90	28/04/2022
Candriam Equities L Europe Optimum Quality	C	EUR	2.53	28/04/2022
Candriam Equities L Europe Optimum Quality	I	EUR	43.46	28/04/2022
Candriam Equities L Europe Optimum Quality	R2	EUR	4.84	28/04/2022
Candriam Equities L Global Demography	C	EUR	3.69	28/04/2022
Candriam Equities L Global Demography	R2	EUR	3.70	28/04/2022
Candriam Equities L Japan	C	JPY	422.60	28/04/2022
Candriam Equities L Japan	R2	JPY	357.40	28/04/2022
Candriam Equities L Oncology Impact	BF - EUR - Unhedged	EUR	39.67	28/04/2022
Candriam Equities L Oncology Impact	C	USD	4.28	28/04/2022
Candriam Equities L Oncology Impact	I	USD	148.00	28/04/2022
Candriam Equities L Oncology Impact	R	USD	3.36	28/04/2022
Candriam Equities L Oncology Impact	R2	USD	4.35	28/04/2022
Candriam Equities L Oncology Impact	R2 - EUR - Hedged	EUR	3.26	28/04/2022
Candriam Equities L Oncology Impact	S - JPY - Asset Hedged	JPY	374.21	28/04/2022
Candriam Equities L Oncology Impact	S - JPY - Unhedged	JPY	368.61	28/04/2022
Candriam Equities L Robotics & Innovative Technology	C	USD	5.67	28/04/2022
Candriam Equities L Robotics & Innovative Technology	R	USD	4.22	28/04/2022

Note 11 - Swing Pricing

For all the sub-funds of the SICAV, provision has been made for the following measure:

On the valuation days on which the difference between the amount of subscriptions and the amount of redemptions in a sub-fund (that is, the net transactions) exceeds a threshold previously set by the Board of Directors (partial Swing), the Board reserves the right to determine the net asset value by adding to the assets (in the case of net subscriptions) or by deducting from the assets (in the case of net redemptions) a flat-rate percentage of fees and expenses corresponding to market practices in the case of purchases or sales of securities for Candriam Equities L Australia, Candriam Equities L Biotechnology, Candriam Equities L Emerging Markets, Candriam Equities L EMU Innovation, Candriam Equities L Europe Innovation, Candriam Equities L Europe Optimum Quality, Candriam Equities L Global Demography, Candriam Equities L Life Care, Candriam Equities L Japan, Candriam Equities L Oncology Impact, Candriam Equities L Robotics & Innovative Technology and Candriam Equities L Meta Globe.

As at December 31, 2022, no swing was applied.

The swing factor is the amount by which the NAV is swung when the swing pricing process is triggered after net subscriptions or redemptions exceed the swing threshold. The factors to consider when setting the swinging factor include:

For equity method:

- Net broker commissions paid by the sub-fund
- Fiscal charges (e.g. stamp duty and sales tax)

Sub-funds	Maximum swing factor Inflow rate (in %)	Maximum swing factor Outflow rate (in %)
Candriam Equities L Australia	0.02	0.02
Candriam Equities L Biotechnology	0.04	0.05
Candriam Equities L Emerging Markets	0.08	0.17
Candriam Equities L EMU Innovation	0.18	0.04
Candriam Equities L Europe Innovation	0.24	0.04
Candriam Equities L Europe Optimum Quality	0.24	0.04
Candriam Equities L Global Demography	0.08	0.05
Candriam Equities L Life Care	0.07	0.04
Candriam Equities L Meta Globe	0.03	0.06
Candriam Equities L Oncology Impact	0.08	0.04
Candriam Equities L Robotics & Innovative Technology	0.05	0.05
Candriam Equities L Japan (see note 1)	0.02	0.02

Note 12 - Cash at bank and broker

The Cash at bank and broker in the statement of net assets comprises the cash accounts and the cash at broker accounts on future contracts and CFD. The counterparty is J.P. Morgan SE.

The part relating to the cash at broker accounts in Cash at bank and broker included in the statement of net assets as at December 31, 2022 is as follows:

Sub-funds	Currency	Cash at broker
Candriam Equities L Europe Optimum Quality	EUR	19,315,877



Other notes to the financial statements

Note 13 - Collateral

In relation with the OTC derivative instruments, cash collateral has been posted to Barclays Bank PLC - Ireland - LC, Citigroup Global Markets Europe AG - Germany - LC, JP Morgan SE.

Sub-funds	Currency	Cash Collateral Posted	Cash Collateral held
Candriam Equities L Risk Arbitrage Opportunities	EUR	(1,010,000)	0

Note 14 - Changes in portfolio composition

A list including the transactions (sales and purchases) in the investment portfolios is available free of charge at the SICAV's registered office.

Note 15 - Significant event during the year

With effect as of July 1, 2022 (the "Effective Date"), Candriam Luxembourg has absorbed its subsidiaries Candriam Belgium and Candriam France via a Luxembourg merger by absorption in accordance with Article 1021-1 (et seq.) of the Luxembourg law on commercial companies of 10 August 1915, as amended. As of the Effective Date, the name of Candriam Luxembourg has been changed to Candriam.

Note 16 - Subsequent events

There is no subsequent event.



Additional unaudited information

Global Risk Exposure

As required by the CSSF Circular 11/512, the Board of Directors of the Company must determine the Company risk management method, using either the commitment approach or the VaR approach.

The Board of Directors of the Company has chosen to adopt the commitment approach for all the sub-funds as the method for determining overall risk, except for Candriam Equities L Risk Arbitrage Opportunities.

The Company uses the absolute "Value at Risk" (VaR) approach, the historical method of calculating the aggregate risk of the sub-fund Candriam Equities L Risk Arbitrage Opportunities. The Euro Short Term Rate (€STR) capitalised index is used as the benchmark for the Relative VaR. As an indication, the leverage of this sub-fund is a maximum of 400% of net assets. The sub-fund could, however, be exposed temporarily to a higher leverage.

This approach measures the maximum potential loss for a given confidence threshold (probability) over a specific time period under normal market conditions. These calculations are performed on the basis of the following parameters: a confidence interval of 99%, a holding period of one day (converted into a holding period of 20 days).

The results of the calculation of the relative VaR for the exercise from January 1, 2022 to December 31, 2022 are:

Sub-fund	Value at risk 99% (20D)		
	Min Var	Max var	Average Var
Candriam Equities L Risk Arbitrage Opportunities	3.94%	14.31%	8.78%

The expected leverage of this sub-fund will be a maximum of 400%. This leverage is calculated for each derivative product on the basis of the commitment method and is added to the securities portfolio of the sub-fund. The sub-fund may nevertheless be exposed to higher leverages.

The levels of leverage for the year from January 1, 2022 to December 31, 2022 are:

Sub-fund	Average leverage
Candriam Equities L Risk Arbitrage Opportunities	147.71%



Additional unaudited information

Engagement & voting policies, use of voting rights

Candriam exercises voting rights for the considered funds.

For all engagement matters, please refer to the engagement policy and to the associated reports, all available under Candriam website <https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>.

Proxy Voting

Since January 1, 2004, Candriam has decided to actively exercise the voting rights attached to the shares of top-tier European companies that it manages on behalf of its clients. This decision indicates Candriam's determination to assume its responsibilities in the context of corporate governance, and to fully exercise its voting rights in companies in which it invests. The details of the voting are available on the web site <https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>.

Non voted meetings result from operational / technical burdens defined in our voting policy (for more details please refer to Candriam voting policy) or others encountered at our third party levels and for which remediation plans have been defined.

The voting rights are exercised for each sub-fund of the SICAV on the basis of its positions in the portfolio except for Candriam Equities L Risk Arbitrage Opportunities for which no voting rights is exercised.

As announced above, details of the voting are available on the web site <https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>. All General Assembly Meetings the Management company attended or was represented at are detailed, as well as the voted resolutions, effective votes and associated rationales when votes against management were registered.

Candriam has formulated and implemented a voting policy based on four principles of corporate governance. Voting decisions are taken in accordance with these principles:

1. Protection of all shareholders' rights in accordance with the "one share – one vote – one dividend" rule.
2. Guaranteed equality of treatment of shareholders, including minority and foreign shareholders.
3. Communication of accurate and transparent financial information.
4. Accountability and independence of the Board of Directors and the external auditors.

As part of its voting decisions, Candriam satisfies itself that it has obtained all the information required for the decision to be taken. Candriam's ESG and financial analysts examine the resolutions presented to the shareholders, taking into account the voting recommendations provided by external corporate governance advisors. Candriam does, however, retain total independence as regards its votes.

This voting policy is available under Candriam website (*) and notably details:

- The definition of the voting scope,
- How conflict of interest are identified and managed,
- The Role of proxy Advisers.

In addition, a Proxy Voting Committee has been established within Candriam, Its role is to evaluate the voting policy and make changes to it when deemed appropriate.

The Committee consists of internal representatives from the Management, Operations, Risk and ESG Research & Stewardship Teams. Representatives of the Legal department may attend meetings upon request.

For funds with securities lending programs, a minimum of 20% of every position is systematically reserved for voting (except for those which trade in 'share blocking' markets, where the reserved proportion may be smaller).

For more information on the way the management company deals with securities lending activities in the voting period, please refer to our Voting policy under <https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>.

(*) <https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>

European directive on shareholders' rights (SRD II) (1)

In accordance with the transparency rules set out in the "Shareholders' Rights" European directive and related to annual disclosures to institutional investors, you can obtain additional information on the investment strategy implemented by Candriam and the contribution of this strategy to the medium to long-term performance of the fund.

You may submit your request to the following address: <https://www.candriam.fr/contact/>.

- (1) *Directive (EU) 2017/828 of the European Parliament and of the Council amending Directive 2007/36/EC as regards the encouragement of long-term shareholder engagement.*

Sub-Funds	Portfolio Turnover Rate (in %)*
Candriam Equities L Australia	-5.36
Candriam Equities L Biotechnology	47.68
Candriam Equities L Emerging Markets	198.57
Candriam Equities L EMU Innovation	73.12
Candriam Equities L Europe Innovation	0.55
Candriam Equities L Europe Optimum Quality	47.38
Candriam Equities L Global Demography	169.88
Candriam Equities L Life Care	104.54
Candriam Equities L Meta Globe	23.74
Candriam Equities L Oncology Impact	11.32
Candriam Equities L Robotics & Innovative Technology	6.93

* Formula used: $[(Total\ purchases + total\ sales) - (total\ subscriptions + total\ redemptions)] / Average\ of\ net\ assets\ during\ the\ year\ under\ review$



Additional unaudited information

Information concerning the remuneration policy

European Directive 2014/91/EU amending Directive 2009/65/EC on undertakings for collective investment in transferable securities, which is applicable to the SICAV, came into force on 18 March 2016. It is implemented in national law under the Luxembourg Act of 10 May 2016 implementing Directive 2014/91/EU. Due to these new regulations, the SICAV is required to publish information relating to the remuneration of identified employees within the meaning of the Act in the annual report.

Candriam holds a double license, first, as a management company in accordance with section 15 of the Law of December 17, 2010 on undertakings for collective investment and, second, as a manager of alternative investment funds in accordance with the Law of July 12, 2013 relating to alternative investment fund managers. The responsibilities incumbent on Candriam under these two laws are relatively similar and Candriam considers that its personnel is remunerated in the same manner for tasks relating to administration of UCITS and of alternative investment funds.

During its financial year ended on December 31, 2022, Candriam paid the following amounts to its personnel:

- Total gross amount of fixed remunerations paid (excluding payments or benefits that can be considered to be part of a general and nondiscretionary policy and to have no incentive effect on risk management): EUR 16,496,391.
- Total gross amount of variable remunerations paid: EUR 7,603,281.
- Number of beneficiaries: 147.

Aggregate amount of remunerations, broken down between senior management and the members of the personnel of the investment manager whose activities have a significant impact on the funds risk profile. The systems of Candriam do not permit such an identification for each fund under management. The numbers below also show the aggregate amount of overall remunerations at Candriam.

- Aggregate amount of the remunerations of the senior management: EUR 4,123,181.
- Aggregate amount of the remunerations of the members of the personnel of Candriam whose activities have a significant impact on the risk profile of the funds of which it is the management company (excluding senior management): EUR 2,274,454.

Remunerations paid by Candriam to the personnel of its Belgian branch (i.e. Candriam – Belgian Branch), acting as investment manager, during the financial year ended on December 31, 2022:

- Total gross amount of fixed remunerations paid (excluding payments or benefits that can be considered to be part of a general and nondiscretionary policy and to have no incentive effect on risk management): EUR 24,652,347.
- Total gross amount of variable remunerations paid: EUR 10,435,950.
- Number of beneficiaries: 256.

Aggregate amount of remunerations, broken down between senior management and the members of the personnel of the investment manager whose activities have a significant impact on the funds risk profile. The systems of the investment manager do not permit such an identification for each fund under management. The numbers below also show the aggregate amount of overall remunerations at the level of the investment manager.

- Aggregate amount of the remunerations of the senior management: EUR: 5,059,679.
- Aggregate amount of the remunerations of the members of the personnel of the investment manager whose activities have a significant impact on the risk profile of the funds of which it is the investment manager (excluding senior management): EUR 4,582,833.

Remunerations paid by Candriam to the personnel of its French branch (i.e. Candriam – Succursale française), acting as investment manager(s), during the financial year ended on December 31, 2022:

- Total gross amount of fixed remunerations paid (excluding payments or benefits that can be considered to be part of a general and nondiscretionary policy and to have no incentive effect on risk management): EUR 18,384,879.
- Total gross amount of variable remunerations paid: EUR 9,558,325.
- Number of beneficiaries: 202.

Aggregate amount of remunerations, broken down between senior management and the members of the personnel of the investment manager whose activities have a significant impact on the funds risk profile. The systems of the investment manager do not permit such an identification for each fund under management. The numbers below also show the aggregate amount of overall remunerations at the level of the investment manager.

- Aggregate amount of the remunerations of the senior management: EUR 3,634,215.
- Aggregate amount of the remunerations of the members of the personnel of the investment manager whose activities have a significant impact on the risk profile of the funds of which it is the investment manager (excluding senior management): EUR 3,398,975.

The remuneration policy was last reviewed by the remuneration committee of Candriam on January 29, 2021 and was adopted by the Board of Directors of Candriam.



Additional unaudited information

Transparency of Securities Financing Transactions of Reuse and amending Regulation (SFTR) (EU) N°648/2012

a) Global data

With respect to securities lending transactions and total return swaps, the total market value of securities on loan at December 31, 2022 is as follows:

Sub-fund	Currency	Market value (in absolute terms)	% of total lendable assets	% total net asset value
Candriam Equities L Biotechnology	USD	107,232,280	6.18	6.07
Candriam Equities L Emerging Markets	EUR	195,701	0.02	0.02
Candriam Equities L EMU Innovation	EUR	3,149,903	5.51	5.35
Candriam Equities L Europe Innovation	EUR	143,865,296	11.78	11.59
Candriam Equities L Europe Optimum Quality	EUR	66,369,061	8.82	8.38

b) Concentration data

- **Securities lending**

The 10 largest counterparties across all securities lending transactions as at December 31, 2022 are as follows:

Candriam Equities L Biotechnology

Counterparty	Gross volumes for open trades
NATIXIS	52,515,957
BP2S	50,939,258
BANK OF NOVA SCOTIA	2,743,366
MORGAN STANLEY EUROPE SE	865,584
GOLDMAN SACHS BANK EUROPE SE EQ	563,935

Candriam Equities L Emerging Markets

Counterparty	Gross volumes for open trades
BP2S	195,958

Candriam Equities L EMU Innovation

Counterparty	Gross volumes for open trades
SOCIETE GENERALE EQUITIES	1,385,963
NATIXIS	1,167,480
CACIB	560,448

Candriam Equities L Europe Innovation

Counterparty	Gross volumes for open trades
CACIB	48,116,954
SOCIETE GENERALE EQUITIES	35,554,286
BARC EQTY	33,019,052
NATIXIS	15,204,731
BP2S	8,089,620
MORGAN STANLEY EUROPE SE	1,821,196

Candriam Equities L Europe Optimum Quality

Counterparty	Gross volumes for open trades
CACIB	44,580,313
SOCIETE GENERALE EQUITIES	15,647,060
BP2S	3,635,603
NATIXIS	1,516,424
UNICREDIT AG	53,400



Additional unaudited information

Transparency of Securities Financing Transactions of Reuse and amending Regulation (SFTR) (EU) N°648/2012 (Continued)

The 10 largest issuers of collateral received from securities lending activities as at December 31, 2022 are as follows:

Candriam Equities L Biotechnology

Counterparty	Gross volumes for open trades
SPLUNK INC	19,582,288
JAPA 20 0.5 12-38	18,946,434
FERGUSON PLC	18,535,636
KOMM 0.625 06-25	13,530,521
ATLIASSIAN CORP-A	13,158,455
WORKDAY INC-A	8,023,584
BANCO SANTANDER	7,828,961
IBERDROLA SA	5,493,025
EURO ST 0.375 09-25	5,459,669
HP ENTE 4.9 10-25	5,208,310

Candriam Equities L Emerging Markets

Counterparty	Gross volumes for open trades
LIBERTY MEDIA-C	19,534
SPLUNK INC	19,532
SKECHERS USA-A	19,527
JAPAN 0.1 03-27	19,521
PINTEREST INC -A	19,519
CROWDSTRIKE HO-A	19,515
ASML HOLDING-NY	19,510
YETI HOLDINGS IN	19,505
DOCUSIGN INC	19,503
JAPAN 1.2 03-35	19,499

Candriam Equities L EMU Innovation

Counterparty	Gross volumes for open trades
AROU 5.375 03-29	205,283
US BAN 0.85 06-24	161,861
CRED SU 0.25 01-26	138,569
MIZU FINA FLR 04-23	138,340
METR LI 1.875 01-27	138,232
BNP PAR FLR 05-23	137,688
WELLS FARGO COMPAN	137,669
HEAL PR 2.125 12-28	116,675
REGE CE 3.7 06-30	116,629
DEUT TEL 8.25 06 30	116,392

Candriam Equities L Europe Innovation

Counterparty	Gross volumes for open trades
ENEL SPA	8,921,221
REPSOL SA	7,784,272
SIKA AG 0.15 06-25	7,331,161
NORDEA BANK ABP	4,811,691
UBS GROUP AG	4,309,261
NINTENDO CO LTD	4,228,390
GOLD SA 3.375 03-25	4,003,698
HORIZON THERAPEU	3,980,677
NIPPON STEEL COR	3,962,624
YARA INTL ASA	3,853,583

Candriam Equities L Europe Optimum Quality

Counterparty	Gross volumes for open trades
NORDEA BANK ABP	8,565,660
ENEL SPA	4,457,167
HORIZON THERAPEU	4,456,103
UBS GROUP AG	4,456,100
REPSOL SA	4,456,098
NINTENDO CO LTD	4,456,089
MIITSUI CHEMICALS	3,459,746
CITIGROUP INC	3,428,575
ASSA ABLOY AB-B	3,393,036
SVEN HA 0.5 02-30	1,564,183



Additional unaudited information

Transparency of Securities Financing Transactions of Reuse and amending Regulation (SFTR) (EU) N°648/2012 (Continued)

- **Reverse repurchase agreement**

The 10 largest counterparties across all reverse repurchase agreements as at December 31, 2022 are as follows:

Candriam Equities L Risk Arbitrage Opportunities

Counterparty	Concentration data for open trades
Caceis Bank, Lux. Branch	26,657,556

The 10 largest issuers of collateral received from reverse repurchase agreements activities as at December 31, 2022 are as follows:

Candriam Equities L Risk Arbitrage Opportunities

Counterparty	Total amount of collateral
Caceis Bank, Lux. Branch	768,000

There is no reuse of collateral related to Total Return Swaps transactions.

c) Safekeeping of collateral received

Each sub-fund has CACEIS Bank, Luxembourg Branch as depository for collateral received. All transactions are tri-party transactions. There is no reuse of collateral related to securities lending transactions.

Sub-Funds	Currency	Cash	Bonds	Equity	Total amount of collateral
Candriam Equities L Biotechnology	USD	0	63,591,447	126,017,500	189,608,947
Candriam Equities L Emerging Markets	EUR	0	168,013	331,144	499,157
Candriam Equities L EMU Innovation	EUR	0	2,558,061	774,183	3,332,244
Candriam Equities L Europe Innovation	EUR	0	45,081,715	112,478,761	157,560,476
Candriam Equities L Europe Optimum Quality	EUR	0	20,781,643	51,289,157	72,070,800

d) Aggregate transaction data

The maturity tenor of the collateral related to SFTs are the following:

- **Securities lending**

Sub-funds	Currency	From 1 month to 3 months	From 3 months to 1 year	More than 1 year	Open maturity	Total amount of collateral
Candriam Equities L Biotechnology	USD	0	0	63,591,447	126,017,500	189,608,947
Candriam Equities L Emerging Markets	EUR	0	0	168,013	331,144	499,157
Candriam Equities L EMU Innovation	EUR	0	0	2,558,061	774,183	3,332,244
Candriam Equities L Europe Innovation	EUR	0	0	45,081,715	112,478,761	157,560,476
Candriam Equities L Europe Optimum Quality	EUR	0	0	20,781,643	51,289,157	72,070,800

- **Reverse repurchase agreement**

Sub-funds	Currency	From 1 month to 3 months	From 3 months to 1 year	More than 1 year	Open maturity	Total amount of collateral
Candriam Equities L Risk Arbitrage Opportunities	EUR	0	0	23,104,500	0	23,104,500



Additional unaudited information

Sustainable Finance Disclosure Regulation (SFDR)

Candriam Equities L Australia, Candriam Equities L Risk Arbitrage Opportunities:

The above-mentioned sub-funds are classified as article 6 under SFDR.

They do not integrate systematically ESG characteristics in the management framework. Nevertheless, sustainability risks are taken into account in investment decisions by Candriam exclusion Policy which exclude some controversial activities.

Taxonomy (Article 6)

The investments underlying of this financial product do not take into account the EU criteria for environmentally sustainable economic activities and as such the sub-fund should not publish information on alignment with the Taxonomy.

Environmental and/or social characteristics

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Did this financial product have a sustainable investment objective?



YES

- It made **sustainable investments with an environmental objective: ___%**
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective: ___%**



NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 90% of sustainable investments
- with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**



To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium.
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

● **How did the sustainability indicators perform?**

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such as climate

change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the «do no harm» principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 33%). The proportion of sustainable investments in the Fund was therefore above this minimum threshold, as detailed in the section «What was the proportion of sustainability-related investments?»

● **... And compared to previous periods?**

Not applicable because no previous period data is available.

● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 33%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its proprietary ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

----- **How were the indicators for adverse impacts on sustainability factors taken into account?**

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

The EU Taxonomy sets out a “do not significant harm” principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The “do no significant harm” principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.



How did this financial product consider principal adverse impacts on sustainability factors?

At Sub-Fund level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means (cfr. Candriam's PAI statement : <https://www.candriam.com/en/private/sfdr/>):

- Engagement & Voting: in order to avoid and/or reduce the adverse impact on sustainable objectives, the Sub-Fund also considered the adverse impacts in its interactions with companies, through dialogue and voting. Candriam prioritised its engagement and voting activities according to an evaluation of the most material and relevant ESG challenges, facing industries and issuers, by considering both the financial and societal / stakeholder impacts. Therefore, the level of engagement with each company within the same product may vary and is subject to Candriam's prioritisation methodology.
 - Dialogue:

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions,
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Our objective is obviously to encourage companies to publicly report on how they align with a 1.5D trajectory and to support such an alignment. Beyond any Net Zero commitment and Scope1-2-3 absolute emissions disclosure, Candriam

thus encourage them to provide insights on how short / mid term targets are aligned with scientifically recognized 1.5D trajectory. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue. As in previous year, we continue to support and actively participate to several collaborative initiatives such Climate Action 100+ . These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (<https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications>) .

Given the geopolitical context and observed increase of inequalities, several engagements have also been performed in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10, PAI11). We also conducted a dedicated Post-covid direct engagement campaign aiming at investigating how relationships with stakeholders were impacted and the changes now integrated as the “new normal” course of business for Candriam’s investee companies. In the same vein, Human capital management is an aspect we address in most of our exchanges with companies. We continue to support Workforce Disclosure Initiative defending a better access to reliable, relevant and comparable data on companies’ direct and indirect workforces.

○ Voting:

The Candriam’s approach to Corporate Governance relies on internationally-recognized standards, notably the principles laid down by the OECD as well as by the International Corporate Governance Network (ICGN).

In that respect, Candriam has exercised its voting rights when available on positions of the portfolio. Shareholders’ rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. Remuneration and directors’ election concentrate most of our votes against management. Indeed, we require companies to respect the pay-for-performance principle and will show our disagreement as soon as we consider the level of remuneration excessive or conditions of attribution not transparent enough nor challenging. Equally, we expect companies to comply with our minimum independence requirements : at boards failing to meet this requirement, we oppose (re-)election of any non-independent director, except CEO. Diversity (PAI13) and expertise level of the board are of course also taken into account in these votes.

In addition, Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote.

In the best interest of its clients, Candriam considers internal ESG opinion on the investee companies but also any outcomes of engagement with them, in its voting choices.

In the context of Candriam’s voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10, PAI11)) and governance-related management and shareholder resolutions. More specifically, Candriam welcomes the introduction of management-sponsored ‘Say-on-Climate’ resolutions. Candriam built a detailed framework to be applied to every Say-on-Climate resolution, which assesses the stringency and the alignment of the company transition strategy with a 2050 net zero emissions pathway. As a result, most of these did not get our support during the period.

- Exclusion: Candriam's negative screening of companies or countries aimed to avoid investments in harmful activities or practices and may led to exclusions linked to comparnies' or issuers' adverse impact.
- Monitoring: calculation and evaluation of the principal adverse impact indicators including the reporting at Sub-Fund level. Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the sub-fund. See below the results of the indicators of this Sub-fund :

PAI indicators	Value
10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises	0.00%
14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)	0.00%



What were the top investments of this financial product?

The list includes the investments constituting the greatest proportion of investments of the financial product during the reference period which is: 31/12/2022

Top investments	Sector	Proportion	Country
REGENERON PHARMACEUTICALS INC	Biotechnology	6.87%	US
GILEAD SCIENCES INC	Biotechnology	6.56%	US
AMGEN INC	Pharmaceuticals	5.85%	US
VERTEX PHARMACEUTICALS INC	Biotechnology	5.38%	US
BIOGEN IDEC INC	Pharmaceuticals	4.12%	US
ALNYLAM PHARMACEUTICALS INC	Pharmaceuticals	4.04%	US
MODERNA INC	Biotechnology	3.71%	US
SEAGEN INC	Biotechnology	2.73%	US
HORIZON THERAPEUTICS PLC	Pharmaceuticals	2.25%	IE
ASTRAZENECA PLC	Pharmaceuticals	2.13%	GB
ILLUMINA INC	Pharmaceuticals	1.84%	US
BIOMARIN PHARMACEUTICAL INC	Biotechnology	1.78%	US
GENMAB AS	Biotechnology	1.78%	DK
XENON PHARMA --- REGISTERED SHS	Pharmaceuticals	1.64%	CA
INCYTE CORP	Biotechnology	1.63%	US


Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



What was the proportion of sustainability-related investments?

What was the asset allocation?

Asset allocation describes the share of investments in specific assets.



#1 Aligned with E/S characteristics includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

#2 Other includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● ***In which economic sectors were the investments made?***

Top sector	Proportion
Biotechnology	50.90%
Pharmaceuticals	40.66%
Banks and other financial institutions	2.51%
Electronics and semiconductors	1.46%
Machine and apparatus construction	1.34%
Miscellaneous services	0.78%
Healthcare	0.60%

Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.


Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.

Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy ¹?

- Yes
- In fossil gas In nuclear energy
- No

The two graphs below show in green the minimum percentage of investments that are aligned with the EU Taxonomy. As there is no appropriate methodology to determine the Taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

What was the share of investments made in transitional and enabling activities?

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?

Not applicable because no previous period data is available

What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?

The Sub-Fund had a share of 0% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2022 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

What was the share of socially sustainable investments?

The Sub-fund had a share of investments with a social objective of 90%

What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?

The investments included under «Other» are present in the Sub-fund for 9.67% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments are planned to be sold;
- Other investments (including single name derivatives) purchased for diversification purposes and that might not be subject to an ESG screening or for which ESG data is not available;
- Non single name derivatives used for efficient portfolio management and/or for hedging purposes and/or temporarily following subscriptions/redemptions



What actions have been taken to meet the environmental and/or social characteristics during the reference period?

In order to respect the environmental and/or social characteristics during the reference period, the sub-fund initiated in issuers with a positive ESG profile, based on Candriam's independent ESG rating assessment. Esai and Zealand Pharmaceuticals, for which we expect also positive clinical news, are two examples of this.

In order to respect the environmental and/or social characteristics during the reference period, the sub-fund increased issuers with a positive ESG profile, based on Candriam's independent ESG rating assessment. Relay, that published good clinical data, is a good example of this, as it's internal ESG rating was increased from 6 to 5 in August (on a scale from 1 to 10, with 1 being the best and 10 the worst).

To give expression to the fact that challenges relating to climate change have been taken into account, the carbon footprint of companies is measured. As at 31/12/2022, the fund's carbon footprint was 2.46 tCO₂-eq / million euro invested, compared to 3.25 tCO₂-eq / million euro invested for the fund benchmark.



How did this financial product perform compared to the reference benchmark?

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

Reference benchmarks are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

Environmental and/or social characteristics

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Did this financial product have a sustainable investment objective?



YES

- It made **sustainable investments with an environmental objective: ___%**
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective: ___%**



NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 73% of sustainable investments
- with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**



To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium.
- achieving a lower carbon footprint than the benchmark
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

● **How did the sustainability indicators perform?**

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the «do no harm» principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 10%). The proportion of sustainable investments in the Fund was therefore above this minimum threshold, as detailed in the section «What was the proportion of sustainability-related investments?»

Sustainability KPI Name	Value	Benchmark
Carbon Footprint - Corporate - Scope 1&2 - Lower than bench	25.41	167.82

● **... And compared to previous periods?**

Not applicable because no previous period data is available.

● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 10%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its exclusive ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of «principal adverse impacts»
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

----- **How were the indicators for adverse impacts on sustainability factors taken into account?**

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

The EU Taxonomy sets out a “do not significant harm” principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The “do no significant harm” principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.



How did this financial product consider principal adverse impacts on sustainability factors?

At Sub-Fund level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means (cfr. Candriam's PAI statement : <https://www.candriam.com/en/private/sfdr/>):

- Engagement & Voting: in order to avoid and/or reduce the adverse impact on sustainable objectives, the Sub-Fund also considered the adverse impacts in its interactions with companies, through dialogue and voting. Candriam prioritised its engagement and voting activities according to an evaluation of the most material and relevant ESG challenges, facing industries and issuers, by considering both the financial and societal / stakeholder impacts. Therefore, the level of engagement with each company within the same product may vary and is subject to Candriam's prioritisation methodology.
 - Dialogue:

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions,
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Our objective is obviously to encourage companies to publicly report on how they align with a 1.5D trajectory and to support such an alignment. Beyond any Net Zero commitment and Scope1-2-3 absolute emissions disclosure, Candriam

thus encourage them to provide insights on how short / mid term targets are aligned with scientifically recognized 1.5D trajectory. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue. As in previous year, we continue to support and actively participate to several collaborative initiatives such Climate Action 100+ . These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (<https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications>) .

Given the geopolitical context and observed increase of inequalities, several engagements have also been performed in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10, PAI11). We also conducted a dedicated Post-covid direct engagement campaign aiming at investigating how relationships with stakeholders were impacted and the changes now integrated as the “new normal” course of business for Candriam’s investee companies. In the same vein, Human capital management is an aspect we address in most of our exchanges with companies. We continue to support Workforce Disclosure Initiative defending a better access to reliable, relevant and comparable data on companies’ direct and indirect workforces.

- Voting:

The Candriam’s approach to Corporate Governance relies on internationally-recognized standards, notably the principles laid down by the OECD as well as by the International Corporate Governance Network (ICGN).

In that respect, Candriam has exercised its voting rights when available on positions of the portfolio. Shareholders’ rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. Remuneration and directors’ election concentrate most of our votes against management. Indeed, we require companies to respect the pay-for-performance principle and will show our disagreement as soon as we consider the level of remuneration excessive or conditions of attribution not transparent enough nor challenging. Equally, we expect companies to comply with our minimum independence requirements : at boards failing to meet this requirement, we oppose (re-)election of any non-independent director, except CEO.

Diversity (PAI13) and expertise level of the board are of course also taken into account in these votes.

In addition, Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote.

In the best interest of its clients, Candriam considers internal ESG opinion on the investee companies but also any outcomes of engagement with them, in its voting choices.

In the context of Candriam’s voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10, PAI11)) and governance-related management and shareholder resolutions. More specifically, Candriam welcomes the introduction of management-sponsored ‘Say-on-Climate’ resolutions. Candriam built a detailed framework to be applied to every Say-on-Climate resolution, which assesses the stringency and the alignment of the company transition strategy with a 2050 net zero emissions pathway. As a result, most of these did not get our support during the period.

- Exclusion: Candriam's negative screening of companies or countries aimed to avoid investments in harmful activities or practices and may led to exclusions linked to companies' or issuers' adverse impact.
- Monitoring: calculation and evaluation of the principal adverse impact indicators including the reporting at Sub-Fund level. Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the sub-fund. See below the results of the indicators of this Sub-fund :

PAI indicators	Value
10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises	3.11%*
14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)	0.00%

**Samsung Electronics currently has a Red flag on Corporate Governance norms, due to concerns surrounding the abuse of power by the company's management and founder family, as well as the lack of independent oversight by the Board of Directors. This makes the company ineligible for SFDR Art 8 funds as a result of Good Governance criteria. On the other hand, we see that Samsung already has a Board-level audit committee and a governance committee composed of outside directors who were nominated through the nomination committee. Samsung's nomination committee is also composed entirely of outside directors. Therefore, on the surface, independent governance criteria seem to be met. Any corporate governance dysfunction at Samsung, hence, likely stem from corporate culture. Consequently, we assess that it is worthwhile to engage with Samsung Electronics in order to better understand the company's culture and determine how corporate governance can be improved. During the engagement period, Samsung is placed under an "Under Review" status on Good Governance criteria. Candriam's holding in Samsung, in the meantime, cannot increase*



What were the top investments of this financial product?

The list includes the investments constituting the greatest proportion of investments of the financial product during the reference period which is: 31/12/2022

Top investments	Sector	Proportion	Country
TAIWAN SEMICONDUCTOR CO	Electronics and semiconductors	6.26%	TW
TENCENT HOLDINGS LTD	Internet and internet services	4.41%	KY
ALIBABA GROUP	Miscellaneous services	3.59%	KY
MEITUAN - SHS 114A/REG S	Internet and internet services	2.76%	KY
PING AN INS (GRP) CO -H-	Insurance	2.32%	CN
JD.COM INC - CL A	Retail trade and department stores	2.25%	KY
SAMSUNG ELECTRONICS CO LTD	Electronics and semiconductors	2.02%	KR
SAMSUNG SDI CO LTD	Electronics and semiconductors	1.79%	KR
RELIANCE INDUSTRIES DEMATERIALIZED	Chemicals	1.73%	IN
HDFC BANK - REGISTERED SHS	Banks and other financial institutions	1.72%	IN
BANK CENTRAL ASIA DEP	Banks and other financial institutions	1.63%	ID
SAMSUNG BIOLOGICS CO LTD	Biotechnology	1.62%	KR
BHARTI AIRTEL LTD(DEMATERIALIZED)	Communication	1.58%	IN
AXIS BANK	Banks and other financial institutions	1.55%	IN
CHAILEASE HOLDING COMPANY LTD	Banks and other financial institutions	1.49%	TW


Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



What was the proportion of sustainability-related investments?

What was the asset allocation?

Asset allocation describes the share of investments in specific assets.



#1 Aligned with E/S characteristics includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

#2 Other includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● ***In which economic sectors were the investments made?***

Top sector	Proportion
Banks and other financial institutions	17.37%
Electronics and semiconductors	14.26%
Internet and internet services	11.66%
Foods and non alcoholic drinks	6.00%
Retail trade and department stores	5.00%
Machine and apparatus construction	4.18%
Chemicals	4.00%
Electrical engineering	3.97%
Pharmaceuticals	3.70%
Miscellaneous services	3.59%
Insurance	3.30%
Communication	3.05%
Biotechnology	2.81%
Road vehicles	2.66%
Transportation	1.93%

Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:


- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.

Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy ¹?


- Yes
- In fossil gas In nuclear energy
- No

The two graphs below show in green the minimum percentage of investments that are aligned with the EU Taxonomy. As there is no appropriate methodology to determine the Taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.

1. Taxonomy-alignment of investments including sovereign bonds*



2. Taxonomy-alignment of investments excluding sovereign bonds*



* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

What was the share of investments made in transitional and enabling activities?

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?

Not applicable because no previous period data is available

What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?

The Sub-Fund had a share of 23.27% in sustainable investments with an environmental objective not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2022 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

What was the share of socially sustainable investments?

The Sub-fund had a share of investments with a social objective of 49.78%

What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?

The investments included under «Other» are present in the Sub-fund for 6.08% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments are planned to be sold;
- Other investments (including single name derivatives) purchased for diversification purposes and that might not be subject to an ESG screening or for which ESG data is not available;
- Non single name derivatives used for efficient portfolio management and/or for hedging purposes and/or temporarily following subscriptions/redemptions



What actions have been taken to meet the environmental and/or social characteristics during the reference period?

In order to respect the environmental and/or social characteristics during the reference period, we excluded/sold the following investments for which the issuers did not have environmental and/or social characteristics :

- S-Oil: Based on Candriam norms-based controversy analysis, S-Oil remained excluded in 2022 for significantly and repeatedly breaching the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. As a result the fund sold its exposure to the name in 2022.
- China Petroleum & Chemical Corporation: Based on Candriam norms-based controversy analysis, China Petroleum & Chemical Corporation remained excluded in 2022 for significantly and repeatedly breaching the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. As a result the fund sold its position in the name.
- Mol Hungarian Oil & Gas: Based on Candriam norms-based controversy analysis, Mol Hungarian Oil & Gas remained excluded in 2022 for significantly and repeatedly breaching the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. As a result the fund sold its position in the company.

"To give expression to the fact that challenges relating to climate change have been taken into account, the carbon footprint of companies is measured. As at 31/12/2022, the fund's carbon footprint was 25.41 tCO₂-eq / million euro invested, compared to 167.82 tCO₂-eq / million euro invested for the fund benchmark."

"The subfund aims to achieve an ESG score, based on Candriam's proprietary ESG methodology, higher than its benchmark. As at 31/12/2022, the subfund's overall ESG score of 47.89, compared to ESG score of 44.87 for the benchmark."



How did this financial product perform compared to the reference benchmark?

Reference benchmarks are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund.

Environmental and/or social characteristics

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Did this financial product have a sustainable investment objective?



YES

- It made **sustainable investments with an environmental objective: ___%**
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective: ___%**



NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 97% of sustainable investments
- with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**



To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium).
- achieving a lower carbon footprint than the benchmark
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

● **How did the sustainability indicators perform?**

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such

Sustainability indicators measure how the environmental or social characteristics promoted by the financial product are attained.

as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the «do no harm» principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 33%). The proportion of sustainable investments in the Fund was therefore above this minimum threshold, as detailed in the section «What was the proportion of sustainability-related investments?»

Sustainability KPI Name	Value	Benchmark
Carbon Footprint - Corporate - Scope 1&2 - Lower than bench	22.20	94.48
ESG Score - Corporate - Higher than bench	60.16	53.34

● **... And compared to previous periods?**

Not applicable because no previous period data is available.

● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 33%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its exclusive ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of «principal adverse impacts»
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

----- **How were the indicators for adverse impacts on sustainability factors taken into account?**

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

The EU Taxonomy sets out a "do not significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.



How did this financial product consider principal adverse impacts on sustainability factors?

At Sub-Fund level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means (cfr. Candriam's PAI statement : <https://www.candriam.com/en/private/sfdr/>):

- Engagement & Voting: in order to avoid and/or reduce the adverse impact on sustainable objectives, the Sub-Fund also considered the adverse impacts in its interactions with companies, through dialogue and voting. Candriam prioritised its engagement and voting activities according to an evaluation of the most material and relevant ESG challenges, facing industries and issuers, by considering both the financial and societal / stakeholder impacts. Therefore, the level of engagement with each company within the same product may vary and is subject to Candriam's prioritisation methodology.
 - Dialogue:

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions,
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Our objective is obviously to encourage companies to publicly report on how they align with a 1.5D trajectory and to support such an alignment. Beyond any Net Zero commitment and Scope1-2-3 absolute emissions disclosure, Candriam thus encourage them to provide insights on how short / mid term targets are aligned with scientifically recognized 1.5D trajectory. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue. As in previous year, we continue to support and actively participate to several collaborative initiatives such Climate Action 100+ . These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (<https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications>) .

Given the geopolitical context and observed increase of inequalities, several engagements have also been performed in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10, PAI11). We also conducted a dedicated Post-covid direct engagement campaign aiming at investigating how relationships with stakeholders were impacted and the changes now integrated as the “new normal” course of business for Candriam’s investee companies. In the same vein, Human capital management is an aspect we address in most of our exchanges with companies. We continue to support Workforce Disclosure Initiative defending a better access to reliable, relevant and comparable data on companies’ direct and indirect workforces.

o Voting:

The Candriam’s approach to Corporate Governance relies on internationally-recognized standards, notably the principles laid down by the OECD as well as by the International Corporate Governance Network (ICGN).

In that respect, Candriam has exercised its voting rights when available on positions of the portfolio. Shareholders’ rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. Remuneration and directors’ election concentrate most of our votes against management. Indeed, we require companies to respect the pay-for-performance principle and will show our disagreement as soon as we consider the level of remuneration excessive or conditions of attribution not transparent enough nor challenging. Equally, we expect companies to comply with our minimum independence requirements : at boards failing to meet this requirement, we oppose (re-)election of any non-independent director, except CEO. Diversity (PAI13) and expertise level of the board are of course also taken into account in these votes.

In addition, Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote.

In the best interest of its clients, Candriam considers internal ESG opinion on the investee companies but also any outcomes of engagement with them, in its voting choices.

In the context of Candriam’s voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10, PAI11)) and governance-related management and shareholder resolutions. More specifically, Candriam welcomes the introduction of management-sponsored ‘Say-on-Climate’ resolutions. Candriam built a detailed framework to be applied to every Say-on-Climate resolution, which assesses the stringency and the alignment of the company transition strategy with a 2050 net zero emissions pathway. As a result, most of these did not get our support during the period.

- Exclusion: Candriam's negative screening of companies or countries aimed to avoid investments in harmful activities or practices and may led to exclusions linked to comparnies' or issuers' adverse impact.
- Monitoring: calculation and evaluation of the principal adverse impact indicators including the reporting at Sub-Fund level. Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the sub-fund. See below the results of the indicators of this Sub-fund :

PAI indicators	Value
10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises	0.00%
14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)	0.00%



What were the top investments of this financial product?

The list includes the investments constituting **the greatest proportion of investments** of the financial product during the reference period which is: 31/12/2022

Top investments	Sector	Proportion	Country
BIOMERIEUX SA	Pharmaceuticals	4.54%	FR
KERRY GROUP -A-	Foods and non alcoholic drinks	4.40%	IE
SCHNEIDER ELECTRIC SE	Electrical engineering	4.28%	FR
DSM KONINKLIJKE	Chemicals	4.23%	NL
CARL ZEISS MEDITEC AG	Pharmaceuticals	4.18%	DE
SYMRISE AG	Chemicals	4.14%	DE
ASML HOLDING NV	Electronics and semiconductors	4.02%	NL
DASSAULT SYST.	Internet and internet services	3.94%	FR
FINECOBANK	Banks and other financial institutions	3.78%	IT
L'OREAL SA	Pharmaceuticals	3.09%	FR
SANOFI	Pharmaceuticals	3.08%	FR
BEIERSDORF AG	Pharmaceuticals	3.04%	DE
KBC GROUPE SA	Banks and other financial institutions	2.98%	BE
ESSILORLUXOTTICA SA	Pharmaceuticals	2.93%	FR
INDITEX SHARE FROM SPLIT	Retail trade and department stores	2.93%	ES


Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



What was the proportion of sustainability-related investments?

What was the asset allocation?

Asset allocation describes the share of investments in specific assets.



#1 Aligned with E/S characteristics includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

#2 Other includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● ***In which economic sectors were the investments made?***

Top sector	Proportion
Pharmaceuticals	23.68%
Internet and internet services	10.88%
Electrical engineering	10.54%
Machine and apparatus construction	10.35%
Banks and other financial institutions	10.14%
Chemicals	9.90%
Electronics and semiconductors	5.38%
Foods and non alcoholic drinks	5.20%
Retail trade and department stores	2.93%
Building materials	2.90%
Biotechnology	2.83%
Real estate	2.36%

Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:


- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.

Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy ¹?


- Yes
- In fossil gas In nuclear energy
- No

The two graphs below show in green the minimum percentage of investments that are aligned with the EU Taxonomy. As there is no appropriate methodology to determine the Taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.

1. Taxonomy-alignment of investments including sovereign bonds*



2. Taxonomy-alignment of investments excluding sovereign bonds*



* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

What was the share of investments made in transitional and enabling activities?

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?

Not applicable because no previous period data is available

What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?

The Sub-Fund had a share of 34.67% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2022 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

What was the share of socially sustainable investments?

The Sub-fund had a share of investments with a social objective of 62.41%

What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?

The investments included under «Other» are present in the Sub-fund for 2.91% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments are planned to be sold;
- Other investments (including single name derivatives) purchased for diversification purposes and that might not be subject to an ESG screening or for which ESG data is not available;
- Non single name derivatives used for efficient portfolio management and/or for hedging purposes and/or temporarily following subscriptions/redemptions



What actions have been taken to meet the environmental and/or social characteristics during the reference period?

In order to respect the environmental and/or social characteristics during the reference period, the sub-fund initiated positions in issuers with a positive ESG profile, based on Candriam’s independent ESG rating assessment. For instance, the fund started a position in Carl Zeiss. Carl Zeiss is a leading player in ophthalmic devices (ophthalmic systems, intraocular lenses, refractive laser, etc.) and surgical microscopes. It is a play on ‘Better Health’, ‘Better aging’ and ‘Digitalization’ with a strong fundamental investment case that scores well on all our criteria as well as on our innovation framework. Thanks to technological leadership, they have been able to grow ahead of peers in most of their business lines.

To give expression to the fact that challenges relating to climate change have been taken into account, the carbon footprint of companies is measured. As at 31/12/2022, the fund’s carbon footprint was 22 tCO₂-eq / million euro invested, compared to 94 tCO₂-eq / million euro invested for the fund benchmark.



How did this financial product perform compared to the reference benchmark?

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

Reference benchmarks are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

Environmental and/or social characteristics

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Did this financial product have a sustainable investment objective?



YES

- It made **sustainable investments with an environmental objective: ___%**
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective: ___%**



NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 98% of sustainable investments
- with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**



To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium).
- achieving a lower carbon footprint than the benchmark
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

● How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such

Sustainability indicators measure how the environmental or social characteristics promoted by the financial product are attained.

as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the «do no harm» principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 33%). The proportion of sustainable investments in the Fund was therefore above this minimum threshold, as detailed in the section «What was the proportion of sustainability-related investments?»

Sustainability KPI Name	Value	Benchmark
Carbon Footprint - Corporate - Scope 1&2 - Lower than bench	17.07	77.43
ESG Score - Corporate - Higher than bench	60.71	53.65

● **... And compared to previous periods?**

Not applicable because no previous period data is available.

● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 33%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its exclusive ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of «principal adverse impacts»
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

----- **How were the indicators for adverse impacts on sustainability factors taken into account?**

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

The EU Taxonomy sets out a “do not significant harm” principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The “do no significant harm” principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.



How did this financial product consider principal adverse impacts on sustainability factors?

At Sub-Fund level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means (cfr. Candriam's PAI statement : <https://www.candriam.com/en/private/sfdr/>):

- Engagement & Voting: in order to avoid and/or reduce the adverse impact on sustainable objectives, the Sub-Fund also considered the adverse impacts in its interactions with companies, through dialogue and voting. Candriam prioritised its engagement and voting activities according to an evaluation of the most material and relevant ESG challenges, facing industries and issuers, by considering both the financial and societal / stakeholder impacts. Therefore, the level of engagement with each company within the same product may vary and is subject to Candriam's prioritisation methodology.
 - Dialogue:

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions,
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Our objective is obviously to encourage companies to publicly report on how they align with a 1.5D trajectory and to support such an alignment. Beyond any Net Zero commitment and Scope1-2-3 absolute emissions disclosure, Candriam thus encourage them to provide insights on how short / mid term targets are aligned with scientifically recognized 1.5D trajectory. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue. As in previous year, we continue to support and actively participate to several collaborative initiatives such Climate Action 100+ . These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (<https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications>) .

Given the geopolitical context and observed increase of inequalities, several engagements have also been performed in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10, PAI11). We also conducted a dedicated Post-covid direct engagement campaign aiming at investigating how relationships with stakeholders were impacted and the changes now integrated as the “new normal” course of business for Candriam’s investee companies. In the same vein, Human capital management is an aspect we address in most of our exchanges with companies. We continue to support Workforce Disclosure Initiative defending a better access to reliable, relevant and comparable data on companies’ direct and indirect workforces.

o Voting:

The Candriam’s approach to Corporate Governance relies on internationally-recognized standards, notably the principles laid down by the OECD as well as by the International Corporate Governance Network (ICGN).

In that respect, Candriam has exercised its voting rights when available on positions of the portfolio. Shareholders’ rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. Remuneration and directors’ election concentrate most of our votes against management. Indeed, we require companies to respect the pay-for-performance principle and will show our disagreement as soon as we consider the level of remuneration excessive or conditions of attribution not transparent enough nor challenging. Equally, we expect companies to comply with our minimum independence requirements : at boards failing to meet this requirement, we oppose (re-)election of any non-independent director, except CEO. Diversity (PAI13) and expertise level of the board are of course also taken into account in these votes.

In addition, Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote.

In the best interest of its clients, Candriam considers internal ESG opinion on the investee companies but also any outcomes of engagement with them, in its voting choices.

In the context of Candriam’s voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10, PAI11)) and governance-related management and shareholder resolutions. More specifically, Candriam welcomes the introduction of management-sponsored ‘Say-on-Climate’ resolutions. Candriam built a detailed framework to be applied to every Say-on-Climate resolution, which assesses the stringency and the alignment of the company transition strategy with a 2050 net zero emissions pathway. As a result, most of these did not get our support during the period.

- Exclusion: Candriam's negative screening of companies or countries aimed to avoid investments in harmful activities or practices and may led to exclusions linked to companies' or issuers' adverse impact.
- Monitoring: calculation and evaluation of the principal adverse impact indicators including the reporting at Sub-Fund level. Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the sub-fund. See below the results of the indicators of this Sub-fund :

PAI indicators	Value
10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises	0.00%
14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)	0.00%



What were the top investments of this financial product?

The list includes the investments constituting **the greatest proportion of investments** of the financial product during the reference period which is: 31/12/2022

Top investments	Sector	Proportion	Country
BIOMERIEUX SA	Pharmaceuticals	4.52%	FR
SYMRISE AG	Chemicals	3.80%	DE
NESTLE SA REG SHS	Foods and non alcoholic drinks	3.61%	CH
KERRY GROUP -A-	Foods and non alcoholic drinks	3.55%	IE
FINECOBANK	Banks and other financial institutions	3.42%	IT
DASSAULT SYST.	Internet and internet services	3.34%	FR
ASML HOLDING NV	Electronics and semiconductors	3.32%	NL
HEXAGON --- REGISTERED SHS - B-	Machine and apparatus construction	3.23%	SE
SCHNEIDER ELECTRIC SE	Electrical engineering	3.22%	FR
ASSA ABLOY -B- NEW I	Machine and apparatus construction	3.19%	SE
DSM KONINKLIJKE	Chemicals	3.14%	NL
HALMA PLC	Electronics and semiconductors	3.00%	GB
TOMRA SYSTEMS ASA	Machine and apparatus construction	2.92%	NO
TECAN GROUP NAM.AKT	Pharmaceuticals	2.79%	CH
CARL ZEISS MEDITEC AG	Pharmaceuticals	2.53%	DE


Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



What was the proportion of sustainability-related investments?

What was the asset allocation?

Asset allocation describes the share of investments in specific assets.



#1 Aligned with E/S characteristics includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

#2 Other includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● ***In which economic sectors were the investments made?***

Top sector	Proportion
Pharmaceuticals	22.10%
Machine and apparatus construction	16.19%
Chemicals	10.85%
Foods and non alcoholic drinks	7.82%
Internet and internet services	7.52%
Electronics and semiconductors	7.17%
Banks and other financial institutions	6.41%
Electrical engineering	4.90%
Biotechnology	4.35%
Miscellaneous consumer goods	2.07%
Precious metals and stones	1.88%
Retail trade and department stores	1.75%
Building materials	1.58%
Insurance	1.58%
Real estate	1.42%

Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.


Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.

Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy ¹?

- Yes
- In fossil gas In nuclear energy
- No

The two graphs below show in green the minimum percentage of investments that are aligned with the EU Taxonomy. As there is no appropriate methodology to determine the Taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

What was the share of investments made in transitional and enabling activities?

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?

Not applicable because no previous period data is available

What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?

The Sub-Fund had a share of 31.73% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2022 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

What was the share of socially sustainable investments?

The Sub-fund had a share of investments with a social objective of 66.62%

What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?

The investments included under «Other» are present in the Sub-fund for 1.65% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments are planned to be sold;
- Other investments (including single name derivatives) purchased for diversification purposes and that might not be subject to an ESG screening or for which ESG data is not available;
- Non single name derivatives used for efficient portfolio management and/or for hedging purposes and/or temporarily following subscriptions/redemptions



What actions have been taken to meet the environmental and/or social characteristics during the reference period?

In order to respect the environmental and/or social characteristics during the reference period, the sub-fund initiated positions in issuers with a positive ESG profile, based on Candriam’s independent ESG rating assessment. For instance, the fund started a position in MIPS. MIPS is a leading component manufacturer for the helmet market and a play on Health & Wellness. Its patented technology, the Brain Protection System, aims to protect the brain from the effects of rotational impact, the most common cause of concussion. MIPS supplies its products to the majority of major helmet manufacturers and is growing quickly aided by increased consumer safety awareness.

To give expression to the fact that challenges relating to climate change have been taken into account, the carbon footprint of companies is measured. As at 31/12/2022, the fund’s carbon footprint was 17 tCO₂-eq / million euro invested, compared to 77 tCO₂-eq / million euro invested for the fund benchmark.



How did this financial product perform compared to the reference benchmark?

Reference benchmarks are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

Environmental and/or social characteristics

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Did this financial product have a sustainable investment objective?	
<input checked="" type="radio"/> <input type="checkbox"/> YES	<input type="radio"/> <input checked="" type="checkbox"/> NO
<input type="checkbox"/> It made sustainable investments with an environmental objective: ___%	<input checked="" type="checkbox"/> It promoted Environmental/Social (E/S) characteristics and while it did not have as its objective a sustainable investment, it had a proportion of 92% of sustainable investments
<input type="checkbox"/> in economic activities that qualify as environmentally sustainable under the EU Taxonomy	<input type="checkbox"/> with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
<input type="checkbox"/> in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy	<input checked="" type="checkbox"/> with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
<input type="checkbox"/> It made sustainable investments with a social objective: ___%	<input checked="" type="checkbox"/> with a social objective
	<input type="checkbox"/> It promoted E/S characteristics, but did not make any sustainable investments



To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium.
- achieving a lower carbon footprint than the benchmark
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

● How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such

as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the «do no harm» principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 33%). The proportion of sustainable investments in the Fund was therefore above this minimum threshold, as detailed in the section «What was the proportion of sustainability-related investments?»

Sustainability KPI Name	Value	Benchmark
Carbon Footprint - Corporate - Scope 1&2 - Lower than bench	27.07	77.43
ESG Score - Corporate - Higher than bench	59.98	53.65

● **... And compared to previous periods?**

Not applicable because no previous period data is available.

● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 33%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its exclusive ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of «principal adverse impacts»
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

--- **How were the indicators for adverse impacts on sustainability factors taken into account?**

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

The EU Taxonomy sets out a "do not significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.



How did this financial product consider principal adverse impacts on sustainability factors?

At Sub-Fund level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means (cfr. Candriam's PAI statement : <https://www.candriam.com/en/private/sfdr/>):

- Engagement & Voting: in order to avoid and/or reduce the adverse impact on sustainable objectives, the Sub-Fund also considered the adverse impacts in its interactions with companies, through dialogue and voting. Candriam prioritised its engagement and voting activities according to an evaluation of the most material and relevant ESG challenges, facing industries and issuers, by considering both the financial and societal / stakeholder impacts. Therefore, the level of engagement with each company within the same product may vary and is subject to Candriam's prioritisation methodology.
 - Dialogue:

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions,
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Our objective is obviously to encourage companies to publicly report on how they align with a 1.5D trajectory and to support such an alignment. Beyond any Net Zero commitment and Scope1-2-3 absolute emissions disclosure, Candriam thus encourage them to provide insights on how short / mid term targets are aligned with scientifically recognized 1.5D trajectory. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue. As in previous year, we continue to support and actively participate to several collaborative initiatives such Climate Action 100+ . These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (<https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications>) .

Given the geopolitical context and observed increase of inequalities, several engagements have also been performed in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10, PAI11). We also conducted a dedicated Post-covid direct engagement campaign aiming at investigating how relationships with stakeholders were impacted and the changes now integrated as the “new normal” course of business for Candriam’s investee companies. In the same vein, Human capital management is an aspect we address in most of our exchanges with companies. We continue to support Workforce Disclosure Initiative defending a better access to reliable, relevant and comparable data on companies’ direct and indirect workforces.

o Voting:

The Candriam’s approach to Corporate Governance relies on internationally-recognized standards, notably the principles laid down by the OECD as well as by the International Corporate Governance Network (ICGN).

In that respect, Candriam has exercised its voting rights when available on positions of the portfolio. Shareholders’ rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. Remuneration and directors’ election concentrate most of our votes against management. Indeed, we require companies to respect the pay-for-performance principle and will show our disagreement as soon as we consider the level of remuneration excessive or conditions of attribution not transparent enough nor challenging. Equally, we expect companies to comply with our minimum independence requirements : at boards failing to meet this requirement, we oppose (re-)election of any non-independent director, except CEO. Diversity (PAI13) and expertise level of the board are of course also taken into account in these votes.

In addition, Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote.

In the best interest of its clients, Candriam considers internal ESG opinion on the investee companies but also any outcomes of engagement with them, in its voting choices.

In the context of Candriam’s voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10, PAI11)) and governance-related management and shareholder resolutions. More specifically, Candriam welcomes the introduction of management-sponsored ‘Say-on-Climate’ resolutions. Candriam built a detailed framework to be applied to every Say-on-Climate resolution, which assesses the stringency and the alignment of the company transition strategy with a 2050 net zero emissions pathway. As a result, most of these did not get our support during the period.

- Exclusion: Candriam's negative screening of companies or countries aimed to avoid investments in harmful activities or practices and may led to exclusions linked to companies' or issuers' adverse impact.
- Monitoring: calculation and evaluation of the principal adverse impact indicators including the reporting at Sub-Fund level. Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the sub-fund. See below the results of the indicators of this Sub-fund :

PAI indicators	Value
10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises	0.00%
14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)	0.00%



What were the top investments of this financial product?

The list includes the investments constituting **the greatest proportion of investments** of the financial product during the reference period which is: 31/12/2022

Top investments	Sector	Proportion	Country
AIR LIQUIDE SA	Chemicals	3.13%	FR
NESTLE SA REG SHS	Foods and non alcoholic drinks	3.03%	CH
KERRY GROUP -A-	Foods and non alcoholic drinks	2.95%	IE
BIOMERIEUX SA	Pharmaceuticals	2.90%	FR
TECAN GROUP NAM.AKT	Pharmaceuticals	2.81%	CH
KBC GROUPE SA	Banks and other financial institutions	2.74%	BE
SCHNEIDER ELECTRIC SE	Electrical engineering	2.67%	FR
L'OREAL SA	Pharmaceuticals	2.66%	FR
BEIERSDORF AG	Pharmaceuticals	2.59%	DE
RECKITT BENCKISER GROUP PLC	Miscellaneous consumer goods	2.51%	GB
DSM KONINKLIJKE	Chemicals	2.51%	NL
ESSILORLUXOTTICA SA	Pharmaceuticals	2.40%	FR
SYMRISE AG	Chemicals	2.39%	DE
ANHEUSER-BUSCH INBEV	Tobacco and alcoholic drinks	2.33%	BE
GENMAB AS	Biotechnology	2.27%	DK


Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



What was the proportion of sustainability-related investments?

● What was the asset allocation?

Asset allocation describes the share of investments in specific assets.



#1 Aligned with E/S characteristics includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

#2 Other includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● ***In which economic sectors were the investments made?***

Top sector	Proportion
Pharmaceuticals	21.78%
Chemicals	11.98%
Foods and non alcoholic drinks	8.52%
Banks and other financial institutions	8.49%
Insurance	6.58%
Internet and internet services	5.44%
Machine and apparatus construction	4.72%
Biotechnology	4.25%
Miscellaneous services	3.76%
Real estate	3.08%
Electrical engineering	2.67%
Miscellaneous consumer goods	2.51%
Tobacco and alcoholic drinks	2.33%
Retail trade and department stores	2.06%
Graphic art and publishing	2.01%

Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:


- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.

Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy ¹?


- Yes
- In fossil gas In nuclear energy
- No

The two graphs below show in green the minimum percentage of investments that are aligned with the EU Taxonomy. As there is no appropriate methodology to determine the Taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.

1. Taxonomy-alignment of investments including sovereign bonds*



2. Taxonomy-alignment of investments excluding sovereign bonds*



* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

What was the share of investments made in transitional and enabling activities?

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?

Not applicable because no previous period data is available

What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?

The Sub-Fund had a share of 30.58% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2022 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

What was the share of socially sustainable investments?

The Sub-fund had a share of investments with a social objective of 61.49%

What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?

The investments included under «Other» are present in the Sub-fund for 4.42% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments are planned to be sold;
- Other investments (including single name derivatives) purchased for diversification purposes and that might not be subject to an ESG screening or for which ESG data is not available;
- Non single name derivatives used for efficient portfolio management and/or for hedging purposes and/or temporarily following subscriptions/redemptions



What actions have been taken to meet the environmental and/or social characteristics during the reference period?

In order to respect the environmental and/or social characteristics during the reference period, the sub-fund initiated positions in issuers with a positive ESG profile, based on Candriam's independent ESG rating assessment. For instance, the fund started a position in Bureau Veritas. Bureau Veritas is the number two in the conformity assessment, inspection, testing and certification market (TIC). The group has leading positions in key markets such as Marine, Industry, Construction and Consumer goods.

To give expression to the fact that challenges relating to climate change have been taken into account, the carbon footprint of companies is measured. As at 31/12/2022, the fund's carbon footprint was 27.07 tCO₂-eq / million euro invested, compared to 77.43 tCO₂-eq / million euro invested for the fund benchmark.

The subfund aims to achieve an ESG score, based on Candriam's proprietary ESG methodology, higher than its benchmark. As at 31/12/2022, the subfund's overall ESG was 59.98 compared to the ESG score of 53.65 for the benchmark.



How did this financial product perform compared to the reference benchmark?

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

Reference benchmarks are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

Environmental and/or social characteristics

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Did this financial product have a sustainable investment objective?	
●● <input type="checkbox"/> YES	● <input checked="" type="checkbox"/> NO
<input type="checkbox"/> It made sustainable investments with an environmental objective: ___%	<input checked="" type="checkbox"/> It promoted Environmental/Social (E/S) characteristics and while it did not have as its objective a sustainable investment, it had a proportion of 72% of sustainable investments
<input type="checkbox"/> in economic activities that qualify as environmentally sustainable under the EU Taxonomy	<input type="checkbox"/> with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
<input type="checkbox"/> in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy	<input checked="" type="checkbox"/> with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
<input type="checkbox"/> It made sustainable investments with a social objective: ___%	<input checked="" type="checkbox"/> with a social objective
<input type="checkbox"/> It made sustainable investments with a social objective: ___%	<input type="checkbox"/> It promoted E/S characteristics, but did not make any sustainable investments



To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium).
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

● **How did the sustainability indicators perform?**

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such

Sustainability indicators measure how the environmental or social characteristics promoted by the financial product are attained.

as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the «do no harm» principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 20%). The proportion of sustainable investments in the Fund was therefore above this minimum threshold, as detailed in the section «What was the proportion of sustainability-related investments?»

Sustainability KPI Name	Value	Benchmark
Carbon Footprint - Corporate - Scope 1&2 - Lower than bench	30.40	51.74

● **... And compared to previous periods?**

Not applicable because no previous period data is available.

● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 20%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its proprietary ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

----- **How were the indicators for adverse impacts on sustainability factors taken into account?**

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

The EU Taxonomy sets out a “do not significant harm” principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The “do no significant harm” principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.



How did this financial product consider principal adverse impacts on sustainability factors?

At Sub-Fund level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means (cfr. Candriam's PAI statement : <https://www.candriam.com/en/private/sfdr/>):

- Engagement & Voting: in order to avoid and/or reduce the adverse impact on sustainable objectives, the Sub-Fund also considered the adverse impacts in its interactions with companies, through dialogue and voting. Candriam prioritised its engagement and voting activities according to an evaluation of the most material and relevant ESG challenges, facing industries and issuers, by considering both the financial and societal / stakeholder impacts. Therefore, the level of engagement with each company within the same product may vary and is subject to Candriam's prioritisation methodology.
 - Dialogue:

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions,
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Our objective is obviously to encourage companies to publicly report on how they align with a 1.5D trajectory and to support such an alignment. Beyond any Net Zero commitment and Scope1-2-3 absolute emissions disclosure, Candriam thus encourage them to provide insights on how short / mid term targets are aligned with scientifically recognized 1.5D trajectory. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue. As in previous year, we continue to support and actively participate to several collaborative initiatives such Climate Action 100+ . These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (<https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications>) .

Given the geopolitical context and observed increase of inequalities, several engagements have also been performed in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10, PAI11). We also conducted a dedicated Post-covid direct engagement campaign aiming at investigating how relationships with stakeholders were impacted and the changes now integrated as the “new normal” course of business for Candriam’s investee companies. In the same vein, Human capital management is an aspect we address in most of our exchanges with companies. We continue to support Workforce Disclosure Initiative defending a better access to reliable, relevant and comparable data on companies’ direct and indirect workforces.

o Voting:

The Candriam’s approach to Corporate Governance relies on internationally-recognized standards, notably the principles laid down by the OECD as well as by the International Corporate Governance Network (ICGN).

In that respect, Candriam has exercised its voting rights when available on positions of the portfolio. Shareholders’ rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. Remuneration and directors’ election concentrate most of our votes against management. Indeed, we require companies to respect the pay-for-performance principle and will show our disagreement as soon as we consider the level of remuneration excessive or conditions of attribution not transparent enough nor challenging. Equally, we expect companies to comply with our minimum independence requirements : at boards failing to meet this requirement, we oppose (re-)election of any non-independent director, except CEO.

Diversity (PAI13) and expertise level of the board are of course also taken into account in these votes.

In addition, Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote.

In the best interest of its clients, Candriam considers internal ESG opinion on the investee companies but also any outcomes of engagement with them, in its voting choices.

In the context of Candriam’s voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10, PAI11)) and governance-related management and shareholder resolutions. More specifically, Candriam welcomes the introduction of management-sponsored ‘Say-on-Climate’ resolutions. Candriam built a detailed framework to be applied to every Say-on-Climate resolution, which assesses the stringency and the alignment of the company transition strategy with a 2050 net zero emissions pathway. As a result, most of these did not get our support during the period.

- Exclusion: Candriam's negative screening of companies or countries aimed to avoid investments in harmful activities or practices and may led to exclusions linked to comparnies' or issuers' adverse impact.
- Monitoring: calculation and evaluation of the principal adverse impact indicators including the reporting at Sub-Fund level. Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the sub-fund. See below the results of the indicators of this Sub-fund :

PAI indicators	Value
10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises	0.00%
14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)	0.00%



What were the top investments of this financial product?

The list includes the investments constituting **the greatest proportion of investments** of the financial product during the reference period which is: 31/12/2022

Top investments	Sector	Proportion	Country
MICROSOFT CORP	Internet and internet services	6.05%	US
ALPHABET INC -A-	Internet and internet services	3.57%	US
APPLE INC	Office supplies and computing	3.20%	US
PROCTER & GAMBLE CO	Miscellaneous consumer goods	3.13%	US
JOHNSON & JOHNSON	Pharmaceuticals	2.92%	US
VISA INC -A-	Miscellaneous services	2.27%	US
AMAZON.COM INC	Retail trade and department stores	2.15%	US
NESTLE SA REG SHS	Foods and non alcoholic drinks	2.08%	CH
MERCK & CO INC	Pharmaceuticals	2.02%	US
LVMH MOET HENNESSY LOUIS VUITTON SE	Textiles and garments	1.94%	FR
BANK OF AMERICA CORP	Banks and other financial institutions	1.85%	US
DANAHER CORP	Machine and apparatus construction	1.76%	US
UNITEDHEALTH GROUP INC	Healthcare	1.69%	US
MORGAN STANLEY	Banks and other financial institutions	1.63%	US
TOTALENERGIESE	Petroleum	1.63%	FR


Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



What was the proportion of sustainability-related investments?

What was the asset allocation?

Asset allocation describes the share of investments in specific assets.



#1 Aligned with E/S characteristics includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

#2 Other includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● ***In which economic sectors were the investments made?***

Top sector	Proportion
Pharmaceuticals	13.14%
Internet and internet services	10.95%
Banks and other financial institutions	8.68%
Machine and apparatus construction	5.82%
Foods and non alcoholic drinks	5.73%
Electronics and semiconductors	5.01%
Office supplies and computing	4.63%
Graphic art and publishing	3.90%
Petroleum	3.86%
Retail trade and department stores	3.86%
Insurance	3.78%
Miscellaneous consumer goods	3.62%
Miscellaneous services	3.08%
Hotels and restaurants	3.03%
Textiles and garments	2.85%

Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:


- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.

Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy ¹?


- Yes
- In fossil gas In nuclear energy
- No

The two graphs below show in green the minimum percentage of investments that are aligned with the EU Taxonomy. As there is no appropriate methodology to determine the Taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.

1. Taxonomy-alignment of investments including sovereign bonds*



2. Taxonomy-alignment of investments excluding sovereign bonds*



* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

What was the share of investments made in transitional and enabling activities?

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?

Not applicable because no previous period data is available

What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?

The Sub-Fund had a share of 23.77% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2022 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

What was the share of socially sustainable investments?

The Sub-fund had a share of investments with a social objective of 47.76%

What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?

The investments included under «Other» are present in the Sub-fund for 7.12% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments are planned to be sold;
- Other investments (including single name derivatives) purchased for diversification purposes and that might not be subject to an ESG screening or for which ESG data is not available;
- Non single name derivatives used for efficient portfolio management and/or for hedging purposes and/or temporarily following subscriptions/redemptions



What actions have been taken to meet the environmental and/or social characteristics during the reference period?

In order to respect the environmental and/or social characteristics during the reference period, the sub-fund initiated in issuers with a positive ESG profile, based on Candriam’s independent ESG rating assessment. Iberdrola, the biggest wind farm operator in Europa is a good example of this.

Further, in order to respect the environmental and/or social characteristics during the reference period, we sold the following investments for which the issuers did not have environmental and/or social characteristics: Meta Platforms’s Best-in-Universe score of 8 is insufficient to be part of the investable universe of the fund.

To give expression to the fact that challenges relating to climate change have been taken into account, the carbon footprint of companies is measured. As at 31/12/2022, the fund’s carbon footprint was 30 tCO₂-eq / million euro invested, compared to 52 tCO₂-eq / million euro invested for the fund benchmark.



How did this financial product perform compared to the reference benchmark?

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

Reference benchmarks are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

Environmental and/or social characteristics

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Did this financial product have a sustainable investment objective?



YES

- It made **sustainable investments with an environmental objective: ___%**
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective: ___%**



NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 87% of sustainable investments
- with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**



To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium).
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such

Sustainability indicators measure how the environmental or social characteristics promoted by the financial product are attained.

as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the «do no harm» principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 33%). The proportion of sustainable investments in the Fund was therefore above this minimum threshold, as detailed in the section «What was the proportion of sustainability-related investments?»

Sustainability KPI Name	Value	Benchmark
ESG Score - Corporate - Higher than bench	55.08	51.03

● **... And compared to previous periods?**

Not applicable because no previous period data is available.

● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 33%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its proprietary ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

----- **How were the indicators for adverse impacts on sustainability factors taken into account?**

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

The EU Taxonomy sets out a "do not significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.



How did this financial product consider principal adverse impacts on sustainability factors?

At Sub-Fund level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means (cfr. Candriam's PAI statement : <https://www.candriam.com/en/private/sfdr/>):

- Engagement & Voting: in order to avoid and/or reduce the adverse impact on sustainable objectives, the Sub-Fund also considered the adverse impacts in its interactions with companies, through dialogue and voting. Candriam prioritised its engagement and voting activities according to an evaluation of the most material and relevant ESG challenges, facing industries and issuers, by considering both the financial and societal / stakeholder impacts. Therefore, the level of engagement with each company within the same product may vary and is subject to Candriam's prioritisation methodology.
 - Dialogue:

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions,
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Our objective is obviously to encourage companies to publicly report on how they align with a 1.5D trajectory and to support such an alignment. Beyond any Net Zero commitment and Scope1-2-3 absolute emissions disclosure, Candriam thus encourage them to provide insights on how short / mid term targets are aligned with scientifically recognized 1.5D trajectory. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue. As in previous year, we continue to support and actively participate to several collaborative initiatives such Climate Action 100+ . These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (<https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications>) .

Given the geopolitical context and observed increase of inequalities, several engagements have also been performed in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10, PAI11). We also conducted a dedicated Post-covid direct engagement campaign aiming at investigating how relationships with stakeholders were impacted and the changes now integrated as the "new normal" course of business for Candriam's investee companies. In the same vein, Human capital management is an aspect we address in most of our exchanges with companies. We continue to support Workforce Disclosure Initiative defending a better access to reliable, relevant and comparable data on companies' direct and indirect workforces.

o Voting:

The Candriam's approach to Corporate Governance relies on internationally-recognized standards, notably the principles laid down by the OECD as well as by the International Corporate Governance Network (ICGN).

In that respect, Candriam has exercised its voting rights when available on positions of the portfolio. Shareholders' rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. Remuneration and directors' election concentrate most of our votes against management. Indeed, we require companies to respect the pay-for-performance principle and will show our disagreement as soon as we consider the level of remuneration excessive or conditions of attribution not transparent enough nor challenging. Equally, we expect companies to comply with our minimum independence requirements : at boards failing to meet this requirement, we oppose (re-)election of any non-independent director, except CEO. Diversity (PAI13) and expertise level of the board are of course also taken into account in these votes.

In addition, Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote.

In the best interest of its clients, Candriam considers internal ESG opinion on the investee companies but also any outcomes of engagement with them, in its voting choices.

In the context of Candriam's voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10, PAI11)) and governance-related management and shareholder resolutions. More specifically, Candriam welcomes the introduction of management-sponsored 'Say-on-Climate' resolutions. Candriam built a detailed framework to be applied to every Say-on-Climate resolution, which assesses the stringency and the alignment of the company transition strategy with a 2050 net zero emissions pathway. As a result, most of these did not get our support during the period.

- Exclusion: Candriam's negative screening of companies or countries aimed to avoid investments in harmful activities or practices and may led to exclusions linked to comparnies' or issuers' adverse impact.
- Monitoring: calculation and evaluation of the principal adverse impact indicators including the reporting at Sub-Fund level. Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the sub-fund. See below the results of the indicators of this Sub-fund :

PAI indicators	Value
10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises	0.00%
14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)	0.00%



What were the top investments of this financial product?

The list includes the investments constituting **the greatest proportion of investments** of the financial product during the reference period which is: 31/12/2022

Top investments	Sector	Proportion	Country
UNITEDHEALTH GROUP INC	Healthcare	8.26%	US
JOHNSON & JOHNSON	Pharmaceuticals	4.05%	US
ELI LILLY & CO	Pharmaceuticals	3.78%	US
ROCHE HOLDING LTD	Pharmaceuticals	3.64%	CH
THERMO FISHER SCIENT SHS	Electronics and semiconductors	3.55%	US
ABBOTT LABORATORIES	Pharmaceuticals	3.02%	US
MERCK & CO INC	Pharmaceuticals	2.94%	US
PFIZER INC	Pharmaceuticals	2.85%	US
MEDTRONIC HLD	Pharmaceuticals	2.84%	IE
DANAHER CORP	Machine and apparatus construction	2.77%	US
NOVO NORDISK	Pharmaceuticals	2.70%	DK
ANTHEM INC	Healthcare	2.66%	US
ABBVIE INC	Pharmaceuticals	2.55%	US
ASTRAZENECA PLC	Pharmaceuticals	2.13%	GB
AMGEN INC	Pharmaceuticals	2.11%	US


Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



What was the proportion of sustainability-related investments?

● What was the asset allocation?

Asset allocation describes the share of investments in specific assets.



#1 Aligned with E/S characteristics includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

#2 Other includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● ***In which economic sectors were the investments made?***

Top sector	Proportion
Pharmaceuticals	64.11%
Healthcare	14.25%
Biotechnology	8.96%
Electronics and semiconductors	4.92%
Machine and apparatus construction	2.77%
Banks and other financial institutions	2.24%
Miscellaneous services	0.86%
Internet and internet services	0.79%
Photographic and optics	0.38%
Chemicals	0.19%

Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:


- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.

Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy ¹?


- Yes
- In fossil gas In nuclear energy
- No

The two graphs below show in green the minimum percentage of investments that are aligned with the EU Taxonomy. As there is no appropriate methodology to determine the Taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.

1. Taxonomy-alignment of investments including sovereign bonds*



2. Taxonomy-alignment of investments excluding sovereign bonds*



* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

What was the share of investments made in transitional and enabling activities?

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?

Not applicable because no previous period data is available

What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?

The Sub-Fund had a share of 3.86% in sustainable investments with an environmental objective not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2022 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

What was the share of socially sustainable investments?

The Sub-fund had a share of investments with a social objective of 83.03%

What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?

The investments included under «Other» are present in the Sub-fund for 2.72% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments are planned to be sold;
- Other investments (including single name derivatives) purchased for diversification purposes and that might not be subject to an ESG screening or for which ESG data is not available;
- Non single name derivatives used for efficient portfolio management and/or for hedging purposes and/or temporarily following subscriptions/redemptions



What actions have been taken to meet the environmental and/or social characteristics during the reference period?

In order to respect the environmental and/or social characteristics during the reference period, we have kept an underweight position in Johnson & Johnson. The company ranks a decent 6 in Candriam’s Best-in-Universe framework, which is on the low side compared to other major health care companies. Even though the company looks appealing from a fundamental side, we keep an underweight compared to the MSCI World Health Care Index.

The subfund aims to achieve an ESG score, based on Candriam’s proprietary ESG methodology, higher than its benchmark. At the end of the year 2022, the subfund’s overall ESG score was 55.08 and which represents 4.05 above the ESG score of the benchmark at the time (51.03).



How did this financial product perform compared to the reference benchmark?

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

Reference benchmarks are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

Environmental and/or social characteristics

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Did this financial product have a sustainable investment objective?



YES

- It made **sustainable investments with an environmental objective: ___%**
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective: ___%**



NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 81% of sustainable investments
- with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**



To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium).
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such

as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the «do no harm» principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 20%). The proportion of sustainable investments in the Fund was therefore above this minimum threshold, as detailed in the section «What was the proportion of sustainability-related investments?»

Sustainability KPI Name	Value	Benchmark
Carbon Footprint - Corporate - Scope 1&2 - Lower than bench	8.15	64.55

● **... And compared to previous periods?**

Not applicable because no previous period data is available.

● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 20%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its proprietary ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

----- **How were the indicators for adverse impacts on sustainability factors taken into account?**

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

The EU Taxonomy sets out a "do not significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.



How did this financial product consider principal adverse impacts on sustainability factors?

At Sub-Fund level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means (cfr. Candriam's PAI statement : <https://www.candriam.com/en/private/sfdr/>):

- Engagement & Voting: in order to avoid and/or reduce the adverse impact on sustainable objectives, the Sub-Fund also considered the adverse impacts in its interactions with companies, through dialogue and voting. Candriam prioritised its engagement and voting activities according to an evaluation of the most material and relevant ESG challenges, facing industries and issuers, by considering both the financial and societal / stakeholder impacts. Therefore, the level of engagement with each company within the same product may vary and is subject to Candriam's prioritisation methodology.
 - Dialogue:

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions,
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Our objective is obviously to encourage companies to publicly report on how they align with a 1.5D trajectory and to support such an alignment. Beyond any Net Zero commitment and Scope1-2-3 absolute emissions disclosure, Candriam thus encourage them to provide insights on how short / mid term targets are aligned with scientifically recognized 1.5D trajectory. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue. As in previous year, we continue to support and actively participate to several collaborative initiatives such Climate Action 100+ . These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (<https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications>) .

Given the geopolitical context and observed increase of inequalities, several engagements have also been performed in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10, PAI11). We also conducted a dedicated Post-covid direct engagement campaign aiming at investigating how relationships with stakeholders were impacted and the changes now integrated as the “new normal” course of business for Candriam’s investee companies. In the same vein, Human capital management is an aspect we address in most of our exchanges with companies. We continue to support Workforce Disclosure Initiative defending a better access to reliable, relevant and comparable data on companies’ direct and indirect workforces.

o Voting:

The Candriam’s approach to Corporate Governance relies on internationally-recognized standards, notably the principles laid down by the OECD as well as by the International Corporate Governance Network (ICGN).

In that respect, Candriam has exercised its voting rights when available on positions of the portfolio. Shareholders’ rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. Remuneration and directors’ election concentrate most of our votes against management. Indeed, we require companies to respect the pay-for-performance principle and will show our disagreement as soon as we consider the level of remuneration excessive or conditions of attribution not transparent enough nor challenging. Equally, we expect companies to comply with our minimum independence requirements : at boards failing to meet this requirement, we oppose (re-)election of any non-independent director, except CEO.

Diversity (PAI13) and expertise level of the board are of course also taken into account in these votes.

In addition, Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote.

In the best interest of its clients, Candriam considers internal ESG opinion on the investee companies but also any outcomes of engagement with them, in its voting choices.

In the context of Candriam’s voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10, PAI11)) and governance-related management and shareholder resolutions. More specifically, Candriam welcomes the introduction of management-sponsored ‘Say-on-Climate’ resolutions. Candriam built a detailed framework to be applied to every Say-on-Climate resolution, which assesses the stringency and the alignment of the company transition strategy with a 2050 net zero emissions pathway. As a result, most of these did not get our support during the period.

- Exclusion: Candriam's negative screening of companies or countries aimed to avoid investments in harmful activities or practices and may led to exclusions linked to comparnies' or issuers' adverse impact.
- Monitoring: calculation and evaluation of the principal adverse impact indicators including the reporting at Sub-Fund level. Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the sub-fund. See below the results of the indicators of this Sub-fund :

PAI indicators	Value
10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises	0.00%
14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)	0.00%



What were the top investments of this financial product?

The list includes the investments constituting **the greatest proportion of investments** of the financial product during the reference period which is: 31/12/2022

Top investments	Sector	Proportion	Country
BROADCOM INC - REGISTERED SHS	Office supplies and computing	3.78%	US
ADOBE INC	Internet and internet services	3.69%	US
IBM CORP	Office supplies and computing	3.53%	US
MICROSOFT CORP	Internet and internet services	3.41%	US
TAIWAN SEMICONDUCTOR CO ADR (REPR 5 SHS)	Electronics and semiconductors	3.31%	US
NVIDIA CORP	Electronics and semiconductors	3.17%	US
ADVANCED MICRO DEVICES INC	Electronics and semiconductors	3.08%	US
QUALCOMM INC	Communication	2.92%	US
APPLE INC	Office supplies and computing	2.78%	US
ALPHABET INC -A-	Internet and internet services	2.76%	US
WALT DISNEY CO	Graphic art and publishing	2.72%	US
PAYPAL HOLDINGS	Miscellaneous services	2.45%	US
AKAMAI TECHNOLOGIES	Internet and internet services	2.21%	US
SIEMENS AG REG	Electrical engineering	2.06%	DE
INTUITIVE SURGICAL	Pharmaceuticals	2.00%	US


Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



What was the proportion of sustainability-related investments?

● What was the asset allocation?

Asset allocation describes the share of investments in specific assets.



#1 Aligned with E/S characteristics includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

#2 Other includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● ***In which economic sectors were the investments made?***

Top sector	Proportion
Internet and internet services	41.31%
Electronics and semiconductors	15.44%
Office supplies and computing	11.17%
Electrical engineering	6.39%
Communication	2.92%
Graphic art and publishing	2.72%
Banks and other financial institutions	2.56%
Miscellaneous services	2.45%
Pharmaceuticals	2.00%
Real estate	1.89%
Machine and apparatus construction	1.67%
Hotels and restaurants	1.33%
Healthcare	0.97%

Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:


- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.

Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy ¹?


- Yes
- In fossil gas In nuclear energy
- No

The two graphs below show in green the minimum percentage of investments that are aligned with the EU Taxonomy. As there is no appropriate methodology to determine the Taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.

1. Taxonomy-alignment of investments including sovereign bonds*



2. Taxonomy-alignment of investments excluding sovereign bonds*



* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

What was the share of investments made in transitional and enabling activities?

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?

Not applicable because no previous period data is available

What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?

The Sub-Fund had a share of 21.68% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2022 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

What was the share of socially sustainable investments?

The Sub-fund had a share of investments with a social objective of 59.6%

What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?

The investments included under «Other» are present in the Sub-fund for 8.19% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments are planned to be sold;
- Other investments (including single name derivatives) purchased for diversification purposes and that might not be subject to an ESG screening or for which ESG data is not available;
- Non single name derivatives used for efficient portfolio management and/or for hedging purposes and/or temporarily following subscriptions/redemptions



What actions have been taken to meet the environmental and/or social characteristics during the reference period?

In order to respect the environmental and/or social characteristics during the reference period, the sub-fund didn't invest in positions from issuers which don't have a positive ESG profile, based on Candriam's independent ESG rating assessment. Even though it makes sense to investing in Meta Platforms from a thematic point of view, we did not invest in the stock. Within the fund we exclude all companies that have a Best-in-Universe score equal of lower than 8 (scoring from 1-10, 10 being the lowest). As at the end of 2022, Meta Platforms was scored 8 in Best-in-Universe. The company isn't shareholder friendly and continues to invest heavily in infrastructure, security, and content, while the management didn't always handle privacy matters with care.

The subfund aims to achieve an ESG score, based on Candriam's proprietary ESG methodology, higher than its benchmark. At the end of the year 2022, the subfund's overall ESG score was 53.51 and which represents 3.15 above the ESG score of the benchmark at the time.



How did this financial product perform compared to the reference benchmark?

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

Reference benchmarks are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

Sustainable investment objective

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Did this financial product have a sustainable investment objective?	
<input checked="" type="checkbox"/> YES	<input type="checkbox"/> NO
<input checked="" type="checkbox"/> It made sustainable investments with an environmental objective: 0%	<input type="checkbox"/> It promoted Environmental/Social (E/S) characteristics and while it did not have as its objective a sustainable investment, it had a proportion of ___% of sustainable investment
<input type="checkbox"/> in economic activities that qualify as environmentally sustainable under the EU Taxonomy	<input type="checkbox"/> with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
<input checked="" type="checkbox"/> in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy	<input type="checkbox"/> with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
<input checked="" type="checkbox"/> It made sustainable investments with a social objective: 93.55%	<input type="checkbox"/> with a social objective
	<input type="checkbox"/> It promoted E/S characteristics, but did not make any sustainable investments



To what extent was the sustainable investment objective of this financial product met?

The attainment of the sustainable investment objectives was measured through the following sustainability indicators:

- Research and development spending: better-than-benchmark research and development spending as a proportion of the company's market capitalisation.
- The level of education of management teams: better-than-benchmark percentage of senior executives holding a doctorate.

Moreover, the following indicators were monitored:

- to assure that there are no investments in companies that are in violation with the OECD Guidelines for Multinational Enterprises or the UN Global Compact.
- to assure that there are no investments in companies that are on the Candriam's SRI exclusion list as a result of the application of Candriam's Exclusion Policy.
- Number of holdings for which Candriam voted.

'The Sub-Fund's reference benchmark has not been designated for the purpose of attaining the sustainable investment objective of the Sub-Fund.

'The Sub-Fund's reference benchmark does not qualify as an EU Climate Transition Benchmark or an EU Paris-Aligned Benchmark under Title III, Chapter 3a, of Regulation (EU) 2016/1011.

However, Candriam being part of the Net Zero Asset Management initiative, the Sub-Fund aims to reduce greenhouse gas emissions in line with the objectives of the Paris Agreement.

● **How did the sustainability indicators perform?**

The Sub-Fund has been managed in accordance with its sustainability indicators as defined below.

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the "do no harm" principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 75%). The proportion of sustainable investments in the Fund was therefore above this minimum threshold, as detailed in the section "What was the proportion of sustainability-related investments?"

Sustainability KPI Name	Value	Benchmark
PhD in Mgmt - Corporate - Higher than bench	23.73%	3.94%
R&D Expense - Corporate - Higher than bench	3.11%	1.19%

● **... And Compared to Previous Periods?**

Not applicable because no previous period data is available.

● **How did the sustainable investments not cause significant harm to any sustainable investment objective?**

Candriam ensured that its sustainable investments did not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate and sovereign issuers. Based on its proprietary ESG Ratings and Scorings, Candriam's ESG methodology set clear requirements and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, do not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

How were the indicators for adverse impacts on sustainability factors taken into account?

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

Sustainability indicators measure how the sustainable objectives of this financial product are attained.

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

The Sub-fund's investments were subject to a norms-based controversy analysis that considered the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.



How did this financial product consider principal adverse impacts on sustainability factors?

At Sub-Fund level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means (cfr. Candriam's PAI statement : <https://www.candriam.com/en/private/sfdr/>):

- Engagement & Voting: in order to avoid and/or reduce the adverse impact on sustainable objectives, the Sub-Fund also considered the adverse impacts in its interactions with companies, through dialogue and voting. Candriam prioritised its engagement and voting activities according to an evaluation of the most material and relevant ESG challenges, facing industries and issuers, by considering both the financial and societal / stakeholder impacts. Therefore, the level of engagement with each company within the same product may vary and is subject to Candriam's prioritisation methodology.
 - Dialogue:

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions,
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Our objective is obviously to encourage companies to publicly report on how they align with a 1.5D trajectory and to support such an alignment. Beyond any Net Zero commitment and Scope1-2-3 absolute emissions disclosure, Candriam thus encourage them to provide insights on how short / mid term targets are aligned with scientifically recognized 1.5D trajectory. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue. As in previous year, we continue to support and actively participate to several collaborative initiatives such Climate Action 100+ . These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (<https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications>) .

Given the geopolitical context and observed increase of inequalities, several engagements have also been performed in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10, PAI11). We also conducted a dedicated Post-covid direct engagement campaign aiming at investigating how relationships with stakeholders were impacted and the changes now integrated as the "new normal" course of business for Candriam's investee companies. In the same vein, Human capital management is an aspect we address in most of our exchanges with companies. We continue to support Workforce Disclosure Initiative defending a better access to reliable, relevant and comparable data on companies' direct and indirect workforces.

- Voting:

The Candriam's approach to Corporate Governance relies on internationally-recognized standards, notably the principles laid down by the OECD as well as by the International Corporate Governance Network (ICGN).

In that respect, Candriam has exercised its voting rights when available on positions of the portfolio. Shareholders' rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. Remuneration and directors' election concentrate most of our votes against management. Indeed, we require companies to respect the pay-for-performance principle and will show our disagreement as soon as we consider the level of remuneration excessive or conditions of attribution not transparent enough nor challenging. Equally, we expect companies to comply with our minimum independence requirements : at boards failing to meet this requirement, we oppose (re-)election of any non-independent director, except CEO. Diversity (PAI13) and expertise level of the board are of course also taken into account in these votes.

In addition, Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote.

In the best interest of its clients, Candriam considers internal ESG opinion on the investee companies but also any outcomes of engagement with them, in its voting choices.

In the context of Candriam's voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10, PAI11)) and governance-related management and shareholder resolutions. More specifically, Candriam welcomes the introduction of management-sponsored 'Say-on-Climate' resolutions. Candriam built a detailed framework to be applied to every Say-on-Climate resolution, which assesses the stringency and the alignment of the company transition strategy with a 2050 net zero emissions pathway. As a result, most of these did not get our support during the period.

- Exclusion: Candriam's negative screening of companies or countries aimed to avoid investments in harmful activities or practices and may led to exclusions linked to comparnies' or issuers' adverse impact.
- Monitoring: calculation and evaluation of the principal adverse impact indicators including the reporting at Sub-Fund level. Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the sub-fund. See below the results of the indicators of this Sub-fund :

PAI indicators	Value
1- GHG Emissions - Scope 1 GHG Emissions	3184.87
1- GHG Emissions - Scope 2 GHG Emissions	2608.30
1- GHG Emissions - Total GHG Emissions	5793.17
2 - Carbon Footprint	3.57
3 - GHG intensity of investee companies	27.23
4 - Exposure to companies active in fossil fuel sector	0.00%
10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises	0.00%
13 - Board gender diversity	31.47%
14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)	0.00%



What were the top investments of this financial product?

The list includes the investments constituting **the greatest proportion of investments** of the financial product during the reference period which is: 31/12/2022

Top investments	Sector	Proportion	Country
ASTRAZENECA PLC	Pharmaceuticals	8.26%	GB
MERCK & CO INC	Pharmaceuticals	8.03%	US
ROCHE HOLDING LTD	Pharmaceuticals	7.05%	CH
REGENERON PHARMACEUTICALS INC	Biotechnology	6.38%	US
THERMO FISHER SCIENT SHS	Electronics and semiconductors	4.59%	US
DANAHER CORP	Machine and apparatus construction	4.19%	US
AMGEN INC	Pharmaceuticals	4.03%	US
MERCK KGAA	Pharmaceuticals	3.93%	DE
SIEMENS HEALTHINEERS	Pharmaceuticals	3.88%	DE
DAIICHI SANKYO CO LTD	Banks and other financial institutions	3.56%	JP
ELI LILLY & CO	Pharmaceuticals	3.55%	US
HOLOGIC INC	Pharmaceuticals	3.54%	US
GENMAB AS	Biotechnology	2.85%	DK
SEAGEN INC	Biotechnology	2.44%	US
IQVIA HOLDINGS INC	Pharmaceuticals	2.27%	US


Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



What was the proportion of sustainability-related investments?

Asset allocation describes the share of investments in specific assets.

● *What was the asset allocation?*



● ***In which economic sectors were the investments made?***

Top sector	Proportion
Pharmaceuticals	51.08%
Biotechnology	25.44%
Electronics and semiconductors	4.98%
Banks and other financial institutions	4.38%
Machine and apparatus construction	4.19%
Chemicals	1.08%
Miscellaneous services	1.00%
Photographic and optics	0.94%
Healthcare	0.49%

Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



To what extent were sustainable investments with an environmental objective aligned with the EU Taxonomy?

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies

- **capital expenditure** (CapEx) showing the green investments made by investee companies, e.g for a transition to a green economy.


- **operational expenditure** (OpEx) reflecting green operational activities of investee companies.

Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy¹?


- Yes
- In fossil gas In nuclear energy
- No

The two graphs below show in green the minimum percentage of investments that are aligned with the EU Taxonomy. As there is no appropriate methodology to determine the Taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.

1. Taxonomy-alignment of investments **including** sovereign bonds*



2. Taxonomy-alignment of investments **excluding** sovereign bonds*



* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

are sustainable investments with an environmental objective that do not take into account the criteria for environmentally sustainable economic activities under the EU Taxonomy.

● **What was the share of investments made in transitional and enabling activities?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment their alignment with the Taxonomy.

● **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?**

Not applicable because no previous period data is available.

● **What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

Therefore, this percentage is considered as nul.



What was the share of sustainable investments with an environmental objective that were not aligned with the EU taxonomy?

The Sub-Fund had a share of 0% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2022 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.



What was the share of socially sustainable investments?

The Sub-Fund had a share of investments with a social objective of 93.55%



What investments were included under “#2 Not sustainable”, what was their purpose and were there any minimum environmental or social safeguards?

The investments included under "Not sustainable" are present in the Sub-fund for 6.42% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions and/or being the result of the market exposure decision of the Sub-fund.
- Investments with issuers considered as sustainable investments at the moment of the investment and that are not fully aligned anymore with the Candriam sustainable investment criteria. These investments are planned to be sold.
- Non single name derivatives used for efficient portfolio management and/or for hedging purposes and/or temporarily following subscriptions/redemptions



What actions have been taken to attain the sustainable investment objective during the reference period?

In order to respect the sustainable investment objective during the reference period, we sold the following investments for which the issuers did not contribute to the achievement of its sustainable investment objective. Johnson & Johnson was sold. The company ranks 6 in Candriam’s Best-in-Universe framework and is thus excluded from the investable universe. As an in-depth analysis of the ESG-team found no reasons for an eventual upgrade, we sold the position.

To achieve its social objective, the sub-fund seeks to outperform the benchmark in the two social indicators, with the aim of evaluating the human and financial resources mobilised by the companies in the battle against cancer: 1/ Research and development spending as a proportion of the company’s market capitalization. 2/ The level of education of management teams, measured as the percentage of senior executives. The fund has outperformed its benchmark on both social indicators. The research and development spending as a proportion of the company's market capitalization totaled 3.1% for the fund and more than 1.2% for the benchmark. The level of education of management teams, measured as the percentage of senior executives holding a doctorate, totaled around 23.73% for the fund and 3.94% for the benchmark.

In addition, the subfund aims to achieve an ESG score, based on Candriam's proprietary ESG methodology, higher than its benchmark. As at the end of 2022, the subfund's overall ESG score was 58, compared to 51 for the benchmark at the time.



How did this financial product perform compared to the reference sustainable benchmark?

Reference benchmarks are indexes to measure whether the financial product attains the sustainable objective.

No specific index is designated as a reference sustainable benchmark to meet the sustainable investment objectives.

Environmental and/or social characteristics

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Did this financial product have a sustainable investment objective?	
<input type="checkbox"/> YES	<input checked="" type="checkbox"/> NO
<input type="checkbox"/> It made sustainable investments with an environmental objective: ___%	<input checked="" type="checkbox"/> It promoted Environmental/Social (E/S) characteristics and while it did not have as its objective a sustainable investment, it had a proportion of 88% of sustainable investments
<input type="checkbox"/> in economic activities that qualify as environmentally sustainable under the EU Taxonomy	<input type="checkbox"/> with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
<input type="checkbox"/> in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy	<input checked="" type="checkbox"/> with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
<input type="checkbox"/> It made sustainable investments with a social objective: ___%	<input checked="" type="checkbox"/> with a social objective
	<input type="checkbox"/> It promoted E/S characteristics, but did not make any sustainable investments



To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium).
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such

as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the «do no harm» principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 20%). The proportion of sustainable investments in the Fund was therefore above this minimum threshold, as detailed in the section «What was the proportion of sustainability-related investments?»

Sustainability KPI Name	Value	Benchmark
Carbon Footprint - Corporate - Scope 1&2 - Lower than bench	7.43	51.74

● **... And compared to previous periods?**

Not applicable because no previous period data is available.

● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 20%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its proprietary ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

----- **How were the indicators for adverse impacts on sustainability factors taken into account?**

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

The EU Taxonomy sets out a “do not significant harm” principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The “do no significant harm” principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.



How did this financial product consider principal adverse impacts on sustainability factors?

At Sub-Fund level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means (cfr. Candriam's PAI statement : <https://www.candriam.com/en/private/sfdr/>):

- Engagement & Voting: in order to avoid and/or reduce the adverse impact on sustainable objectives, the Sub-Fund also considered the adverse impacts in its interactions with companies, through dialogue and voting. Candriam prioritised its engagement and voting activities according to an evaluation of the most material and relevant ESG challenges, facing industries and issuers, by considering both the financial and societal / stakeholder impacts. Therefore, the level of engagement with each company within the same product may vary and is subject to Candriam's prioritisation methodology.
 - Dialogue:

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions,
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Our objective is obviously to encourage companies to publicly report on how they align with a 1.5D trajectory and to support such an alignment. Beyond any Net Zero commitment and Scope1-2-3 absolute emissions disclosure, Candriam thus encourage them to provide insights on how short / mid term targets are aligned with scientifically recognized 1.5D trajectory. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue. As in previous year, we continue to support and actively participate to several collaborative initiatives such Climate Action 100+ . These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (<https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications>) .

Given the geopolitical context and observed increase of inequalities, several engagements have also been performed in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10, PAI11). We also conducted a dedicated Post-covid direct engagement campaign aiming at investigating how relationships with stakeholders were impacted and the changes now integrated as the “new normal” course of business for Candriam’s investee companies. In the same vein, Human capital management is an aspect we address in most of our exchanges with companies. We continue to support Workforce Disclosure Initiative defending a better access to reliable, relevant and comparable data on companies’ direct and indirect workforces.

o Voting:

The Candriam’s approach to Corporate Governance relies on internationally-recognized standards, notably the principles laid down by the OECD as well as by the International Corporate Governance Network (ICGN).

In that respect, Candriam has exercised its voting rights when available on positions of the portfolio. Shareholders’ rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. Remuneration and directors’ election concentrate most of our votes against management. Indeed, we require companies to respect the pay-for-performance principle and will show our disagreement as soon as we consider the level of remuneration excessive or conditions of attribution not transparent enough nor challenging. Equally, we expect companies to comply with our minimum independence requirements : at boards failing to meet this requirement, we oppose (re-)election of any non-independent director, except CEO.

Diversity (PAI13) and expertise level of the board are of course also taken into account in these votes.

In addition, Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote.

In the best interest of its clients, Candriam considers internal ESG opinion on the investee companies but also any outcomes of engagement with them, in its voting choices.

In the context of Candriam’s voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10, PAI11)) and governance-related management and shareholder resolutions. More specifically, Candriam welcomes the introduction of management-sponsored ‘Say-on-Climate’ resolutions. Candriam built a detailed framework to be applied to every Say-on-Climate resolution, which assesses the stringency and the alignment of the company transition strategy with a 2050 net zero emissions pathway. As a result, most of these did not get our support during the period.

- Exclusion: Candriam's negative screening of companies or countries aimed to avoid investments in harmful activities or practices and may led to exclusions linked to comparnies' or issuers' adverse impact.
- Monitoring: calculation and evaluation of the principal adverse impact indicators including the reporting at Sub-Fund level. Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the sub-fund. See below the results of the indicators of this Sub-fund :

PAI indicators	Value
10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises	0.00%
14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)	0.00%



What were the top investments of this financial product?

The list includes the investments constituting **the greatest proportion of investments** of the financial product during the reference period which is: 31/12/2022

Top investments	Sector	Proportion	Country
EMERSON ELECTRIC CO	Electrical engineering	4.63%	US
ALPHABET INC -A-	Internet and internet services	4.10%	US
SIEMENS AG REG	Electrical engineering	3.97%	DE
PTC INC	Internet and internet services	3.53%	US
MICROSOFT CORP	Internet and internet services	3.29%	US
ROCKWELL AUTOMATION	Electrical engineering	3.27%	US
ANALOG DEVICES INC	Electronics and semiconductors	3.22%	US
APPLIED MATERIALS INC	Electronics and semiconductors	3.18%	US
ASML HOLDING NV	Electronics and semiconductors	3.15%	NL
SCHNEIDER ELECTRIC SE	Electrical engineering	2.85%	FR
STMICROELECTRONICS NV	Electronics and semiconductors	2.81%	NL
SILICON LABORATORIES INC	Electronics and semiconductors	2.52%	US
SERVICENOW INC	Internet and internet services	2.45%	US
ADVANCED MICRO DEVICES INC	Electronics and semiconductors	2.41%	US
KEYENCE CORP	Electronics and semiconductors	2.39%	JP


Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



What was the proportion of sustainability-related investments?

● What was the asset allocation?

Asset allocation describes the share of investments in specific assets.



#1 Aligned with E/S characteristics includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

#2 Other includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● ***In which economic sectors were the investments made?***

Top sector	Proportion
Electronics and semiconductors	32.19%
Internet and internet services	30.82%
Electrical engineering	17.85%
Machine and apparatus construction	5.44%
Pharmaceuticals	4.10%
Road vehicles	1.92%
Communication	1.68%
Miscellaneous services	1.13%
Investments funds	0.08%

Minor differences may be present between the data above and the corresponding ones in the section "Investment portfolio" of the annual report due to the number rounding process



To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:


- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.

Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy ¹?


- Yes
- In fossil gas In nuclear energy
- No

The two graphs below show in green the minimum percentage of investments that are aligned with the EU Taxonomy. As there is no appropriate methodology to determine the Taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.

1. Taxonomy-alignment of investments including sovereign bonds*



2. Taxonomy-alignment of investments excluding sovereign bonds*



* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

What was the share of investments made in transitional and enabling activities?

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?

Not applicable because no previous period data is available

What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?

The Sub-Fund had a share of 23.57% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2022 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

What was the share of socially sustainable investments?

The Sub-fund had a share of investments with a social objective of 64.76%

What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?

The investments included under «Other» are present in the Sub-fund for 4.82% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments are planned to be sold;
- Other investments (including single name derivatives) purchased for diversification purposes and that might not be subject to an ESG screening or for which ESG data is not available;
- Non single name derivatives used for efficient portfolio management and/or for hedging purposes and/or temporarily following subscriptions/redemptions



What actions have been taken to meet the environmental and/or social characteristics during the reference period?

In order to respect the environmental and/or social characteristics during the reference period, we sold/reduced the following investments for which the issuers did not have environmental and/or social characteristics: we sold the position in Ericsson at the beginning of the year. The company was an investment in the development of 5G, but the company was linked to bribery practices. This provoked a breach in our Norms-based analysis and led to an exclusion of the stock from the investible universe.

The subfund aims to achieve an average ESG score, based on Candriam's proprietary ESG methodology, higher than its benchmark. As at the end of December 2022, the subfund's overall ESG score was 55, compared to 51 for the benchmark at the time.

To give expression to the fact that challenges relating to climate change have been taken into account, the carbon footprint of companies is measured. At the end of the year 2022, the fund's carbon footprint was 7.43 tCO₂-eq / million euro invested, compared to 51.74 tCO₂-eq / million euro invested for the fund benchmark.



How did this financial product perform compared to the reference benchmark?

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

Reference benchmarks are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.